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Fused Positron Emission Tomography and Computed Tomography (PET/CT) is an 
emerging investigative tool in cardiovascular disease that provides an imaging-based 
quantification of pathophysiological processes of interest. The purpose of this thesis 
was to study the application of PET to identify fundamental pathophysiological 
processes driving 3 forms of cardiovascular disease: aortic stenosis, myocardial 
infarction, and atherosclerosis. 
 
Methods.  
Aortic Stenosis. Patients with a spectrum of calcific aortic valve disease (n=121) who 
underwent PET-CT imaging for the identification of valvular calcification (18F-
fluoride) and inflammation (18F-fluorodeoxyglucose, 18F-FDG) underwent serial 
imaging and clinical follow-up over 2 years. Baseline imaging findings were compared 
with echocardiographic and CT markers of disease progression and clinical outcome. 
 
Myocardial Infarction. Patients underwent PET-CT imaging with 18F-fluciclatide (a 
novel αvβ3-selective radiotracer highlighting active angiogenesis, inflammation and 
fibrosis) after ST-segment elevation MI (n=21), alongside stable patients with chronic 
total occlusion (CTO) of a major coronary vessel (n=7), and healthy volunteers (n=9). 
Myocardial radiotracer uptake was compared with clinical and cardiac magnetic 
resonance imaging (CMR) markers of infarction and remodeling. 
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Atherosclerosis. Patients with a spectrum of atherosclerotic disease categorized as 
stable or unstable (recent MI) underwent PET/CT imaging with 18F-fluciclatide 
(n=46). Thoracic aortic 18F-fluciclatide uptake was compared with aortic 
atherosclerotic burden quantified by CT plaque thickness, plaque volume and calcium 
scoring. 
 
Histological validation. Tissue from the aortic valve, myocardium and carotid arteries 




Aortic Stenosis. Baseline valvular 18F-fluoride uptake correlated strongly with the rate 
of progression in AVC (r=0.80, p<0.001) and with haemodynamic progression (mean 
aortic valve gradient r=0.32, p=0.001). It emerged as independently associated with 
clinical outcome after age and sex-adjustment (HR 1.55 [1.33-1.81], p<0.001). 18F-
FDG demonstrated moderate correlations with disease progression as assessed by CT 
(r=0.43, p=0.001) and echocardiography (18F-FDG r=0.30, p=0.001), and was 
associated with clinical outcomes independent of age and sex (HR 1.35 [1.16-1.58], 
p<0.001). Valvular 18F-fluoride uptake correlated with immunohistochemical 
markers of calcification activity. There was no correlation between 18F-FDG uptake 
and inflammation. 
 
Myocardial Infarction. 18F-Fluciclatide binding was demonstrated in ex vivo peri-
infarct myocardium and uptake was increased in vivo at sites of acute infarction 
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compared to remote myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 
vs 0.85±0.17 respectively, p<0.001) and myocardium of healthy volunteers 
(TBRmean 1.34±0.22 vs 0.70±0.03; p<0.001). There was no 18F-fluciclatide uptake 
at sites of established prior infarction in patients with CTO, with myocardial activity 
similar to healthy volunteers (TBRmean 0.71±0.06 vs. 0.70±0.03,p=0.83). 18F-
Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall motion index 
≥1 vs 0; TBRmean 0.93±0.31 vs 0.80±0.26 respectively, p<0.001), was increased in 
segments displaying functional recovery (TBRmean 0.95±0.33 vs 0.81±0.27, 
p=0.002) and associated with increase in probability of regional recovery.  
 
Atherosclerosis. 18F-Fluciclatide vascular binding ex vivo co-localised with regions 
of increased αvβ3 integrin expression, and markers of inflammation and angiogenesis.  
18F-Fluciclatide uptake in vivo correlated with measures of aortic atherosclerotic 
burden: plaque thickness (r=0.57, p=0.001), total plaque volume (r=0.56, p=0.001) 
and the CT aortic calcium score (r=0.37, p=0.01). Patients with recent MI had greater 




In a range of cardiovascular diseases, PET-CT can provide insights into key 
pathophysiological processes, guide patient risk stratification and prognosis, and 
identify important biomarkers of disease activity that can be used for the development 
of future therapeutic interventions. 
  








Positron emission tomography (PET) is a nuclear medicine medical scanning 
technology that produces a 3-D image of disease processes occurring within the body. 
The technique enables us to measure the activity of these processes, identifying 
potentially important disease changes earlier than they might be seen on more common 
imaging techniques such as computed tomography (CT), and at a stage where 
treatment may be targeted more effectively. Within this thesis we explore new 
techniques for combined PET/CT imaging in cardiovascular disease.  
 
Firstly, we have used PET/CT imaging to assess a common heart valve condition 
called ‘aortic stenosis’. The aortic valve allows blood to exit the heart, and through a 
process involving inflammation and progressive calcium formation (calcification), the 
valve may become narrowed and cause an obstruction to blood flow. We used PET/CT 
imaging to successfully identify inflammation and calcification as it occurs within the 
heart valve. Over time, we determined that patients with more inflammation and 
calcification activity visible in their aortic valve on PET scanning were more likely to 
require an operation to replace the valve, or to die. This technique therefore may enable 
us to identify patients at greater risk, potentially offering us a way to direct treatment 
towards high-risk individuals and monitor the effectiveness of their treatment.  
 
Secondly, we have used a new type of PET/CT imaging to assess the repair 
mechanisms that occur within the heart muscle after a heart attack. The healing 
processes following a heart attack are complex, and in some patients over time there 
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may be a deterioration in heart structure and function rather than an improvement. 
These patients are at risk of developing ‘heart failure’ and would benefit from more 
intensive medication and monitoring. Using PET scanning to identify the formation of 
microscopic blood vessels and scar tissue within the heart, we have developed a 
technique where we can visualise heart muscle repair activity as it occurs. 
Furthermore, the areas of heart muscle damage that displayed higher activity on their 
PET scan demonstrated greater  functional improvement. This technology potentially 
provides a means of identifying those patients who may be at risk of ‘dysfunctional’ 
repair processes and ‘heart failure’.  
 
Finally, we have demonstrated that this method of visualising the formation of new 
microscopic blood vessels using PET scanning may also be used to highlight areas of 
narrowing within the blood vessels that are a sign of heart disease, potentially allowing 
us to identify those patients who may be at an increased risk of a heart attack or stroke. 
 
In summary, these novel uses of PET imaging provide a way to recognise forms of 
early heart disease, potentially providing a way to treat and monitor heart disease in a 
manner that is tailored to the individual patient. However, further work is now required 
prior to its routine use in the hospital setting.  




Chapter 1.   
Positron Emission Tomography: Novel 

























Excerpts from this chapter have been published in the review article by Jenkins WS, 
Chin C, Rudd JH, Newby DE and Dweck MR. What can we learn about valvular 
heart disease from PET/CT? Future Cardiol. 2013 Sep;9(5):657-67.  
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1.1.  Overview 
 
Cardiovascular disease represents the primary cause of morbidity and mortality 
worldwide.(1) With an aging population, this burden of disease is set to increase. To 
address this, we require a thorough understanding of cardiovascular disease 
physiology, isolating relevant pathological processes, understanding their relevance in 
cardiovascular physiology, and determining the consequence of modifying those 
processes in vivo. 
 
It is increasingly appreciated that despite diversity in the clinical presentations of 
cardiovascular disease, there exists significant overlap in the pathophysiological 
mechanisms that initiate and propagate these disease states, with implications on 
clinical investigation and therapeutic targets. Aortic Stenosis, atherosclerosis and 
adverse myocardial remodeling are 3 cardiovascular diseases accountable for a 
significant proportion of cardiovascular disease burden. Phenotypically, each disease 
differs in its clinical presentation; historically this has ensured distinct management 
considerations. However, there are several key pathophysiological processes that are 
relevant within each condition to varying degrees, including calcification, 
inflammation, fibrosis and angiogenesis. 
 
Here, we assess the application of novel non-invasive imaging methods to quantify 
these processes. Specifically we have employed Computed Tomography (CT) and 
combined Positron Emission Tomography - Computed Tomography (PET-CT) in 
aortic stenosis, adverse myocardial remodeling and atherosclerosis. Combined 
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PET/CT is a novel non-invasive imaging technique that allows the identification and 
quantification of specific physiological and pathophysiological processes occurring 
within the body, with a spatial resolution of between 4 and 6 mm. Its clinical use in 
cardiovascular disease has previously been limited to myocardial perfusion imaging, 
but with an appropriate radiotracer in theory the activity of any pathological process 
can be studied, and PET/CT has provided novel pathological insights into 
atherosclerosis, myocardial infarction and valvular heart disease.(2-6)  
 
The purpose of this thesis was to examine the utility of novel PET radiotracers in 
assessing common pathophysiological processes that drive aortic stenosis, adverse 
myocardial remodeling and atherosclerosis, gaining unique insight into these disease 
states with potential diagnostic and prognostic implications. 
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1.2 Positron Emission Tomography 
 
1.2.1. The Physics of Positron Emission Tomography  
 
Positron emission tomography (PET) is a non-invasive imaging technique that permits 
the identification and quantitation of active biochemical processes as they occur within 
the body. The positron is the anti-particle of the electron and is released by unstable 
positron-emitting nuclei, such as 18F-fluoride, 15O-oxygen or 11C-carbon, following 
radioactive decay of a proton to a neutron (beta decay).(7) The positron travels a short 
distance (millimeters) before colliding with an electron. This collision results in 
annihilation of both particles and the release of two photons that travel at almost 180º 
degrees to one another with a fixed energy of 511 keV (Figure 1.1). 
 
These fixed diverging photons provide the foundation of PET imaging, and may be 
detected using a ring of photon detectors that surround the patient. On the basis that 
two 511 keV photons detected in close temporal proximity by two opposing detectors 
are likely to have originated from an event somewhere along a straight line of response 
between them (the line of coincidence), a 3-dimensional (3D) PET image may be 
reconstructed using a summation of the detection events over a fixed period of 
scanning, and the computation of origins to these collisions (Figure 1.1).(7) 
 
PET tracers consist of a positron emitter combined to a molecular vehicle designed to 
interrogate a specific pathophysiological process of interest. 18F-Fluoride is the most 
commonly used positron emitter, as its relatively long half-life permits commercial 
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production and distribution. These tracers are injected into the patient and accumulate 
in areas where activity of that process is increased. The PET scanner detects the 
emitted radiation and constructs a map of tracer uptake. Given the short distance 
travelled by the positron before annihilation, PET images tend to lack spatial 
resolution compared to CT or MR datasets. Therefore, PET imaging is often performed 
using a combined scanner, incorporating both PET and CT within the same gantry. 
Patients lie in the same position for both scans, which allows the PET and CT scans to 
be superimposed upon one another. This serves two purposes. First, the CT can be 
used to perform accurate attenuation correction of PET data. As photons emerge from 
the body their path is slowed or indeed blocked by the surrounding tissue, which will 
distort the activity detected by the scanner and the resultant image. Information from 
CT can be used to measure the relative densities of the tissues in the body and correct 
for this effect, providing a more accurate, map of tracer accumulation. Second, co-
registration of the PET and CT images allows the more precise localisation of tracer 
uptake within the body.(8)  Radiation exposure is increased on account of performing 
both scans but remains modest, amounting to around 5 millisieverts using conventional 
tracers.  
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Figure 1.1.  The physics of positron emission tomography 
 
A diagram summarising the detection of diverging photons that are created following 
the collision and annihiliation of a positron and a nearby electron. Applying the 
assumption that detected protons will have originated at some point along the line of 
coincidence, an image is derived over the period of scanning to provide a 3-
dimensional topographic map of the emission of positrons, and hence the 








1.2.2. PET Image analysis 
 
Quantification of PET activity is most commonly performed using the fused 3D image 
dataset by placing regions of interest around the anatomical structure in question and 
measuring the concentration of radiotracer that has accumulated within that tissue of 
interest using the calculated mean or maximum standardized uptake values (SUVs). 
The SUV is the decay-corrected tissue concentration of a tracer divided by the injected 
dose per body weight; each image voxel (a 3D pixel) represents an SUV value that is 
derived during image reconstruction.  
 
These aggregate values may be further corrected for residual blood pool activity by 
expressing the activity as a ratio between activity within a vascular lumen (the superior 
vena cava, right atrium or left ventricle) and the tissue of interest: the tissue-to-
background ratio (TBR). Cardiovascular PET imaging may be hampered by both 
cardiorespiratory motion and the significant proximity to the blood pool. These factors 
amount to potential sources of error when quantifying the radiotracer signal within a 
cardiovascular tissue of interest, making the use of TBR quantification preferential 
over SUV values alone.  
 
Alternative methods for quantifying PET activity utilise a dynamic imaging approach. 
In this form, PET acquisition is started at the point of intravenous radiotracer 
administration and the PET data continuously acquired over a period of 30-90 minutes. 
The PET dataset may then be reconstructed to combine multiple 3D PET images of a 
shorter duration, forming a single dataset with sequential SUV values encompassing 
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the entire period of scanning. This allows the calculation of a time/activity curve 
(TAC) for each image voxel, enabling assessment of the tissue kinetics of the 
radiotracer; specifically, the rate of radiotracer uptake within each tissue, radiotracer 
half-life and rate of excretion, and the method by which the radiotracer interacts with 
the molecular process of interest. This may establish whether the radiotracer is 
reversibly or irreversibly incorporated into the tissue of interest, and therefore whether 
a quantification of cumulative SUV values are appropriate.(9-11) 
  
PET/CT imaging of the heart presents some unique challenges, most notably those 
related to cardiac motion. Whilst the heart is more stationary in diastole, significant 
motion occurs during the course of the cardiac cycle, which if uncorrected can lead to 
imperfect signal localization. However, the PET signal can be configured to the 
electrocardiogram so that only counts arising from diastole, when the heart is relatively 
stationary, are used for image reconstruction. This ‘gating’ can greatly refine the 
resolution of a cardiac PET signal, and can be extended to account for motion that 
accompanies respiration, which can further improve the accuracy of signal 
localization.(12,13)  
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1.3.  Pathophysiology of Aortic Stenosis: targets for 
molecular imaging 
 
1.3.1.  Prevalence and mechanisms of aortic stenosis 
 
Calcific aortic stenosis represents a major cause of morbidity and mortality in the 
western world. A recent population-based survey noted the prevalence of valve disease 
to be 2.5% in the adult population: a figure that is set to increase with a progressively 
aging population.(14) Despite this underappreciated and mounting health burden, we 
lack medical therapies and accurate means of predicting disease progression. In part 
this reflects our relatively poor understanding of the pathological processes underlying 
these conditions, and increasingly investigators are turning to new imaging techniques, 
to improve this knowledge and to identify novel targets for pharmacological 
intervention. 
 
Macroscopically, calcific aortic valve disease develops as early focal leaflet thickening 
and/or calcification without haemodynamic consequence. This ‘aortic sclerosis’ does 
not invoke a transvalvular pressure gradient. Over time valvular thickening and 
calcification causes reduction in the functional aortic valve area resulting in impedance 
to outflow and a significant transvalvular pressure gradient between the left ventricle 
and the aorta.(15)  This may be quantified as mild, moderate and severe in severity 
depending on the degree of haemodynamic obstruction. The left ventricle initially 
adapts to this increase in pressure afterload with a cardiomyocyte hypertrophic 
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response. Ultimately however, the degree of haemodynamic obstruction will result in 
ventricular decompensation and reduction in cardiac output, characterized by the 
evolution of heart failure, myocardial ischaemia or arrhythmia.(16) 
 
On a cellular level, there are four main active pathological processes that precipitate 
and propagate calcific thickening of the aortic valve; Inflammation, Calcification, 
Fibrosis and Angiogenesis.(17,18) Each will be discussed in due course. 
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1.3.2  Valvular Inflammation 
 
The initial development and the progression of calcific aortic stenosis shares many 
similarities with the active atheroinflammatory processes seen in atherosclerosis.  
Histological evaluation of early valve lesions show subendothelial thickening on the 
aortic side of the leaflets with overlying disruption of the basement membrane and 
accumulation of lipid, protein, extracellular mineralization and cellular infiltration of 
macrophages, lipid-laden foam cells and T-lymphocytes.(19) This is in contrast to the 
standard presence of scattered macrophages and mast cells, but no T-lymphocytes, 
found in normal aortic valves.(20)  
 
As with atherosclerosis, these early aortic valve lesions comprising of lipid-laden foam 
cells accumulate at sites of low shear stress and high mechanical stress (19,21). A 
combination of endothelial damage and lipoprotein accumulation likely triggers an 
inflammatory process within the valve. The low density lipoprotein (LDL) and 
lipoprotein(a) found within sclerotic valve leaflets are those also implicated in 
atherogenesis (22) and undergo oxidative modification. These oxidized lipoproteins 
are highly cytotoxic and proinflammatory, influencing the influx of macrophages and 
expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-
1) and vascular cell adhesion molecule-1 (VCAM-1), complement receptors C3a and 
C5a, transforming growth factor-β1 (TGF- β1) and interleukin-1β. (23) 
 
Systemic increases of C-reactive protein concentrations in patients with aortic 
stenosis, (24) and an increase in temperature in stenotic aortic valve cusps (25) 
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reinforce the concept of a significant inflammatory component to CAVD 
pathophysiology. However as yet the benefit of anti-inflammatory lipid-lowering 
therapy in aortic stenosis remains unproven.(26,27)  
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1.3.3. Valvular Fibrosis 
 
Stenotic aortic valve leaflets exhibit extensive remodeling of the extracellular matrix, 
manifested macroscopically as widespread leaflet thickening. Microscopically this 
fibrotic process is driven by fibroblast-like cells, or valve interstitial cells. These 
differentiate into myofibroblasts under the influence of the proinflammatory and 
profibrotic cytokines, integrin expression, TGF- β1 and angiotensin. These cells 
secrete α-smooth muscle actin (α –SMA) and type I collagen fibres, the production of 
which is increased in aortic stenosis leaflets.(28) They are also responsible for the 
imbalance of matrix metalloproteinases (MMP’s) and tissue-inhibitors of 
metalloproteinases (TIMP’s) that drives extracellular matrix remodeling.(29) 
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1.3.4. Valvular Angiogenesis 
 
Upregulation of intraleaflet angiogenesis maintains the inflammatory environment 
within stenotic valve leaflets. While phenotypically normal valve tissue is avascular, 
thickened valves are characterised histologically by abundant T-lymphocytes and 
evolving microvasculature, found in the highest density around cell nodules and in 
calcifying areas.(30,31)  The origin of these immature blood vessels is thought to be 
the valvular endothelial cells, proven capable of forming capillary-like sprouts and 
undergoing a partial transdifferentiation into vascular endothelium ex vivo.(32)  
 
Expression of angiogenesis-promoting factors such as integrin receptor αvβ3 , Vascular 
Endothelial Growth Factor (VEGF), its receptors Flk-1 and Flt-1, intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) are 
increased in neovasculature in animal and human models,(30,33) stimulated by 
decreased oxygen tension and allowing inflammatory cell entry. This friable leafet 
neovasculature is prone to rupture and subsequent haemorrhage, itself a potentially 
pathological mechanism associated with increased macrophage infiltration and more 
rapid rates of disease progression.(34) 
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1.3.5. Valvular Calcification 
 
The extent of aortic valvular calcification (AVC) burden on CT imaging is closely 
associated with the degree of haemodynamic severity,(35,36), and as a consequence 
may offer significant prognostic utility in the clinical assessment of aortic stenosis 
progression and outcome.(37-39) Progressive valvular calcification predominates the 
later stages of aortic stenosis and is largely responsible for its haemodynamic 
progression. In early sclerotic valve lesions microscopic areas of calcification exist as 
nodules containing hydroxyapatite, adherent to the extracellular matrix and co-
localising to sites of lipid deposition and inflammatory cell infiltration. Indeed, it is 
likely that valvular calcification occurs as a dysfunctional healing response to 
endothelial injury and oxidative stress.(18) In approximately 1/6th  of patients with 
aortic sclerosis, progressive leaflet calcification propagates, and ultimately the valve 
mineralization shows increasing histological similarities to lamellar bone, with 
features of active bone remodeling (osteoblastic bone formation and osteoclastic bone 
resorption), microfractures and haematopoetic tissue.(40,41)  The process is driven by 
osteoblasts, which differentiate from myofibroblasts and endothelial cells under the 
influence of the Runx2 pathway,(42) the osteoprotegerin (OPG)/Receptor Activator 
of Nuclear factor Kappa B (RANK)/RANK ligand (RANKL) pathway and increased 
levels of TNF-α.(43,44)  Numerous studies have also demonstrated the presence of 
osteogenic markers and osteoblast-specific proteins in calcified aortic valves. These 
include osteocalcin, osteopontin, bone morphogenic protein 2 (BMP2) and bone 
sialoprotein.(41,45)  
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The clinical management of aortic stenosis relies heavily on visualising and 
quantifying aortic valve function.  Current guidelines advise regular clinical follow-
up to track progression of haemodynamic obstruction and ultimately plan timely 
medical and / or surgical intervention. Echocardiography provides the most validated 
and established technique to evaluate aortic valve morphology, the degree of 
haemodynamic obstruction and the subsequent impacts on left ventricular structure 
and function. Cheap, portable and widely available, standardized echocardiographic 
measurements using Doppler analysis may clearly define the clinical severity of aortic 
stenosis allowing for serial comparisons over time. However, the technique is 
operator-dependent and vulnerable to variations in body-habitus, arrhythmia and 
cardiac output. More recently, alternative modalities have been evaluated including 
cardiac MRI with assessment of flow volumes, and the quantification of valvular 
calcification using computed tomography.(39,217)  These techniques offer superior 
anatomical resolution, and in the latter case prognostic information, but are expensive, 
less widely available and involve the use of ionizing radiation. 
 
The potential value that PET/CT offers over these aforementioned techniques is its 
ability not just to define clinical anatomy and the sequelae of a pathological process, 
but to define the activity of the pathological process itself. Whilst in principle PET can 
image any pathological process of interest, in practice clinical studies are limited by 
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the availability of tracers that have been approved for use in humans. As a result, with 
respect to the use of PET in aortic valve disease, the current literature has focused on 
two tracers, 18F-fluoride and 18F-fluorodeoxyglucose, which were originally 
developed for non-cardiac imaging but have recently provided key insights into 
different forms of cardiovascular disease (Figure 1.2).  
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Figure 1.2. PET in Aortic Stenosis 
 
Fused PET/CT images of the heart. A) An axial PET/CT image of the thorax taken 60 
mins following the adminstration of 125MBq of 18F-fluoride. Intense tracer uptake 
(red,yellow) is observed within the skeleton but also in the aortic valve in the centre 
of image B) An ECG-gated, short-axis PET/CT image of a mildly calcified aortic valve 
showing 18F-fluoride tracer uptake (red, yellow) adjacent to an area of established 
calcium on CT (white). C) A cross-sectional PET/CT image using the radiotracer 18F-
fluorodeoxyglucose (18F-FDG), displaying the intense myocardial uptake of 
radiotracer that is seen without a period of carbohydrate fasting prior to scanning D) 
A short-axis PET/CT image of the aortic valve following administration of 18F-FDG. 
Diffuse activity is observed within the calcified aortic valve. 
 
  





18F-FDG is a glucose analogue that is irreversibly taken up into cells by glucose 
transporter proteins, where it enters the glycolytic metabolic pathway. It is 
phosphorylated to 18F-FDG-6-phosphate, which cannot be metabolized further and 
becomes trapped within the cell. 18F-FDG therefore accumulates within cells with 
high metabolic (glycolytic) requirements. 18F-FDG PET is widely used in oncology 
practice, due to the increased metabolic activity exhibited by most cancer cells. More 
recently however, it has been used as a marker of metabolic activity of atherosclerosis. 
The arterial 18-FDG signal correlates with plaque macrophage burden, symptom 
status and cardiovascular risk factors.(46-49)  In addition, early data suggests that high 
arterial 18F-FGD uptake might be linked to future vascular events.(50-52)  Imaging 
of the coronary arteries and other structures close to the heart is difficult, because 
glucose is the major energy source for the myocardium. Intense myocardial activity is 
therefore frequently observed, which may spill over, obscuring the structure of interest 
(Figure 1.1C).  
 
The early stages of aortic stenosis share many similarities with atherosclerosis. 
Mechanical stress is believed to result in endothelial damage that permits lipid and 
inflammatory cell infiltration into the valve. These cells (predominantly macrophages) 
then secrete a series of inflammatory cytokines that drive the subsequent pro-fibrotic 
and pro-calcific processes responsible for progressive valve orifice narrowing.(17,18)  
There is therefore a clear rationale for using 18F-FDG to investigate the contribution 
of inflammation to aortic stenosis and this has been the focus of two recent studies.  




Marincheva-Savcheva and colleagues retrospectively examined 18F-FDG activity in 
the aortic valves of 42 patients with aortic stenosis and 42 subjects with normal valves 
who underwent PET/CT as part of an oncological assessment.(53)  They observed a 
diffuse increase in 18F-FDG activity within the valves of those patients with aortic 
stenosis compared to controls.  
 
Our group followed this with a prospective study of 121 patients with a full spectrum 
of calcific aortic valve disease, including 20 control subjects with normal valves and 
20 subjects with aortic sclerosis.(2)  These participants did not have cancer and were 
recruited into the study from cardiology clinics. Once more there was an increase in 
the 18F-FDG signal amongst patients with aortic sclerosis and aortic stenosis 
compared to the control subjects (Figure 1.1), and the 18F-FDG signal steadily 
increased with progressive valve narrowing with no drop off amongst patients with 
severe stenosis (n=23).  
 
To reduce myocardial 18F-FDG uptake we asked patients to avoid carbohydrates in 
the 24 hours prior to scanning in an attempt to switch the myocardium to a fat based 
metabolism, currently standard protocol in cardiac 18F-FDG imaging,(54), but this 
was only successful in two-thirds of subjects. However a combined approach where 
we also derived co-axial short axis images and restricted regions of interest to the 
center of the valve provided excellent measures of reproducibility without 
underestimating activity (presumably due to the diffuse nature of the 18F-FDG signal).   
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In combination, these studies demonstrate that the quantification of 18F-FDG activity 
in the aortic valve is both feasible and reproducible, and support an inflammatory basis 
for the pathophysiology of aortic stenosis. Further studies are required to provide 
histological validation of the 18F-FDG signal in the valve and to assess whether this 
technique might provide a useful marker of disease activity and progression.  
 
  





18F-Fluoride has been used as PET bone tracer for 40 years. It is directly incorporated 
into hydroxyapatite, a key structural component of both bone and vascular 
calcification, via an exchange mechanism with hydroxyl groups. In the skeleton, 18F-
fluoride uptake correlates with osteoblastic and osteoclastic activity, with uptake 
increased in conditions associated with high bone turnover and reduced in patients 
with osteoporosis (Figure 1.1).(55-57) Furthermore 18F-fluoride is used clinically for 
the detection of primary bone tumours and bony metastases. Its mechanism of uptake 
in the vasculature is less well understood.  Similar to bone it is believed to act as a 
marker of calcification activity, again binding to hydroxyapatite, which is laid down 
in the very earliest stages of new vascular calcium formation.  
 
Calcification is a key contributor to the development and progression of aortic 
stenosis.(17)  In the very early stages, microscopic areas of calcification exist as 
nodules containing hydroxyapatite that adhere to the extracellular matrix and can be 
observed co-localising to areas of lipid deposition and inflammatory cell infiltration. 
With time, fibroblasts within the valve differentiate first into myofibroblasts and then 
osteoblasts which subsequently co-ordinate calcification within the valve in a manner 
akin to skeletal bone formation.(42-44)  Indeed, by the later stages of the disease, 
hydroxyapatite crystals coalesce and remodel to form bone-like structures within the 
valve.(40)  The amount of established calcium present within the valve can be 
quantified using both CT and echocardiography, measures of which correlate closely 
with disease severity, progression and clinical outcomes in patients with  aortic 
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stenosis.(35,36,38,39)   However these techniques do not identify nor quantify the 
process of active calcification and remodeling, which is the rationale for 18F-fluoride 
PET scanning.  
 
Hyafil et al performed a pilot study of 5 patients with aortic stenosis and 10 patients 
with normal aortic valves, using 18F-fluoride PET/CT. Unlike with 18F-FDG PET 
imaging of the heart, there is very little tracer uptake within the myocardium and 
dietary restrictions are unnecessary. 18F-Fluoride activity measured in the aortic 
valves of patients with known AS were about 50% higher compared to those in patients 
free of valvular calcification.(58) 
 
Our group performed 18F-fluoride scanning on the same cohort of patients that had 
18F-FDG PET imaging, described above.(2) In total 45% of patients with aortic 
sclerosis and 91% of those with aortic stenosis had increased 18F-fluoride uptake. 
Interestingly the pattern of 18F-fluoride activity in the valve was often poorly aligned 
with the presence of established calcium on CT (Figure 1.1B), indicating that these 
two techniques provide different yet complementary information.  Similar to 18F-
FDG, 18F-fluoride uptake rose progressively with increasing valvular stenosis, 
however the rate of rise for 18F-fluoride was much steeper so that particularly in those 
with moderate and severe aortic stenosis it considerably outweighed the 18-FDG 
signal.  This suggests that calcification may predominate in the more advanced stages 
of the disease, supported by the increased CT calcium scores observed in the valves of 
these patients.  
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The pathological similarities between aortic stenosis and atherosclerosis led to the 
hypothesis that statin therapy might prove beneficial in the former. However this drug 
class has failed to impact on the progression of calcific aortic valve disease in three 
major randomised control trials: why was this?(26,27,59)   Comparisons of 18F-
fluoride and 18F-FDG activity in the valves of patients with aortic stenosis with their 
uptake in regions of coincident aortic atheroma were revealing. Calcification activity 
was greater in the valve compared to atheroma, based on their respective 18F-fluoride 
signals  (18F-fluoride TBR: 2.66±0.84 vs.2.11±0.31, P = 0.001) but interestingly the 
reverse was true for 18-FDG with inflammatory activity being higher in regions of 
atherosclerosis (18F-FDG TBR: 1.56±0.21 vs. 1.81±0.24, respectively, P <0.001).(60) 
This observation suggests key differences in the pathophysiology of these two 
conditions, indicating that inflammation may have a lesser role in aortic stenosis than 
atherosclerosis and perhaps explaining the differential effects of statins. 
  
The above studies underline the potential that PET/CT holds in assessing the 
pathological processes underlying aortic stenosis. It would appear that 18F-fluoride 
and 18F-FDG provide measures of calcification and inflammatory activity 
respectively, however several key questions still remain. First, there is a need to 
validate the PET signal histologically, particularly in the case of 18F-fluoride which 
has largely only been studied in bone. Secondly, it remains unclear whether this 
technique has the ability to predict disease progression in aortic stenosis. This remains 
clinically challenging, and a technique that might predict how quickly patients 
progress towards the need for intervention would be invaluable.  
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1.5. Pathophysiology of myocardial remodeling after 
myocardial infarction: targets for molecular imaging 
 
1.5.1 Pathophysiology of myocardial remodeling  
 
Over 1 million people suffer a myocardial infarction (MI) each year in the USA 
alone.(1) With improved treatment, more patients are surviving, resulting in an 
increased pool of candidates for maladaptive ventricular remodeling and heart failure 
after MI.(61) Importantly, as clinical presentation is changing with declining incidence 
of ST-elevation MI (STEMI) (62) and increasing age of the patients, the understanding 
of ventricular remodeling and approaches to risk stratification must also evolve.  
 
Adverse left ventricular (LV) remodeling is comprised of both short- and long-term 
changes in the LV shape, size, function and both cellular type and configuration after 
MI.(63,64) On a histological basis it evolves as a combination of myocyte hypertrophy 
and apoptosis, myofibroblast proliferation and interstitial fibrosis, both in the region 
of myocardial infarct and in the remote myocardium.(65,66) Macroscopically this is 
manifested as ventricular hypertrophy, dilatation and the formation of replacement 
collagen scar. While these alterations are necessary to preserve and restore myocardial 
integrity, adverse remodeling, clinically defined as an increase in LV dimensions 
following MI by at least 20%,(67) may develop in up to 30% of patients with MI.(68) 
Although clinical definitions of adverse remodeling and reports of prevalence may 
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vary, it universally infers significant increase in risk of heart failure and death. (66,69-
71) 
 
Multiple pathophysiological factors govern the extent of remodeling and the risk of 
progression to heart failure. The foremost determinants are extent of the initial 
myocardial insult, and the sufficiency of the post-MI reparative process. (64,72) 
Improvements in the early identification of MI using high-sensitivity biomarkers and 
increasingly efficient and effective revascularization techniques continue to address 
the former.(62) However, understanding and successfully manipulating the latter 
proves more challenging and elusive, in part because of the difficulty in translating 
potential pathophysiological targets into successful therapeutic practices. 
 
Myocardial healing following infarction can be divided into 3 sequential overlapping 
phases; an inflammatory phase, a proliferative phase (72hrs-7 days), and a maturation 
phase (7-14days).(73,74)  During these stages, an interplay of angiogenesis, 
inflammation and fibrogenesis determines the subsequent extent of preservation and 
restoration of myocardial integrity.(63)  
 
The inflammatory phase 
 
Shortly after the onset of irreversible cardiomyocyte ischaemia, cell necrosis and 
apoptosis results in the release of intracellular contents and the initiation of an intense 
inflammatory response. Complement activation, oxidative stress and toll-like 
receptor-mediated pathways serve to activate the nuclear factor kappa-B system, 
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which in turn promotes the release of inflammatory cytokines, chemokines and cell 
adhesion molecules.(64,73,75)  The subsequent margination and ingress of 
neutrophils, mast cells and monocytes into the infarcted region promotes ingestion of 
apoptotic debris and degradation of the extracellular matrix (ECM) through the release 
of matrix metalloproteinases to encourage formation of granulation tissue.(74,76) This 
inflammatory response is highly regulated however, and neutrophil levels peak early 
within myocardial infarct prior to apoptosis and clearance by activated 
monocytes/macrophages.(77)  Indeed, exaggerated inflammation within the infarct 
may encourage degradation in ECM integrity, and elevated concentrations of 
circulating neutrophils and monocytes after MI have been associated with increased 
risk of adverse remodeling through LV dilatation and aneurysm formation. (74,78,79) 
 
The proliferative phase 
 
The progression into a proliferative phase of infarct healing is promoted by the 
inflammatory-cell-rich environment capable of repression of pro-inflammatory signals 
and regulating a process of angiogenesis, fibroblast proliferation and ECM 
metabolism.(80)  This is stimulated firstly by the upregulation of cytokines and 
cellular adhesion molecules by macrophages and epithelial cells, including avb3 
integrin, TGF-ß, Tissue necrosis factor (TNF)-a, VGEF, hypoxia-inducible factor 
(HIF)-1, interleukin (IL)-6 and IL-1ß.(81,82) Secondly, there is an upregulation of the 
sympathetic nervous system secondary to a fall in cardiac output, and the subsequent 
increase in naturetic peptides and activation of the renin- angiotensin-aldosterone 
system (RAAS), promoting angiotensin II and reactive oxygen species release. 




At this stage the infarct may be infiltrated by vascular cells and fibroblasts.(80) The 
ensuing process of angiogenesis occurs as a means of restoring vascular integrity to 
infarcted tissue. This process is manifested in the formation of new blood vessels 
within the infarcted tissue (vasculogenesis), the proliferation of blood vessels in the 
ischaemic penumbra (angiogenesis) and re-epithelialisation of established vasculature 
perfusing the infarcted region.(82) Among other regulators, the avb3 integrin cell-
surface receptor has been identified as a critical modulator of angiogenesis, and 
angiogenic vessels display increased expression of the avb3 integrin in response to 
angiogenic growth factors. These receptors are fundamental to endothelial cell 
migration, adhesion, proliferation and survival.(83)  
 
The process of fibrogenesis may be further encouraged through the restoration of a 
capillary network. In this proliferative phase, enabled by migration and proliferation, 
activated fibroblasts become the dominant cell type within infarct tissue.(84) There 
are no reports of myofibroblasts in normal myocardial tissue.(85,86) Myofibroblasts 
express and incorporate a number of contractile proteins in the ECM, including a-
smooth muscle actin (a-SMA), serving to limit the size of the infarct zone while also 
producing high amounts of type III interstitial collagen to increase the structural 
integrity of replacement fibrosis. Sharing similarities with activated vascular 
endothelial cells, myofibroblasts express high levels of avb3 integrin that are essential 
for the promotion of collagen genes and reducing the expression of genes encoding 
MMP’s.(87-89) 
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The maturation phase 
 
Maturation of infarct scar follows restoration of vascular and ECM integrity. 
Myofibroblasts and vascular cells undergo apoptosis through a number of regulatory 
signaling systems including Fas, TGF-ß1 and angiotensin II receptor pathways.(86,90-
92) However, reduction in wall stress is a potent inducer of myofibroblast apoptosis 
in vivo,(93)  and a failure to normalize mechanical wall stress alongside the myocardial 
upregulation of the RAAS system may encourage ongoing myofibroblast activity long 
after the proliferative phase. In some circumstances, maladaptive persistent processes 
may encourage remodeling and infarct expansion to extend into the myocardium long 
after the initial causative injury abates.(94)  As a consequence of globally altered wall 
stress, myocardial interstitial modifications of the ECM post-MI is not limited to the 
site of infarction, and myofibroblast-driven fibrotic expansion may be seen in the 
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1.5.2 The avb3 integrin receptor and ventricular remodeling after MI 
 
Cell–cell and cell–extracellular matrix interactions provide the structural, chemical, 
and mechanical substrate required for regulation of cellular phenotype in specific 
environments. Integrins are a group of molecules responsible for intercellular adhesion 
and signalling, providing the critical interface between the cell and the matrix and may 
serve as a candidate mechanotransducer during cardiac development or in response to 
injury during pathophysiological stress.(119) They comprise a superfamily of 
heterodimeric receptors that are composed of 18 different a and b subunits. In 
combination, they can generate 24 different receptor subtypes with a range of 
physiological and pathophysiological functions.(97) The avb3 integrin cell-surface 
receptor recognises the amino-acid arginine-glycine-aspartate (RGD) motif present on 
a number of ligands responsible for proliferation and migration, including fibrinogen, 
fibronectin, laminin, TGF-ß1, VEGF-R2, MMP2 and von Willebrand factor. It allows 
vital cell-cell and cell-ECM interactions, in turn promoting intracellular processes and 
gene upregulation accordingly.  
 
The avb3 integrin is a unique receptor in that it is barely detectable on mature quiescent 
endothelial cells, monocytes and fibroblasts, but is markedly upregulated on activated 
vascular endothelial cells, macrophages and myofibroblasts to allow them to respond 
to extracellular ligands.(83,87,89,98,99) As such, avb3 integrin may be promoted as a 
prime candidate molecule for monitoring and manipulating the processes of 
angiogenesis, inflammation and fibrosis within the myocardium. Indeed, the receptor 
has been the focus of extensive oncological research as a potential target for diagnosis 
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and anti-angiogenic treatment. Numerous specialities have documented a reduction in 
pathological angiogenic activity through the modulation of avb3 integrin receptor 
activity. (100-106), and as a consequence it has become the focus of molecular 
imaging modalities that allow the real-time interrogation of angiogenic activity in 
vivo.(9,107,108) 
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1.5.3.  The evolution of RGD nuclear imaging probes 
 
A number of RGD-based imaging probes have been in development for over a decade. 
(109-113) Initially focused on oncological targets, they have shown utility in assessing 
the response to anti-angiogenic or cytotoxic therapy in both animal and human studies 
of malignancy.(9,109,114-117) Furthermore these tracers experience predominantly 
renal tracer elimination, resulting in low background activity in most regions of the 
body including lung and healthy myocardium.(10,110) High inter- and intra-individual 
variance in tracer accumulation between patients have been demonstrated, suggesting 
substantial heterogeneity of αvβ3 integrin expression.(110,112) 
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1.5.4  Integrin avb3 imaging and myocardial remodeling  
 
It is recognised that expression of avb3 integrin by vascular endothelial cells facilitates 
angiogenesis in the peri-infarct zone, while also mediating the activated macrophage 
response to inflammatory signals and governing myofibroblast differentiation through 
the activation of latent TGF-b1.(118-120)  As a result, there have been several pre-
clinical studies assessing the utility of avb3 integrin following acute MI. In 
predominantly murine models of myocardial infarction, RGD-based radiotracers have 
been seen to accumulate in the peri-infarct site as early as 3 days post-MI, and peak 
between 1-3 weeks, representative of acute LV remodeling (Figure 1.3, panel 
A).(119,121-132)  At later timepoints post-MI, the expression of avb3 integrin may 
persist and extend to myocardial regions remote to the infarct site.(119)  Indeed, 
Higuchi et. al. reported persistent low-grade avb3 integrin expression within the 
myocardial scar up to 6 months after infarction, long after the initial inflammatory and 
angiogenic remodeling phase abates and during a delayed phase of LV remodeling that 
is predominantly myofibroblast-driven (Figure 1.3, panel A). (86,121) They present 
serial histological assessments identifying vascular endothelial cells as the principal 
origin of myocardial avb3 integrin expression early after infarction (day 3), whereas 
diffuse myofibroblasts were the predominant source of avb3 integrin expression 1-3 
weeks and 6 months post-infarction.(121) A full summary of the preclinical findings 
are tabulated in Table 1.1. 
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Figure 1.3.  The temporal and spacial distribution of avb3 integrin 
expression following myocardial infarction. 
 
Panel A displays 18F-Galacto-RGD uptake on autoradiography in the murine heart 
after ischaemia and reperfusion (adapted from Higuchi et. al. 2008); the left image 
displays the distribution of uptake in apex, middle, and basal segments at different 
time points. The right image plots the time course of myocardial 18F-Galacto-RGD 
uptake along with sham-operated animals. Panel B displays co-localization of RGD-
tracer uptake on SPECT 3 weeks after MI with CMR-verified evidence of fibrosis at 1 
year (adapted from Verjans et. al. 2010). The first row demonstrates CMR images of 
anterior wall scar (white arrows) in short axis and 2-chamber views after 1 year. The 
second row shows equivalent views with 99mTc-RIP uptake 3 weeks after MI, 
corresponding to the subsequent scar formation on SPECT/MR fusion images on the 
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Table 1.1  Assessment of myocardial remodeling using RGD-imaging probes. 
 























Rats; day 14. 
Canines; days 
1,7 & 21. 
Uptake in myocardial tissue 
corresponding to regions of 
reduced perfusion, uptake 
peaking between 1-3 weeks 
post-MI 
avb3 integrin localized 
to peri-infarct and 














Days 1, 3 & 7  
Weeks 3,12 & 
26. 
Sham rats; day 
7. 
No uptake in sham operated 
rats. Absent uptake at day 1, 
peaking between 1-3 weeks. 
Persistent low-grade uptake at 
6 months. Uptake in infarct 
periphery at day 3, expanding 
into central infarct at day 7. 
avb3 integrin staining 
localizing to peripheral 
angiogenic cells on day 
3, and diffuse 
myofibroblast cells at 








VGEF or saline 
intramyocardial 





n=14 1 month 
(14 days after 
VGEF 
injection) 
RGD-tracer uptake ratio 1.7 ± 
0.1 of in infarct: remote 
myocardium in VGEF injected 
pigs. Ratio 1.0 ± 0.1 in sham-
injected pigs. 
None Greater RGD-tracer 
























animals; week 4 
Peak infarct RGD-tracer 
uptake at 2-weeks, persistent 
but reduced uptake in weeks 4 
and 12. Greater uptake in 
remote myocardium compared 
with sham operated. 
Direct correlation of 
RGD-tracer uptake 
with myofibroblasts 




uptake reduced after 
captopril or captopril± 
losartan (both 
p<0.001) compared 
with untreated rats.  
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3 days, weeks 1 
and 3, 4 months.  
 
RGD-tracer uptake in infarct 
from day 3 post-MI, peaking 
between 1 - 3 weeks. Uptake at 
4 months remained greater than 
sham-operated animals. 
infarct uptake peaking 
between 1- 3 weeks. 
avb3 Integrin localizing 














1 week. RGD-tracer uptake increased 
in infarct compared with 
remote myocardium and sham-










with remodeling at 12-
weeks (∆EDV; r=-













n=31 1 week RGD-tracer uptake increased 
in infarct, correlating with 
regions of hypoperfusion. 
RGD infarct uptake 















4 weeks RGD-tracer uptake increased 
in infarct and peri-infarct 
regions 
RGD infarct uptake 












n=4 Days 7, 14, and 
28  
Increased RGD-tracer uptake 
in hibernating myocardium, 
peaking at 7 days.  
RGD infarct uptake 




n et. al. 
2016.(127) 
Minipigs. MI 







Days 7 and 28. Increased RGD-tracer uptake 










Abbreviations: LAD, left anterior descending coronary artery; LCA, left coronary artery; LCx, left circumflex artery; MI, myocardial infarction; PET/CT, 
fused positron emission tomography / computed tomography; SPECT,single-photon emission computed tomography; VEGF,vascular endothelial growth 
factor. 
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Within these preclinical studies investigators addressed the potential for avb3 integrin 
imaging in the prediction of clinical outcome and to assess the response to therapeutic 
intervention. In a study by Johnson et. al. a VEGF-rich solution was injected directly 
into the myocardium of pigs 20 days after partial-thickness MI. Using single photon 
emission computed tomography (SPECT) 1 month after infarction, significantly 
greater RGD-radiotracer myocardial uptake was present in those animals receiving 
intra-myocardial VEGF compared with a similar injection of isotonic saline. 
Consistent with this observation, Sherif et. al. reported significant associations 
between increasing degrees of RGD-tracer infarct uptake on PET imaging performed 
1 week after MI, and improvements in ejection fraction and end-diastolic 
volume.(129) Conflictingly however, Van den Borne documented an opposite 
response to therapy with captopril with or without losartan in rats; those treated with 
RAAS-inhibitors displayed significantly reduced levels RGD-radiotracer infarct 
uptake on SPECT imaging 4 weeks after MI when compared to non-treated 
animals.(128)  
 
Despite encouraging preclinical findings however, there are limited translational 
studies reporting the use of RGD-radiotracers following MI in humans.(133-135) Sun 
et. al. report a series of 23 patients who underwent PET/CT with the RGD-tracer 68Ga-
PRGD2 between 3 days – 2 years after myocardial infarction. They observed 
myocardial uptake in 20 of these patients, although little additional clinical detail is 
provided. In the most thorough assessment to date in a cohort of 10 patients, Vergans 
et. al. report a close relationship between RGD-radiotracer myocardial uptake on 
SPECT imaging 3- and 8-weeks following acute myocardial infarction and residual 
myocardial fibrosis on cardiac MRI 6 months later.(134)   




Non-invasive molecular imaging of the avb3 integrin receptor in acute MI therefore 
holds the potential offer a comprehensive and potentially modifiable quantification of 
myocardial remodeling activity. However, data from human studies remain sparse, 
with small numbers of patients studied, an absence of control groups, clinical follow-
up, or histological validation. (119,121)  
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1.6.  Atherosclerosis; pathophysiology and targets for 
molecular imaging 
 
1.6.1. The role of nuclear imaging in atherosclerosis 
 
Atherosclerotic cardiovascular disease is the commonest cause of death in the 
developed world. Elucidating the mechanisms underlying the propagation and rupture 
of the atherosclerotic plaque therefore remain a key public health goal.(1) Considered 
a systemic inflammatory disease, atherosclerosis develops over a period of decades as 
a continuum of early vascular endothelial dysfunction, circulating macrophage 
recruitment and intimal accumulation, plaque maturation into a necrotic core, 
atherosclerotic plaque destabilisation and ultimately cap erosion or rupture.(136,137)  
The majority of plaque disease remains sub-clinical (asymptomatic). Some lesions 
may become obstructive, inducing symptoms of flow-limitation (eg. angina, 
intermittent claudication or mesenteric ischaemia), while a small proportion may 
develop features of vulnerability with predisposition towards thrombosis.(138-140) 
The erosion or rupture of unstable atherosclerotic plaque within the coronary or carotid 
circulation represents the primary cause of myocardial infarction, and 1/3rd of 
cerebrovascular accidents.(141)  
 
Over the last two decades’ enormous progress has been made in the understanding of 
atherosclerosis pathophysiology. Despite this, on an individual basis the accurate 
prediction of clinical events remains elusive.(142) It is well known that the risks of 
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atherosclerotic plaque rupture are poorly correlated with the severity of stenosis; 
indeed for an assessment of future cardiovascular risk in the asymptomatic patient, an 
accurate quantification of luminal stenosis using coronary CT angiography may be 
equivalent to the simpler technique of coronary calcification quantification.(143) The 
majority of plaque erosion or rupture is subclinical in nature, and driven by a number 
of local and systemic factors which each individually may not dictate a clinical 
outcome.(144-146)  There is therefore increasing demand for non-invasive imaging 
strategies that compliment luminal imaging and measure disease activity within the 
vasculature.(140)  Furthermore, a broadening in focus from the identification and 
targeted treatment of a single vulnerable plaque to identifying effective global markers 
of atherosclerotic disease activity may provide incremental risk prediction to the 
quantification of disease burden alone.(147) Indeed, sub-clinical atherosclerotic 
disease frequently co-exists in several vascular beds, representing a multi-systemic 
marker of adverse cardiovascular prognosis.(148-152) 
 
Fused PET/CT imaging holds great potential as a novel tool in the assessment of 
atherosclerotic disease, with an ability to non-invasively visualize active biological 
processes and thereby provide real-time quantification of multiple potentially 
modifiable processes driving atherosclerotic disease.(6,136,153) This technique is 
appealing to not only improve our understanding of plaque biology, but as a method 
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1.6.2. PET and the vulnerable plaque 
 
Inflammation and Calcification in the atherosclerotic plaque 
 
There are a number of pathophysiological processes of importance in atherosclerosis 
which hold the potential for visualisation using positron emission tomography. In 
particular, inflammation plays a critical role in plaque formation, progression and 
vulnerability. This chronic inflammatory state is initiated following the accumulation 
of low density lipoproteins (LDL) beneath sites of vascular endothelial disruption. In 
brief, these LDL particles undergo a process of oxidation and accumulation that results 
in an upregulation of pro-inflammatory molecules by the vascular endothelial cells, 
and the ingress of circulating monocytes and macrophages.(154,155) Regulated by 
avb3 integrin expression, monocyte-derived macrophages phagocytose oxidized LDL 
particles to create lipid-laden foam cells, forming a lipid pool. (156,157) This 
pathological intimal thickening is encapsulated through the formation of a ‘fibrous 
cap’, consisting of varying quantities of smooth muscle cells (SMC) within a 
collagenous-proteoglycan matrix.(138,155)  
 
With time, cellular apoptosis and autophagy result in the development of a necrotic 
core, consisting of macrophages and cellular debris within the lipid pool. Macrophages 
drive expansion of the necrotic core, and secrete matrix metalloproteinases that 
weaken the fibrous cap, predisposing it to rupture. Macrophage density within plaque 
correlates closely with progression and the size of the necrotic core and therefore 
represent a feature of high risk plaque morphology.(155,158) Early deposits of 
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microcalcification may develop within this necrotic core, and are also associated with 
plaque vulnerability.(159) The exact link between calcification and inflammation is 
unclear, however they are thought to be exocytosed from the cell membranes of 
apoptotic macrophages and vascular smooth muscle cells and therefore are closely 
linked to the inflammatory process.(160)  
 
Imaging of vascular inflammation using PET has been well documented. The glucose-
analogue 18F-FDG has been visualized in the aorta and carotid and coronary arteries, 
representing predominantly macrophage activity within atheromatous 
deposits.(4,6,48,49,161) Extensively validated, it is now being utilized as an imaging 
end-point in anti-atherosclerotic pharmaceutical intervention.(162,163) More recently, 
Dweck et al. have established the radiotracer 18F-fluoride as a marker of active 
calcification within both unstable and stable coronary disease,(6,60,164) and 
prospective trials assessing its utility in the prediction of future cardiovascular events 
is ongoing. 
 
Angiogenesis in the atherosclerotic plaque 
 
With an expanding necrotic core, increasing macrophage metabolic requirements and 
increased oxidative stress, the growth of fibroatheromatous plaque results in both an 
increased oxygen demand and impaired endothelial oxygen diffusion. This hypoxic 
environment creates a powerful angiogenic stimulus, and as a consequence a potential 
target for molecular imaging.(165,166) In response to hypoxia and inflammation, pro-
angiogenic growth factors including vascular endothelial growth factor A (VEGF-A), 
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platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) are released 
by macrophages, SMC’s and endothelial cells. These factors serve to both further 
recruit circulating inflammatory cells and promote endothelial proliferation, 
migration, and the formation of the vascular tubes.(167,168) The migration and 
adherence of endothelial cells to the ECM is mediated and enabled by avb3 integrin 
upregulation and the formation of a avb3 integrin / VEGF-receptor complex.(167) 
 
The histological characteristics of plaque angiogenesis reveal fragile microvessels 
sprouting from the adventitial vasa vasorum to perfuse the necrotic core. They are 
found in clusters within the  shoulder regions, the intima-media border and in the 
fibrous cap – regions predisposed to fissuring and rupture.(167)  While also providing 
a means of entry for inflammatory cells, these vessels often lack pericytes and smooth 
muscle cells and have poorly formed endothelial cell junctions, making them prone to 
leakage and rupture.(169) Microvessel rupture and intraplaque haemorrhage is a 
proinflammatory event  and a key determinant of plaque destabilization. (166,167,170-
173) 
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1.6.3. The imaging of integrin avb3 in atherosclerosis 
 
The avb3 integrin plays a key role in atherosclerosis in humans, both in the mediation 
of angiogenesis and the regulation of macrophages within fibroatheromatous plaque. 
(174-177)  Plaque inflammation and angiogenesis are two key pathological processes 
associated with disease progression, plaque rupture and clinical events.  A non-
invasive imaging technique that can inform about the activity of these two adverse 
pathological processes might therefore be useful in identifying patient with active 
high-risk atheroma.  
 
Several preclinical studies have utilized the avb3 integrin receptor for in vivo imaging 
of atherosclerosis. First reports used αvβ3-targeted paramagnetic nanoparticles to 
identify atherosclerosis within the aortic wall of hypercholesterolaemic rabbits on MRI 
imaging.(178,179) Laitinen et. al. subsequently assessed the RGD-based radiotracer 
18F-galacto-RGD alongside the 18F-FDG mimetic 3H-deoxyglucose in the aorta of 
hypercholesterolaemic mice using PET/CT.(180) They demonstrated increased uptake 
in atherosclerotic plaque that was associated with macrophage density on histology 
and showed equivalence to 3H-deoxyglucose uptake. Little angiogenesis was 
demonstrated within the atheroma, although further murine studies using SPECT and 
PET imaging have demonstrated aortic uptake of RGD-tracers within atherosclerotic 
plaque that correlated with histological markers of both inflammation and 
angiogenesis.(181-184) Importantly, serial PET/CT imaging by Saraste et. al. have 
shown that aortic 18F-galacto-RGD uptake may be modified using lipid-lowering diet 
intervention.(185)  




Murine models of hypercholesterolaemic atherosclerosis are limited by the lack of 
chronicity, and subsequently a difference in plaque morphology when compared to 
human atheroma. Although Golestani et. al demonstrated an ex vivo association 
between RGD-tracer uptake and neovasculature by imaging carotid endarterectomy 
specimens using microPET,(186) the in vivo assessment of RGD-tracers in human 
atherosclerotic disease is limited to a single PET/CT study of symptomatic carotid 
atherosclerosis. Within a group of 10 patients, 18F-galacto-RGD accumulation was 
demonstrated in stenotic atherosclerotic carotid plaques. Following endarterectomy, 
the in vivo PET/CT uptake correlated with histological quantification of avb3 integrin 
expression but only weakly with macrophage and endothelial cell staining.(187) 
 
The imaging of avb3 integrin expression in human atherosclerotic disease therefore 
remains in its infancy. Meanwhile, the oncological applications of RGD-tracer 
imaging have already demonstrated utility in the use of avb3 integrin imaging and 
assessment of response to antiangiogenic therapy.(188) Though early, the potential for 
avb3 integrin receptor blockade has been assessed both for the prevention of 
atherosclerosis and restenosis following arterial angioplasty,(175-177,189) furthering 
potential for the use of RGD-tracer imaging in the assessment of therapy response in 
humans. However, data from human studies remain sparse, and further studies are 
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1.7. 18F-Fluciclatide development and 
pharmacokinetics 
 
The RGD tracer 18F-fluciclatide has been developed by GE Healthcare as a PET 
imaging probe for imaging human αvβ3 integrin expression. Pilot studies have 
confirmed that it is safe, metabolically stable and able to detect breast cancer lesions 
by PET in most anatomical sites.(9) 18F-Fluciclatide was either homogeneously 
distributed in the tumors or appeared within the tumor rim, consistent with general 
principles regarding the distribution of angiogenesis within the viable outer zones of 
breast tumors.(9) Biodistribution studies confirm that 18F-fluciclatide-αvβ3 integrin 
receptor binding is predominantly irreversible within the imaging timeframe (70min) 
and therefore can be assessed using a 2-compartmental kinetic model derived from 
18F-FDG uptake analysis (the ‘patlak’ analysis). The biological half-life of 18F-
fluciclatide in whole blood is 0.25 ± 0.07 h. The blood clearance is biexponential, 
meaning that there is a fast redistribution component through the tissue compartments 
and a slower renal clearance component. The reported half-life value is a composite 
of both, confirming suitability for an imaging timepoint beyond 20 minutes post-
administration. However, while the faster component has a half-life of about 10 
minutes, the slower component has a half-life of around 6 hours. Therefore beyond 1 
hour post-administration it is this second term that predominates and imaging later is 
unlikely to improve a contrast to background ratio. Fortunately the mean (±SEM; 7 
patients) percentage of parent radioligand in plasma at 60 min after injection of 18F-
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fluciclatide was 74.48±3.18%, confirming minimal metabolism, with no evidence of 
active metabolites. (9,190,191) 
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1.8 Aims and hypotheses 
 
The overall aims of these studies are to assess the role of novel PET/CT imaging 
techniques in cardiovascular disease. A multimodality approach for assessment of 
PET/CT markers of calcification, inflammation, angiogenesis and fibrosis was 
undertaken. Specifically, we extend the work of Dweck et. al. with a focus on the 
validation and prognostic utility of 18F-FDG and 18F-fluoride PET-CT as markers of 
inflammation and active calcification in aortic stenosis.(2) Additionally, we will 
conduct an in-depth assessment of the ability for the novel αvβ3 integrin radiotracer 
18F-fluciclatide to provide complementary information to current imaging techniques 
in the assessment of atherosclerotic disease and remodeling following myocardial 
infarction.  
 
In Chapter 3, we will develop the methodology for a validation of 18F-FDG and 18F-
fluoride imaging of the aortic valve by combining a histological study of localising 
calcific and inflammatory processes with in vivo imaging findings and the 
confirmation of the specificity of radiotracer tissue uptake using autoradiography. We 
will then assess the ability of aortic valvular uptake of 18F-FDG and 18F-fluoride in 
vivo to predict the progression of aortic stenosis in a subgroup of patients using both 
echocardiographic and CT measures of disease severity. 
 
In Chapter 4, we will evaluate the associations between 18F-FDG and 18F-fluoride 
aortic valvular uptake and both progression of aortic stenosis and clinical outcome in 
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a large cohort of patients over a prolonged follow-up period. Further comparisons will 
be made with current gold standard prognostic assessments of aortic stenosis severity. 
 
In Chapter 5 we will perform a multimodality imaging and histological assessment of 
the heart following acute MI. Specifically, we will develop a methodology evaluating 
myocardial uptake of the novel radiotracer 18F-fluciclatide at multiple time points 
following MI using gated PET/CT, assessing its ability to assess myocardial 
remodeling activity in vivo and determining associations with temporal changes in 
myocardial structure and function on serial cardiac magnetic resonance imaging. 
Myocardial uptake of 18F-fluciclatide following MI will be compared to subjects with 
stable coronary disease and to healthy control patients. 
 
In Chapter 6 we will perform a multimodality imaging assessment of atherosclerosis 
within the thoracic aorta using the novel αvβ3 integrin radiotracer 18F-fluciclatide. 
Specifically, we aim to evaluate the ability for 18F-fluciclatide to quantify the activity 
of inflammation and angiogenesis within a spectrum of atherosclerotic disease severity 
and stability, validating our findings with a histological and autoradiographical study 
of carotid plaque.  
 
The following hypotheses will be addressed:   
 
1. That 18F-FDG and 18F-fluoride PET/CT provide an in vivo quantification of 
valvular inflammation and calcification respectively in calcific aortic stenosis 
(Chapter 3) 




2. That 18F-FDG and 18F-fluoride PET/CT aortic valvular uptake would 
correlate with subsequent disease progression and clinical outcome. (Chapter 
3 and 4) 
 
3. That the novel radiotracer 18F-Fluciclatide could identify the expression of the 
ανβ3 integrin receptor in vivo in man in 2 major cardiovascular disease areas; 
acute myocardial infarction and aortic atherosclerosis. Specifically, we 
hypothesized that 18F-Fluciclatide would 
a. Demonstrate selective uptake within the region of myocardial 
infarction in the early phase of recovery (1-3 weeks). (Chapter 5) 
b. Bind in both the infarct and remote regions of patients with substantial 
myocardial infarction in the later phases of recovery (6-12 weeks). 
(Chapter 5)  
c. Demonstrate associations with the temporal alterations in myocardial 
structure and function after myocardial infarction. (Chapter 5) 
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2.1  Overview. 
 
The specific study designs and methodology for each of the cohorts are described in 
detail in the relevant chapters. The following sections will provide the overview of the 
patient populations and the novel imaging modalities utilised in these studies.  
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2.2 Study Populations 
 
This thesis is based upon the study of 2 patient groups prospectively recruited from 
the Royal Infirmary of Edinburgh, Edinburgh, UK. One group of patients with a 
spectrum of calcific aortic valve disease had undergone PET imaging with 18F-FDG 
and 18F-fluoride as part of a pre-existing research study (‘The Ring of Fire Study’, 
NCT01358513). In the second group a population of patients with either ischaemic 
heart disease or calcific aortic valve disease underwent PET imaging with 18F-
fluciclatide. All PET-CT and CMR studies were performed by speciality radiographers 
under the supervision of study investigators at the Clinical Research Imaging Centre 
(CRIC) in the University of Edinburgh. Validation of the in vivo imaging findings was 
obtained through histological and autoradiographical analysis of human tissue samples 
obtained from the study population and carried out in the Queens Medical Research 
Institute of the University of Edinburgh. The studies were performed with the written 
informed consent of all participants.  
 
  
Novel Applications of PET in Cardiovascular Disease 
 
82 
2.2.1. 18F-Fluoride and 18F-FDG in Aortic Stenosis 
 
Patients aged >50 years with aortic sclerosis and mild, moderate or severe aortic 
stenosis attending the outpatient department of the Royal Infirmary of Edinburgh were 
considered for participation in this prospective cohort study, alongside age- and sex-
matched control subjects, as described previously.(2,164) Exclusion criteria were 
insulin-dependent diabetes mellitus, blood glucose >200 mg/dL, end-stage renal 
failure (estimated glomerular filtration rate <15 ml/min), life expectancy of <2 years, 
metastatic malignancy, and inability to undergo PET/CT scanning. In the prospective 
cohort, an additional exclusion condition included planned aortic valve surgery (and 
therefore symptoms attributed by their physician to their valve disease). In addition, 
for the purposes of a histological validation of PET findings patients with severe 
symptomatic aortic stenosis under evaluation for surgical aortic valve replacement 
were considered for PET/CT imaging pre-operatively. Intra-operatively the resected 
aortic valve tissue was retained for histological examination and autoradiography. 
Patients were not approached if they fulfilled any of the exclusion criteria or if their 
clinician felt participation was not appropriate. Control subjects were selected on an 
age- and sex-matched basis with a structurally normal aortic valve and similar degree 
of co-morbidity.  
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2.2.2. 18F-Fluciclatide in Myocardial Infarction and Aortic 
Atherosclerosis 
 
PET/CT scanning with 18F-fluciclatide and CMR were performed in participants 
recruited from Royal Infirmary of Edinburgh. Exclusion criteria were age <40 years, 
women of childbearing potential not taking contraception, severe renal failure (serum 
creatinine >2.8 mg/dL) or hepatic failure (Childs-Pugh grade B or C), atrial 
fibrillation, contrast allergy, inability to undergo scanning and inability to provide 
informed consent. Patients were not approached if they fulfilled any of the exclusion 
criteria, showed evidence of clinical instability or if the designated clinical team felt 
participation was not appropriate. The following 4 groups of participants were 
considered: 
 
• Acute MI group. Patients with recent acute ST-segment elevation MI and peak 
high-sensitivity cardiac troponin I (hs-cTnI) >10,000 ng/L treated at the Royal 
Infirmary of Edinburgh. 
• Chronic Total Occlusion (CTO) group. Patients with an angiographically-
documented complete occlusion of a major epicardial artery and stable cardiac 
symptoms for >6 months. 
• Control group. Healthy volunteers with normal left ventricular systolic 
function, no structural heart disease, and no symptoms of heart failure or MI 
underwent a single PET/CT with 18F-fluciclatide and CMR. 
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• Aortic Stenosis group. Patients with aortic sclerosis and mild, moderate and 
severe aortic stenosis attending the outpatient department of the Royal 
Infirmary of Edinburgh.  
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2.2.3. 18F-Fluciclatide histological validation studies 
 
For ex vivo histological validation studies, two groups of patients were considered. 
These patients did not undergo 18F-fluciclatide PET/CT imaging: 
• Myocardial biopsy group. Patients with large ST-elevation MI (<14 days, hs-
cTnI >10,000 ng/L) scheduled to undergo coronary artery bypass grafting at 
the Royal Infirmary of Edinburgh were considered for intra-operative 
myocardial biopsy.  
• Carotid endarterectomy group. Patients with a recent TIA or minor ischemic 
stroke and a high grade internal carotid artery stenosis (≥50% by NASCET 
(North American Symptomatic Carotid Endarterectomy Trial) criteria for men, 
≥70% for women) scheduled to undergo carotid endarterectomy (CEA) were 
considered for retention of endarterectomy samples.(192) 
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2.3.  Ethical considerations 
 
All studies gained ethical approval from the South East Scotland Research Ethics 
Committee and were conducted in accordance with the Declaration of Helsinki of the 
World Medical Association. Administration of the radiopharmaceutical was approved 
by the Administration of Radioactive Substance Advisory Committee, United 
Kingdom. The studies were registered on www.clinicaltrials.gov (reference numbers 
NCT01358513, NCT01813045 and NCT01837160). Written informed consent was 
obtained for all patients.  
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2.4 Positron Emission Tomography and Computed 
Tomography 
 
For each patient enrolled in to the PET/CT studies, combined PET/CT scans of the 
thorax were performed using a hybrid scanner (Biograph mCT, Siemens Medical 
Systems, Erlangen, Germany).  On arrival in the CRIC all following study procedures 
were reviewed and opportunities for study withdrawal at any stage were clearly 
emphasised. Patient height and weight were measured on a consistent set of scales, 
calibrated to the PET scanner. An intravenous cannula was inserted and 30 mls of 
blood drawn. Clinical assessment was performed including clinical examination, 
measurement of blood pressure and pulse rate and 12-lead electrocardiography. 
Bloods were sent for measurement of full blood count, urea and electrolytes, serum 
calcium, phosphate and alkaline phosphatase. Serum C-reactive protein concentration 
was measured using the MULTIGENT CRP Vario assay on the ARCHITECT system 
(Abbott Laboratories, Abbott Park, IL, USA). The remainder was centrifuged at room 
temperature (10 minutes, 3000rpm) and serum was aliquoted and stored in event of 
future use at -70 degrees Celsius. Patients were then transferred to the lead lined uptake 
room where video surveillance was performed throughout. Patients rested on 
phlebotomy couches for the duration of radiotracer uptake. Toileting facilities with 
restricted access to the general public and other staff members were in close proximity 
and patients were encouraged to bring reading material with them.  A proportion of 
patients underwent dynamic PET acquisition from the moment of IV radiotracer 
administration. Following PET/CT scanning, patients were allowed to leave the 
department under instruction to avoid close physical contact with babies or pregnant 
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females for the remainder of the day. Standardised pre-scan procedures and image 
acquisition varied for each radiotracer studied and are described below. Although 
additional 18F-fluoride and 18F-FDG PET/CT scans were performed for the purposes 
of the histological validation study, the imaging protocols for the ‘Ring of Fire’ study 
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2.4.1. 18F-Fluoride PET/CT 
 
18F-Fluoride tracer was synthesized in the Clinical Research Imaging Centre by 
radiopharmaceutical staff and administered intravenously to the patient in the uptake 
room. A target dose of 125 MBq was delivered with precautions taken to minimize 
radiation exposure to the operator. Patients rested in the quiet environment of the 
uptake room for 60-minutes before being transferred to the PET scanner. Patients lay 
supine with their hands above their head and 3-lead ECG monitoring was attached to 
permit ECG-gating. An attenuation correction CT scan (non-enhanced low-dose 120 
kV and 50 mAs, pitch 0.8, field of view 780mm, 5mm slice thickness, 3mm increment, 
B19f LowDose kernel, standard filtered back projection reconstruction algorithm) was 
performed followed by PET imaging covering two bed positions centered over the 
heart in 3-dimensional mode for 10 min. Immediately after PET acquisition an ECG-
gated breath-hold cardiac CT scan (non enhanced, 40 mAs/rot [CareDose], 100 kV, 
Pitch 0.24, field of view 210mm, 3mm slice thickness, 1.5mm increment, B35f kernel, 
standard filtered back projection reconstruction algorithm) was performed for 
calculation of the aortic valve calcium scores. Under standardized acquisition 
protocols the mean radiation dose for each 18F-fluoride PET scan was 2.9±0.1mSv 
(range 2.8-3.1mSv). The mean attenuation correction CT acquisition radiation dose 
was 1.0 ± 0.4mSv (range 0.5-1.8mSv) and CT calcium scoring scan dose 1.3±0.5 mSv. 
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2.4.2. 18F-FDG PET/CT 
 
The 18F-FDG tracer was synthesized in the Clinical Research Imaging Centre by 
radiopharmaceutical staff and administered intravenously to the patient in the uptake 
room. A target dose of 200 MBq 18F-FDG was injected and patients rested in the 
uptake room for 90 min. Patients were then transferred to the PET scanner in a similar 
manner but without ECG gating. Combined PET/CT imaging was then performed as 
described for the 18F-fluoride scan but over an acquisition period of only 15min. The 
duration of radiotracer uptake for 18F-fluoride and 18F-FDG was based on previous 
cardiovascular PET studies and aimed to allow for optimal contrast between the aortic 
valve and blood pool.(49,193,194) 
 
Due to the high metabolic requirements of cardiomyocytes, 18F-FDG is naturally 
sequestered within the left ventricle in cardiomyocyte uptake, leading to significant 
spillover of PET signal into adjacent structures. While certain diagnostic applications 
of 18F-FDG PET may utilize this, aortic valve imaging requires suppression of this 
uptake. All patients undergoing 18F-FDG imaging were asked to observe a 
carbohydrate-free diet for 24 hours prior to their 18F-FDG scan to switch 
cardiomyocytes from a glucose to free-fatty acid metabolism.(54,195) Patients were 
provided with a list of food and drink to avoid. Adequate myocardial tracer uptake was 
then assessed during image analysis by measuring the maximum standardised uptake 
value (SUV, kBq/mL) in the LV septum.  The SUV is a semiquantitative unit of 
radiotracer activity within the tissue of interest that is corrected for both isotope decay 
and the injected dose per body weight. It is a widely used and validated measure of 
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tissue radiotracer uptake.(196) Low myocardial 18F-FDG uptake was derived as an 
SUV value <5.0 kBq/mL uptake, indicating successful myocardial suppression. 
Inadequately suppressed myocardial uptake was defined by measurements ≥5.0 
kBq/mL.(197)  Under standardized acquisition protocols the mean radiation dose for 
each 18F-FDG PET/CT scan was 4.9±0.5 mSv.  
 
2.4.3. 18F-Fluciclatide PET/CT 
 
18F-Fluciclatide was manufactured at the Clinical Research Imaging Centre on an 
automated module (FASTlab synthesiser; GE Healthcare) by coupling an amino-oxy-
functionalized peptide precursor (AH111695) with 4-18F-fluorobenzaldehyde at pH 
3.5 to form 18F-fluciclatide. A full description of this synthesis has been published 
previously. (117,190,198)  Subjects were administered a target dose of 230 MBq. To 
assess 18F-fluciclatide cardiovascular pharmacodynamics and the optimum timing of 
PET scanning following radiotracer administration, dynamic PET imaging of the 
thorax was performed in the first 20 subjects in 3-dimensional mode with a single bed 
position for 70 min. These patients received radiotracer administration within the 
scanner simultaneous to initiating PET acquisition. The remainder of study subjects 
underwent static imaging performed at the optimal time point (40 min post-injection) 
using a single 30-min bed position in list mode. An attenuation-correction CT scan 
(non-enhanced 120 kV and 50 mA, 3-mm slices) was performed prior to PET 
acquisition, and electrocardiographic (ECG) gating was performed throughout.  Under 
standardized acquisition protocols the mean radiation dose for each 18F-fluciclatide 
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PET scan was 5.9 mSv (range 5.2-6.4 mSv). The mean attenuation correction CT 
acquisition radiation dose was 1.4 mSv (range 0.8-1.9 mSv).  
 
To enable an accurate definition of cardiac anatomy cardiac CT angiography was 
performed on the hybrid scanner immediately after the PET acquisition. If necessary 
and clinically appropriate, 5 mg intravenous metoprolol was administered in patients 
with a heart rate of greater than 60 beats/min. For the acquisition, the following 
settings were used: 330 ms rotation time, 100 (body mass index <25 kg/m2) or 120 
(body mass index >25 kg/m2) kV tube voltage, 160-245 mAs tube current, 3.8 
mm/rotation table feed, prospective (heart rate regular and <60 /min), or retrospective 
(heart rate >60 /min) electrocardiogram-gated. Depending on the body mass index, a 
bolus of 80-100 mL contrast (400 mgI/mL; Iomeron, Bracco, Milan, Italy) was 
injected intravenously at 5 mL/s, after determining the appropriate trigger delay with 
a test bolus of 20 mL contrast material. Cardiac CT contrast angiography dosing was 
6.7mSv (range 2.1-11.7 mSv); the wide dose range accounted for the potential 
presence of atrial fibrillation that prevents prospective ECG gating. 
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2.5 Image Reconstruction and Analysis 
 
2.5.1. Image reconstruction 
 
The PET data were reconstructed using the Siemens Ultra-HD (time of flight +True 
X) reconstruction algorithm. Corrections were applied for attenuation, dead time, 
scatter and random coincidences.  All image analysis was performed on fused PET/CT 
data sets. For 18F-FDG and 18F-fluoride scans, the field of view was 780mm and a 
512 matrix size was used for reconstructions so the voxel size was 1.5 × 1.5 × 3.0mm.    
 
For the static gated 18F-fluciclatide imaging datasets, ECG-gated PET images were 
reconstructed in diastole (40-70 min post-injection, 50–75% of the R-R interval) using 
the Ultra-HD algorithm in 2 iterations, 24 subsets with zoom of x2 and 200 pixels. For 
the kinetic analysis of 18F-fluciclatide scans, the dynamic PET data were 
reconstructed with the Ultra-HD algorithm, in 2 iterations, 21 subsets, 256 pixels and 
1.6-mm pixel size. Using a dynamic protocol without ECG gating, following time 
frames were applied; 60s x 5, 120s x 5, 180s x 5, 300s x 8.  
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2.5.2. Image Analysis 
 
Anonymised PET image datasets were analysed by experienced observers blinded to 
the clinical details using an OsiriX workstation (OsiriX version 6.0 64-bit; OsiriX 
Imaging Software, Geneva, Switzerland). The PET images were fused with CT or 
contrast CT datasets and regions of interest (ROI’s) were drawn within the tissues of 
interest. (2,6,48,60,161,164) The mean and maximum SUV measurements from each 
ROI were collated in each tissue of interest to derive a mean measure of radiotracer 
accumulation corrected for residual blood pool activity within the superior vena cava 
(SVC). Specifically, quantification of aortic valve PET uptake was performed on 
modified co-axial views of the non-contrast fused PET/CT datasets (Figure 2.1), while 
myocardial 18F-fluciclatide uptake was quantified on modified co-axial views of the 
left ventricle using contrast-enhanced CT/PET, both by delineating regions of 
myocardial infarct confirmed on cardiac MRI, and additionally by segmenting the 
myocardium into a standardised 16-segment model (Figure 2.2).  Aortic 18F-
fluciclatide uptake was quantified using non-contrast CT/PET images in the axial 
views (Figure 2.3).  
 
Kinetic analysis was undertaken on the dynamic PET data to examine the mechanisms 
of uptake of 18F-fluciclatide within the myocardium and vasculature. ROI’s drawn in 
the tissue of interest were used to derive time-activity curves after decay correction. 
An input function calculation based on the PET image–derived activity curve from the 
aorta blood pool (199) and the myocardial time-activity curve were used to estimate 
the tissue influx rate Ki (the slope of the linear regression) and the volume of 
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distribution (the y-axis intercept) using a 2-tissue irreversible Patlak model.(9,10) 
Thoracic 18F-fluciclatide dynamic activity was then normalized for the blood-pool 
input function on a voxel-by-voxel basis, and after 3D Gaussian filtering (5-mm 
FWHM) a parametric 3-dimensional image of 18F-fluciclatide uptake was generated 
(PMod version 3.409, Pmod technologies limited, Switzerland). Using this image, 
regions of 18F-fluciclatide binding were identified and manually delineated for 
subsequent Ki analysis. 
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Figure 2.1.  Quantifying radiotracer uptake within the aortic valve  
 
18F-Fluoride and 18F-FDG valvular uptake was quantified by re-orientating the 
sagittal (A) and coronal (B) views to create a modified co-axial view of the aortic 
valve (C). The PET dataset was then re-registered into this plane (D) and fused with 
the CT (E). Regions of interest around the aortic valve were drawn (F) to calculate 
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Figure 2.2.  Assessment of myocardial 18F-fluciclatide uptake.  
 
For quantification of myocardial 18F-fluciclatide uptake, the sagittal and axial planes 
of the CT coronary angiogram (CTCA) (A) were reorientated to provide a short axis 
view of the left ventricle (B) that corresponds to the views obtained from late 
gadolinium enhancement (LGE) imaging during cardiac MRI (C). 18F-Fluciclatide 
PET datasets were re-registered to the short axis CTCA images (D) and fused to create 
a PET/CTCA image (E). Assisted by the location of myocardial infarct on LGE 
imaging (i), we can delineate the regions of myocardial infarct (ii; anterior, 
anteroseptal and inferoseptal segments) and remote myocardium (iii; basal lateral 
and inferolateral segments) (F) to calculate standardized uptake values. 
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Figure 2.3.  Assessment of aortic 18F-Fluciclatide uptake 
 
In this illustration, we can identify regions of calcified and non-calcified atheroma 
within the descending aorta on the axial CTCA images (A). By manually drawing 
regions of interest along the adventitial border of the aorta on the attenuation CT (B), 
we both calculated CT calcium scores (C) and applied them to the PET image to derive 
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2.6.  PET Repeatability Studies 
 
The reproducibility of the quantification of aortic valvular 18F-FDG and 18F-fluoride 
uptake has been previously reported.(2) Each analysis favoured a method re-
orientating the PET/CT images into a modified-coaxial plane, providing a short-axis 
view of the aortic valve, left ventricular outflow tract (LVOT) and ascending aorta. 
Briefly, quantification of 18F-fluoride valvular uptake (TBRmean) displayed excellent 
reproducibility. There were no fixed or proportional biases, and the majority of data 
fell within narrow limits of agreement (±0.20). Intraclass coefficients for interobserver 
and intraobserver repeatability were all >0.95. 
 
The reproducibility of 18F-FDG valvular uptake quantification was impacted by 
potential spillover of PET signal from adjacent myocardium, necessitating the use of 
smaller regions of interest limited to the central portion of the valve.  This was termed 
the ‘center-valve technique’, and demonstrated no fixed or proportional biases in the 
differences between interobserver and intraobserver measurements with narrow limits 
of agreement (<±0.20). Intraclass coefficients were all >0.90, indicating excellent 
agreement.(2) 
 
All repeatability studies in this thesis were performed with the observers blinded to 
identifying data within the PET datasets using cloaking programs within the image 
analysis software, with the assistance of study investigators. Similarly, in histological 
repeatability studies the assessor was blinded to any identifiable information by a 
separate study investigator. 




The intraobserver and interobserver reproducibility of myocardial 18F-fluciclatide 
uptake quantification was assessed by two experienced observers (Dr. William 
Jenkins, Dr. Catriona Moles) in both the blood pool and the myocardium in 10 subjects 
selected at random. Residual blood pool radiotracer activity was quantified within both 
the SVC and right atrium. 
 
For the assessment of aortic 18F-fluciclatide uptake, datasets from 10 randomly 
selected subjects were assessed independently by two experienced observers (Dr. 
William Jenkins and Dr. Anna Vickers) and the inter-observer reproducibility of 18F-
fluciclatide SUV and TBR measurements assessed. 
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2.7.  Histological Validation Studies 
 
2.7.1.  Overview 
 
In order to determine the validity of the imaging observations made during these 
studies we applied a number of histological techniques in valvular, myocardial and 
vascular tissue. The histological analyses were performed by study investigators (Dr 
William Jenkins, Dr Marc Dweck and Dr Alexander Vesey) under the guidance and 
tuition of the Queens Medical Research Institute histopathology director (Dr Mike 
Miller) with support of Consultant Pathologists Dr William Wallace and Professor 
Donald Salter. Specifically we assessed for ex vivo evidence of calcification (tissue-
specific alkaline phosphatase [TNAP], osteocalcin, von kossa stain), inflammation 
(CD68), fibrogenesis (smooth muscle actin [SMA]), angiogenesis (CD31) and the 
presence of integrin αvβ3 antibody.  
 
Calcification is the key propagator of calcific aortic valve disease, and was studied 
histologically using measures of calcification activity (TNAP, osteocalcin) and 
established calcification (von Kossa staining). The enzyme TNAP is a key regulator 
of the availability of extracellular pyrophosphate, and its expression leads to a 
reduction in the inhibition of biomineralisation.(200) Osteocalcin is a small protein 
secreted by osteoblasts and is an active modulator of VSMC cell signaling and 
osteochondrogenic differentiation. (201,202) The histological assessment of TNAP 
and osteocalcin has been associated with 18F-fluoride uptake in the vasculature. (6) 
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Von Kossa stain allows the identification of elemental phosphate (i.e. calcium 
orthophosphate) through a precipitation-reaction. 
 
Inflammation is a key component of calcific aortic valve disease, atherosclerosis and 
myocardial remodeling.(17,203,204) The glycoprotein CD-68 is a expressed on 
activated macrophages, and its cellular staining has previously closely correlated with 
carotid uptake of 18F-FDG.(49)  
 
The tissue detection of active fibrogenesis may be visualized histologically using 
staining for alpha-SMA (aSMA). Activated myofibroblasts that express the protein 
complex aSMA are key to the proliferative phase of scar formation within the 
myocardium(75,80) and as such, histological examination for aSMA-positive 
myofibroblasts provides a well validated measure of fibrogenesis. (205) Similarly, the 
CD31, or platelet endothelial cell adhesion molecule-1 (PECAM-1), is found in large 
quantities on the surface of activated vascular endothelial cells, and plays a major role 
in a number of cellular interactions during angiogenesis.(206)It is a well validated 
marker of angiogenesis activity and has been utilized both in the assessment of 
atherosclerosis and the healing response post-MI. (207,208)  
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2.7.2. Aortic Valve Histological Assessment 
 
In the patients undergoing aortic valve replacement, the aortic valve was removed at 
the time of operation with care taken to preserve the integrity of the valve architecture. 
Samples were then fixed in 4% paraformaldehyde for 24 hours. Plaques were 
decalcified in ethylenediaminetetraacetatic acid for 10 days, embedded in paraffin and 
5-µm sections prepared. Immunohistochemical staining for osteocalcin (anti-human 
mouse mAb ab13418, Abcam), CD68 (anti-human mouse clone PG-M1 m0876, 
DAKO) and tissue non-specific alkaline phosphatase (TNAP; anti-human rabbit pAb 
CAT#LF PA50004, Abfrontier) was then undertaken following heat-induced epitope 
retrieval (HIER) using a Citrate Buffer pH 6 (Novocastra Leica microsystems) in a 
decloaking chamber. Osteocalcin staining required no HIER. Sections were stained 
using a Leica Vision Biosystems Bond x immunostaining robot. After blocking in 
peroxide for 10 min, sections were incubated with the specific anti-human antibodies 
for 2 hours at room temperature at the following dilutions: osteocalcin 1:200, tissue 
non-specific alkaline phosphatase 1:100 and CD-68 1:100. All incubation steps were 
followed by washing in TBS/Tween.  Sections for osteocalcin and CD68 were 
incubated for 15 min with pre-polymer/post primary followed by 15 min with polymer 
(HRP) for all antibodies prior to DAB (3,3’diaminobenzidine) visualization and 
haematoxylin counterstain. Sections were dehydrated in graded ethanol, cleared in 
xylene before cover slipping in Pertex.  
 
Images were taken on a Zeiss Axioskop2 fitted with an Axiocam MRc digital camera 
using Axiovision software. Tissue cross-sectional area on each section was manually 
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delineated using Image Pro Plus 5 (Rockville, MD, USA). Immunohistochemical 
staining for osteocalcin and TNAP was identified by visual assessment and quantified 
using automated color-based segmentation by a trained observer blinded to the PET 
data.  Staining was expressed as a percentage of the total valve area. Macrophage 
infiltration using CD68 was assessed using a similar approach but with an object size 
set threshold applied at 20 x 10 pixels, to limit counting to cell-sized objects. The 
density of cell staining in the valve tissue was expressed as cells per mm2. This 
technique was also utilized to identify cellular staining for TNAP and osteocalcin.  
 
Interobserver reproducibility of the immunohistochemical data was also investigated. 
Tissue staining with alkaline phosphatase, CD68 and osteocalcin was quantified in 5 
valves independently by two trained observers (Dr William Jenkins, Dr Alex Vesey). 
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2.7.3. Aortic Valve Autoradiography 
 
Clinical PET systems have limited resolution. In order to gain further information 
about the precise localization of the 18F-fluoride signal in aortic valve tissue, we 
undertook autoradiography.  Non-decalcified valvular tissue was rapidly cooled in dry 
ice and then sectioned at 7-µm thickness using a cryostat (CM1520 Wetzlar, 
Germany).  Sections for autoradiography were mounted on Superfrost slides (Gerhard 
Menzel, Braunschweig, Germany) before treatment with spray fixative.  Sections were 
bathed in a solution of 18F-fluoride at a concentration close to in vivo imaging 
concentrations (1 kBq/mL) for 60 min and then rinsed with PBS.  A freshly blanked 
phosphor screen was then placed over the slides and an overnight exposure 
undertaken.  The screen was then read using a FujiFilm FLA-5100 Fluorescent Image 
Analyser (Raytek Scientific Limited, Sheffield, UK).  Sections adjacent to those used 
for autoradiography were stained for elemental phosphate (i.e. calcium 
orthophosphate) using Von Kossa’s stain, and following surface decalcification in situ 
with Von Ebner’s solution, for TNAP and osteocalcin.  Sections were then manually 
registered and examined for co-localization with 18F-fluoride signal. 
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2.7.4. Myocardial biopsy histological assessment 
 
Myocardial biopsy samples were obtained from patients undergoing coronary artery 
bypass grafting following myocardial infarction. A core cardiac biopsy was taken 
intra-operatively under direct visualisation by an experienced surgeon from the peri-
infarct zone. Samples were fresh frozen and mounted in cryosection medium. The 
tissue samples were then cut in sequential, longitudinal 4-µm sections at -20 °C and 
thaw-mounted onto microscope slides. They were dried for 15 min and spray-fixed 
with neutral buffered formalin. After rinsing in distilled water, sections were stained 
with hematoxylin-eosin (HE) and van-Gieson (VG) for conventional histopathological 
examination. In order to optimize immunohistochemistry, an antigen-unmasking step 
was performed by microwave treatment for 30 s. Endogenous peroxidase was blocked 
by incubation with hydrogen peroxide for 5 min. Sections were subsequently 
incubated with the primary antibodies; smooth muscle actin, CD31, CD68 (clone PG-
M1), and integrin αvβ3 antibody, clone LM609 (Millipore) for 30 min at room 
temperature. After washing the sections were incubated with Envision Flex (DAKO, 
K5007) for 30 min at room temperature, followed by incubation with 
diaminobenzamine (Sigma) for 10 min. The slides were finally counterstained with 
hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, UK) before assessment. 
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2.7.5. Carotid atheroma histological assessment 
 
After obtaining informed consent, four human carotid intimal samples were obtained 
from patients undergoing carotid endarterectomy for symptomatic carotid artery 
atherosclerotic disease. Segments of dissected carotid atheroma were frozen in 
mounting medium. The tissue samples were then cut in sequential, longitudinal 4 µm 
and 20 µm slices sections at -20°C and thaw-mounted onto microscope slides. Effort 
was made to align segments of ruptured plaque alongside non-atheromatous segments 
within the same slide. The slides were then dried for 15 min and spray-fixed with 
neutral buffered formalin. After rinsing in distilled water the 4 µm sections were 
stained with hematoxylin-eosin (HE) and van-Gieson (VG) for conventional 
histopathological examination. In order to optimize immunohistochemistry, an 
antigen-unmasking step was performed by microwave treatment for 30 s. Endogenous 
peroxidase was blocked by incubation with hydrogen peroxide for 5 min. Sections 
were subsequently incubated with the primary antibodies; smooth muscle actin, CD31, 
CD68 (clone PG-M1), and integrin αVβ3 antibody, clone LM609 (Millipore) for 30 
min at room temperature. After washing, the sections were incubated with Envision 
Flex (DAKO, K5007) for 30 min at room temperature, followed by incubation with 
diaminobenzamine (Sigma) for 10 min. The slides were finally counterstained with 
hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, UK). 
 
  
Novel Applications of PET in Cardiovascular Disease 
 
108 
2.7.6. Carotid atheroma autoradiography 
 
To gain more detailed information about the precise localization of 18F-fluciclatide 
binding in atherosclerotic tissue, we undertook autoradiography. The 20 µm frozen 
sections adjacent to those used for immunohistochemical analysis were warmed to 
room-temperature and bathed in a solution of 18F-fluciclatide at a concentration close 
to in vivo imaging concentrations (1 kBq/mL) for 60 minutes and then rinsed with 
phosphate buffer solution. An unlabeled highly concentrated solution of fluciclatide 
was added to selected slides in order to competitively bind to αvβ3 to assess for non-
specific tracer uptake. A freshly blanked phosphor screen was then placed over the 
slides and an overnight exposure undertaken. The screen was read using a FujiFilm 
FLA-5100 Fluorescent Image Analyser (Raytek Scientific Limited, Sheffield, UK). 
Sections were then manually registered and examined for co-localization with 
histological markers of atherosclerotic disease activity.  
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2.8.  Cardiac MRI 
 
Cardiac MRI was performed at 3 T (MAGNETOM Verio, Siemens AG, Healthcare 
Sector, Erlangen, Germany), within the Clinical Research Imaging Centre, University 
of Edinburgh. For the sake of patient convenience, great effort was made to ensure 
patients received MRI scanning on the day of PET/CT imaging. For the assessment of 
left ventricular function, short-axis cine images from the mitral valve annulus to the 
apex were obtained using a balanced steady-state free-precession sequence (8-mm 
parallel slices with 2-mm spacing). Quantification of left ventricular function and 
volumes indexed to body surface area was assessed with dedicated software (Siemens 
AG Healthcare Sector, Erlangen, Germany). Regional systolic function assessments 
were performed from the basal, mid, and apical short-axis slices by calculating the 
end-diastolic and end-systolic wall thicknesses and expressed as the wall motion score 
index (WMSI; 0, normal; 1, mild or moderate hypokinesia; 2, severe hypokinesia; 3, 
akinesia; 4, dyskinesia).(95) The assessment of focal replacement myocardial fibrosis 
was performed with late gadolinium enhancement (LGE) imaging, 15 min after 
administration of 0.1 mmol/kg gadobutrol (Gadovist/Gadavist, Bayer Pharma AG, 
Berlin, Germany). An inversion recovery fast gradient-echo sequence was applied to 
the left ventricular short-axis stack with the inversion time optimized to achieve 
satisfactory nulling of the myocardium. The amount of LGE was quantified with 
QMASS software (Medis Medical Imaging Systems, Leiden, the Netherlands) using a 
signal intensity threshold greater than twice the standard deviation above the mean 
value in a normal region of myocardium sampled on the same short-axis image. The 
transmural extent of infarction within each segment was classified using a 
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transmurality score (transmurality index; 0, no LGE; 1, 1-50%; 2, 51-75% or 3, 76-
100%) and recorded as either subendocardial (1-2) or transmural (3).(209)  Areas 
thought to represent inversion artefact or blood pool contamination were manually 
excluded. Myocardial extracellular volume fraction (ECV) has been demonstrated to 
act as a measure of myocardial fibrosis in a variety of cardiac conditions.(210,211) 
Recently, our group has described a highly reproducible standardized approach to 
analyze myocardial ECV.(212) Briefly, myocardial T1 mapping was performed in the 
mechanism cohort using the modified look-locker inversion recovery sequence: flip 
angle, 35°; minimum TI, 100 ms; TI increment, 80 ms; and time delay, 150 ms with a 
heartbeat acquisition scheme of 3-3-5.(213)  Regions of interest were drawn around 
the myocardium on the short-axis, pre-contrast, motion-corrected myocardial T1 maps 
and copied onto corresponding 20-min post-contrast maps, with minor adjustments 
made to avoid partial volume effects and artifact (OsiriX version 4.1.1, Geneva, 




∆R1=(1/postcontrast T1−1/precontrast T1). 
 
Hematocrit was sampled at the time of MRI.(214)  
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2.9. Statistical Analysis 
 
Specific statistical analysis has been described in each chapter. Statistical analysis was 
performed with Graph Pad Prism version 6 (GraphPad Software Inc., California USA), 
JMP version 10.0 (SAS Software, North Carolina, USA) or SPSS 19.0 (SPSS Inc., 
Chicago, Illinois) where appropriate. Continuous data were assessed for normality 
visually and using the D’Agostino-Pearson omnibus test. Parametric variables were 
expressed as mean ± standard deviation and compared using Student’s t-tests or repeat 
measure one-way ANOVA. Non-parametric data were presented as median 
[interquartile range] and compared with Mann-Whitney test or Wilcox matched-pairs 
signed rank where appropriate. Reproducibility was estimated using the Bland Altman 
method and presented as mean bias ± 2 standard deviation and intra-class correlation 
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18F-Fluoride and 18F-fluorodeoxyglucose (18F-FDG) are promising novel 
biomarkers of disease activity in aortic stenosis. We compared 18F-fluoride and 18F-
FDG uptake with histological characterization of the aortic valve and assessed whether 
they were associated with disease progression.  
 
Thirty patients with aortic stenosis underwent combined positron emission and 
computed tomography (PET/CT) using 18F-fluoride and 18F-FDG radiotracers. In 12 
patients undergoing aortic valve replacement surgery (10 for each tracer), radiotracer 
uptake (mean TBR) was compared to CD68 (inflammation), alkaline phosphatase and 
osteocalcin (calcification) immunohistochemistry of the excised valve. In 18 patients 
(6 aortic sclerosis; 5 mild, 7 moderate), aortic valve CT calcium scoring was performed 
at baseline and after 1 year.  
 
Aortic valve 18F-fluoride uptake correlated with both alkaline phosphatase (r=0.65, 
P=0.04) and osteocalcin (r=0.68, P=0.03) immunohistochemistry. There was no 
significant correlation between 18F-FDG uptake and CD68 staining (r=-0.43, P=0.22). 
After 1 year, aortic valve calcification increased from 314 (193-540) to 365 (207-934) 
Agatston units (P<0.01). Baseline 18F-fluoride uptake correlated closely with the 
change in calcium score (r=0.66, P<0.01) and this improved further (r= 0.75, P<0.01) 
when 18F-fluoride uptake overlying CT-defined macrocalcification was excluded. No 
significant correlation was noted between valvular 18F-FDG uptake and change in 
calcium score (r=-0.11, P=0.66). 




In conclusion, valvular 18F-fluoride uptake identifies active tissue calcification and is 
associated with disease progression in patients with calcific aortic stenosis.  
 
  





The mechanisms underlying aortic stenosis remain incompletely understood and the 
accurate prediction of disease progression remains a challenge.(14) Calcification and 
inflammation are believed to play key pathophysiological roles. Indeed, the amount of 
established calcium in the valve correlates with disease severity and predicts future 
adverse cardiovascular events.(38,39,216) Whilst computed tomography and 
echocardiography can provide measures of established valvular calcification, they 
cannot directly assess ongoing calcification activity, which is considered to be the 
main driver of disease progression. 
 
Recent reports have investigated two positron emission tomography (PET) 
radiotracers, 18F-fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG), as 
measures of calcification activity and inflammation respectively in the aortic valve,(2) 
coronary arteries(6,164) and major vessels.(49,193) 18F-FDG PET has become a 
widely used tool for the assessment of inflammation in the aorta and carotid arteries 
with uptake correlating with macrophage burden.(47) Several studies have 
investigated its uptake in aortic stenosis although histological validation is 
lacking.(2,53) 18F-Fluoride has been used as a bone tracer for over 40 years, 
displaying increased activity in conditions associated with increased bone metabolism 
such as Paget’s disease. In bone, it is believed to bind and then incorporate into 
exposed hydroxyapatite crystals, via an exchange mechanism with hydroxyl groups to 
form fluoroapatite. Given that hydroxyapatite is also a key structural component of 
calcification in the aortic valve and vascular atheroma, it is presumed that similar 
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mechanisms explain its accumulation in these tissues. However, this remains 
hypothetical. The principal aims of the present study were therefore to validate the use 
of 18F-fluoride and 18F-FDG in aortic stenosis by comparing in vivo radiotracer 
uptake with immunohistochemistry of calcification and inflammation in excised 
valvular tissue, and to investigate whether either of these agents may be associated 
with disease progression over 1 year.  
 
  





3.3.1 Patient Populations 
 
Two cohorts of patients with aortic stenosis were recruited into this study: (i) 12 
patients undergoing valve replacement surgery, and (ii) 18 patients with asymptomatic 
disease under surveillance at the Edinburgh Heart Centre. The latter cohort were 
randomly selected for repeat scanning from a larger, previously described population 
who underwent baseline PET imaging.(2,60,164)  
 
All patients were aged >50 years and exclusion criteria included a normal aortic valve, 
insulin-dependent diabetes mellitus, end-stage renal failure, life expectancy of <2 
years, and metastatic malignancy. Patients with severe AS were excluded from the 
cohort of patients under surveillance because of the potential for disease progression 
and symptom development before the follow up 1-year scan. The study was performed 
in accordance with the Declaration of Helsinki and after local research ethics 
committee approval. All patients provided written informed consent before 
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3.3.2 Baseline Assessment 
 
All patients underwent full clinical assessment at baseline and aortic stenosis severity 
was assessed using Doppler and two-dimensional echocardiography by means of the 
peak transvalvular velocity, mean gradient and aortic valve area according to 
American Heart Association/American College of Cardiology guidelines.(217) Aortic 
sclerosis was defined as thickening of the aortic valve cusps in the absence of 
accelerated flow (<2 m/s) through the valve. Combined positron emission and 
computed tomography (PET/CT) scans of the aortic valve were performed using a 
hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany) 60 
min after administration of 125 MBq of 18F-fluoride. Subsequently a second PET/CT 
scan was performed using the same hybrid scanner 90 min following administration 
of 200 MBq of 18F-FDG. The total effective radiation dose from study participation 
was 9.73±1.19mSv: 18F-Fluoride (3.8±0.3 mSv) and 18F-FDG (4.9±0.5 mSv) PET-
CT, and calcium score (1.3±0.5 mSv). Glucose is a major energy source of the 
myocardium, so that intense 18F-FDG uptake frequently occurs, spilling over and 
contaminating the signal in the valve. We attempted to reduce myocardial uptake by 
asking patients to avoid carbohydrates for 24 hours prior to their 18F-FDG scan, 
thereby switching the myocardium from glucose to free fatty-acid metabolism. 
Myocardial 18F-FDG uptake was assessed within regions of interest placed in the 
basal septum of the left ventricle and classified as being adequately suppressed if mean 
SUV values were <5.0.(2) An ECG-gated breath-hold CT scan (non-contrast 
enhanced, 40 mA/rot [CareDose], 100 kV) was performed for calculation of the aortic 
valve calcium score using dedicated analysis software (VScore, Vital Images, 
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Minnetonka, USA) on axial scans.(35) Particular care was taken to differentiate 
valvular calcium from that in the aortic root and mitral valve annulus. At one-year 
follow up, patients in the surveillance cohort underwent repeat clinical assessment and 
CT calcium scoring using the same protocol.  
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3.3.3 Quantification of Aortic Valve PET activity 
 
18F-Fluoride and 18F-FDG uptake in the aortic valve was quantified using an Osirix 
workstation (OsiriX version 3.5.1 64-bit; OsiriX Imaging Software, Geneva, 
Switzerland) as reported previously.(2,6) Briefly, fused PET-CT images were re-
orientated into the plane of the valve and circular regions of interest (ROIs) drawn on 
adjacent 3-mm slices until the entire valve had been examined. For 18F-fluoride, ROIs 
were placed around the perimeter of the valve whilst excluding the aortic root (whole-
valve technique). In order to reduce the potential for myocardial 18F-FDG activity 
contaminating the aortic valve signal, ROIs for this tracer were drawn in the center of 
the valve as previously described (center-valve technique).(2,53) Within these ROIs, 
mean standard uptake values (SUV) were calculated for each slice, averaged and 
corrected for blood pool activity to provide mean tissue-to-background ratios (TBRs). 
Mean TBRs were selected prospectively for subsequent comparisons with histology 
and disease progression as this measure was felt to best represent tracer uptake across 
the valve as a whole.  
 
Distribution of 18F-fluoride in the aortic valve relative to calcium scoring  
 
We undertook a voxel-by-voxel analysis comparing the distribution of calcium on CT 
with 18F-fluoride uptake. Regions of interest were drawn around the valve, and each 
voxel was assessed for the presence of calcium (>130 HU) and increased 18F-fluoride 
uptake (TBR max >1.97, based upon the highest uptake in the control cohort of our 
previous study (2)) using dedicated software MATLAB® (Mathworks inc., 
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Massachusetts USA). We hypothesized that regions of completely novel calcium 
development might have an even more important impact upon disease progression and 
we therefore calculated the percentage of the valve with increased radiotracer uptake 
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3.3.4 Histological Assessment 
In the patients undergoing aortic valve replacement, the aortic valve was removed at 
the time of operation with care taken to preserve the integrity of the valve architecture. 
Samples were then fixed in 4% paraformaldehyde for 24 hours. Plaques were 
decalcified in ethylenediaminetetraacetatic acid for 10 days, embedded in paraffin and 
5-µm sections prepared. Immunohistochemical staining for osteocalcin (anti-human 
mouse mAb ab13418, Abcam), CD68 (anti-human mouse clone PG-M1 m0876, 
DAKO) and tissue non-specific alkaline phosphatase (TNAP; anti-human rabbit pAb 
CAT#LF PA50004, Abfrontier) was then undertaken following heat-induced epitope 
retrieval (HIER) using a Citrate Buffer pH 6 (Novocastra Leica microsystems) in a 
decloaking chamber. Osteocalcin staining required no HIER. Sections were stained 
using a Leica Vision Biosystems Bond x immunostaining robot. After blocking in 
peroxide for 10 min, sections were incubated with the specific anti-human antibodies 
for 2 hours at room temperature at the following dilutions: osteocalcin 1:200, tissue 
non-specific alkaline phosphatase 1:100 and CD-68 1:100. All incubation steps were 
followed by washing in TBS/Tween.  Sections for osteocalcin and CD68 were 
incubated for 15 min with pre-polymer/post primary followed by 15 min with polymer 
(HRP) for all antibodies prior to DAB (3,3'-diaminobenzidine) visualization and 
haematoxylin counterstain. Sections were dehydrated in graded ethanol, cleared in 
xylene before cover slipping in Pertex.  
 
Images were taken on a Zeiss Axioskop2 fitted with an Axiocam MRc digital camera 
using Axiovision software. Tissue cross-sectional area on each section was manually 
delineated using Image Pro Plus 5 (Rockville, MD, USA). Immunohistochemical 
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staining for osteocalcin and TNAP was identified by visual assessment and quantified 
using automated color-based segmentation by a trained observer blinded to the PET 
data.  Staining was expressed as a percentage of the total valve area. Macrophage 
infiltration using CD68 was assessed using a similar approach but with an object size 
set threshold applied at 20 x 10 pixels, to limit counting to cell-sized objects. The 
density of cell staining in the valve tissue was expressed as cells per mm2. This 




Interobserver reproducibility of the immunohistochemical data was investigated. 
Tissue staining with alkaline phosphatase, CD68 and osteocalcin was quantified in 5 
valves independently by two trained observers (Dr William Jenkins, Dr Alex Vesey).  
 
  




Clinical PET systems have limited resolution. In order to gain further information 
about the precise localization of the 18F-fluoride signal in aortic valve tissue, we 
undertook autoradiography.  Non-decalcified valvular tissue was rapidly cooled in dry 
ice and then sectioned at 7-µm thickness using a cryostat (CM1520 Wetzlar, 
Germany).  Sections for autoradiography were mounted on Superfrost slides (Gerhard 
Menzel, Braunschweig, Germany) before treatment with spray fixative.  Sections were 
bathed in a solution of 18F-fluoride at a concentration close to in vivo imaging 
concentrations (1 kBq/mL) for 60 min and then rinsed with PBS.  A freshly blanked 
phosphor screen was then placed over the slides and an overnight exposure 
undertaken.  The screen was then read using a FujiFilm FLA-5100 Fluorescent Image 
Analyser (Raytek Scientific Limited, Sheffield, UK).  Sections adjacent to those used 
for autoradiography were stained for elemental phosphate (i.e. calcium 
orthophosphate) using Von Kossa’s stain, and following surface decalcification in situ 
with Von Ebner’s solution, for TNAP and osteocalcin.  Sections were then manually 
registered and examined for co-localization with 18F-fluoride signal. 
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3.3.6 Statistical methods 
Continuous variables were assessed for normality both visually and using the 
D’Agostino-Pearson test. Variables were expressed as either mean ± standard 
deviation or median with interquartile ranges subject to whether they approximated a 
normal distribution. Categorical data were presented as n (%).  The 95% normal range 
for differences between sets of immunohistochemical measurements (the limits of 
agreement) were estimated using  Bland-Altman analysis by multiplying the standard 
deviation of the mean difference by 1.96.(215) Intra-class correlation coefficients with 
95% confidence intervals were calculated for inter-observer variation. Baseline and 
follow-up calcium scores approximated a normal distribution, and were compared 
using a paired t-test. However, despite attempts at data transformation, the changes in 
calcium scores were not normally distributed and correlations with CT progression 
data were assessed using Spearman’s correlation and linear regression analysis. We 
acknowledge the limitations in using linear regression in the context of a non-normal 
distribution. A two-sided P<0.05 was regarded as statistically significant. Statistical 
analysis was performed with the use of Graph Pad Prism version 6.0 (GraphPad 
Software Inc, California USA). 
  





3.4.1 Histology Cohort 
Twelve patients with symptomatic aortic stenosis were recruited into the histology 
cohort (8 male, age 76±6, peak aortic valve velocity 4.6±0.9 m/s). Patients underwent 
PET scanning a median of 92 days prior to surgical aortic valve replacement. Eight 
patients received both 18F-fluoride and 18F-FDG PET scans. Additionally, two had a 
single 18F-fluoride scan whilst two more had a single 18F-FDG scan. Thus 10 valves 
were available for the histological validation of each tracer. No patient suffered a 
significant peri-operative complication (Table 3.1). Effective myocardial suppression 
of 18F-FDG activity was achieved in 40% (median myocardial SUV 5.4, IQR 1.9-
10.4). 
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Table 3.1. Baseline characteristics of histology cohort  
 
Baseline Characteristics 
Number 12   
Age (years) 76±6   
Male  9 (75)   
Hypertension 8 (66)   
Hyperlipidaemia 5 (42)   
Ischaemic Heart Disease 4 (33)   
Cigarette Smoking 1 (8)   
Diabetes 0 (0)   
Serum Creatinine (µmol/L) 87±26   
Peak aortic valve velocity (m/s) 4.6±0.9   
Aortic Valve area (cm2) 0.70 (0.53-0.97)   
Mean Gradient (mmHg) 48 (44-65)   
Aortic Valve Calcium Score (AU) 5343 (3114-6292)   
Aortic sclerosis 0 (0%)   
Mild aortic stenosis  0 (0%)   
Moderate aortic stenosis  3 (25%)   
Severe aortic stenosis  9 (75%)   
Time between 18F-NaF scan & AVR (days) 92 (24-345)   
Time between 18F-FDG scan & AVR (days) 96 (23 – 331)   
18F-FDG dose injected (MBq) 200 (193-209)   
18F-NaF dose injected (MBq) 129 (119-132) 
 
  
In vivo aortic valve PET Data 
18F-NaF Uptake (mean TBR) 2.15 (1.98-2.48)   
18F-FDG Uptake (mean TBR) 1.40 (1.31–1.76)   





 Osteocalcin TNAP CD-68 
Number 10 10 10 
Mean valve area analysed (mm2) 234±152 253±116 190±86 
% staining of the valve 17±7 17±5 n/a 
Positive cellular staining (cells/mm2) 130 (85-274) 225 (143-328) 172 (73-271) 
Inter-observer Reproducibility 
     Mean Difference -2.1% -1.5% 0.8% 
     Limits of Agreement -13.4-9.3% -8.0-5.0% -7.9-9.6% 
     ICC 0.88 (0.60-0.97) 0.90 (0.35-0.99) 0.99(0.99-1.00) 
 
Categorical data is displayed as n (%). Normally distributed data displayed as mean±SD. 
Non-normally distributed data as median (inter quartile range). Inter-class correlation 
coefficients (ICC) as value (95% confidence interval). Abbreviations: AVR – aortic valve 
replacement, 18F-NaF – 18F- fluoride, 18F-FDG – 18F-fluorodeoxyglucose.  
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Immunohistochemistry and Autoradiography 
 
All valve samples displayed positive cellular staining for TNAP (225 cells/mm2 valve 
tissue; IQR 143-328), osteocalcin (130 cells/mm2 valve tissue, IQR 85-274) and CD68 
(172 cells/mm2 valve tissue; IQR 73-271) (Figure 3.1). Extensive TNAP and 
osteocalcin staining was also observed in the extracellular matrix, occupying 
approximately a sixth of the valve area sampled (17±5% and 17±7% respectively).  
 
On autoradiography, 18F-fluoride uptake was observed to co-localise closely with 
staining for structural calcium phosphate, TNAP and osteocalcin (Figure 3.1).  
However signal was also clearly apparent in areas free of macroscopically visible 
calcium thus highlighting the sensitivity of 18F-fluoride in the detection of newly 
evolving calcification. 
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Figure 3.1. Histology and 18F-fluoride autoradiography of excised aortic 
valve tissue from patients with aortic stenosis. 
 
A-F; Fixed, decalcified and paraffin embedded aortic valve tissue after exposure to tissue 
non-specific alkaline phosphatase (TNAP), osteocalcin and CD68 antibodies. Images A-C 
display widespread positive staining for TNAP, osteocalcin and CD68 (x4 magnification) in 
the extracellular matrix (ECM), which is also observed on an individual cellular level (D-F, 
x20 magnification) respectively.  
 
G-I; Three adjacent and consecutive aortic valve leaflet sections displaying positive 
immunohistochemical staining for osteocalcin (I, x4 magnification) that co-localizes to areas 
of maximal 18F-fluoride uptake on autoradiography (H). These likely represent areas of 
ongoing calcification activity, which extend beyond the areas of established calcium identified 
in black by Von Kossa’s stain (G, x4 magnification). 
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Reproducibility of Immunohistochemistry 
 
Interobserver reproducibility was good for the quantification of osteocalcin and TNAP 
staining as well as CD68 cell counting. All observations were characterised by an 
absence of fixed or proportional biases, narrow limits of agreement (-13.4-9.3%, -8.0-
5.0% and -7.9-9.6% respectively) and ICC values of 0.90 (0.35-0.99), 0.88 (0.60-0.97) 
and 0.99 (0.99-1.00) respectively (Table 3.1).   
 
Correlation with radiotracer uptake 
 
There was a good correlation between in vivo valvular 18F-fluoride uptake and both 
alkaline phosphatase (r=0.65 (95% confidence interval: 0.03-0.90), P=0.04) and 
osteocalcin (r=0.68 (0.10-0.91), P=0.03; Figure 3.2) staining of the excised tissue. By 
comparison there was no association between 18F-FDG uptake and CD68 staining in 
the valve (r=-0.43 P=0.22).  
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Figure 3.2. Correlations between in vivo aortic valve PET activity and 
histological markers of calcification and inflammation. 
 
Panel A displays the close association between the percentage aortic valve tissue staining for 
tissue non-specific alkaline phosphatase (TNAP) and valvular 18F-fluoride activity (mean 
tissue to background ratio, TBR); r=0.65, P=0.04. A similar association can be seen in panel 
B  between the percentage surface area of the valve stained with osteocalcin and the aortic 
valve 18F-fluoride PET activity (mean TBR); r=0.68, P=0.03. In panel C we observe a poor 
association between CD68 staining on immunohistochemistry and 18F-FDG PET activity in 
the aortic valve (mean TBR); r=-0.43, P=0.22.   
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3.4.2 Disease Progression  
 
Of the 18 patients (age 75±6 years, 17 male, peak aortic-jet velocity 2.6±0.9 m/s) 
reassessed at a median interval of 386 days (Table 3.2), 6 had aortic sclerosis, and 7 
had mild and 5 moderate aortic stenosis. Effective myocardial suppression of 18F-
FDG uptake was achieved in 66% (median myocardial SUV 3.6, IQR 2.0 – 5.4). 
 
A correlation was observed between baseline aortic valve calcium scores on CT and 
18F-fluoride activity on PET (r=0.74 (0.42-0.90), P≤0.001). However, as described 
previously the pattern of 18F-fluoride uptake was distinct from the distribution of 
established calcium.(2,60,193) Indeed 18F-fluoride uptake in the absence of 
underlying calcium occupied a median of 8.3%  (IQR 1.6-23.4) of the total valve area, 
emphasizing that 18F-fluoride provides distinct and complementary information to CT 
calcium scoring (Figure 3.3). 
 
At one year, aortic valve calcium scores increased from 314 (193-540) to 365 (207-
934) AU (P<0.01). Interestingly these regions of novel calcium developed in much the 
same distribution as the observed baseline 18F-fluoride uptake (Figure 3.3A-B). 
Indeed we observed an excellent correlation between baseline valvular 18F-fluoride 
PET uptake and the change in calcium score after 1 year (r=0.66 (0.27-0.86), P=0.003; 
Figure 3.3C). This was similar to that observed for the current gold-standard method 
of prediction: the baseline calcium score (r=0.58 (0.15-0.82), P=0.01; Figure 3.3D) 
and improved further when only increased 18F-fluoride uptake in the absence of 
underlying CT macrocalcification was considered (r= 0.75 (0.42-0.90), P=0.01). No 
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statistically significant correlation was observed between 18F-FDG uptake and the 
subsequent change in CT calcium score (r=-0.11 (-0.56-0.39), P=0.66; Figure 3.3E).  
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Table 3.2. Baseline Characteristics of Progression Cohort 
 







Number 18 6 (33) 7 (39) 5 (28) 
Age (years) 75 (71-79) 74 (70-78) 74 (69-80) 79 (70-83) 
Male  15 (83) 4 (66) 7 (100) 4 (80) 
Hypertension 13 (72) 3 (50) 5 (71) 5 (100) 
Hyperlipidaemia 12 (67) 4 (66) 5 (71) 3 (60) 
Diabetes 5 (28) 1 (16) 4 (57) 0 (0) 
Ischaemic Heart Disease 13 (72) 4 (66) 6 (86) 3 (60) 
Serum Creatinine (µmol/L) 92±29 85 (72-92) 91 (67-125) 84 (69-133) 
Cigarette Smoking 0 (0) 0 (0) 0 (0) 0 (0) 
Peak aortic valve velocity (m/s) 2.6 (1.8-3.1) 1.7 (1.6-1.8) 2.4 (2.1-2.6) 3.4 (3.2-3.6) 
Aortic Valve area (cm2) 1.68 (1.26-2.28) 1.92 (1.8-2.1) 1.63 (1.42-1.87) 1.03 (0.78-1.18) 
Mean Gradient (mmHg) 10.8 (7.0-16.5) 6.2 (4.8-7.0) 11.0 (9.3-14.0) 22.0 (18.8-27.2) 



































Categorical data is displayed as total number (percentage). Median data (inter quartile 
range). Abbreviations: CT - Computed tomography, 18F-NaF – 18F-fluoride, 18F-FDG – 
18F-fluorodeoxyglucose  
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Figure 3.3.  Change in aortic valve CT calcium score and 18F-fluoride PET 
activity after 1 year 
 
A-B; Co-axial short axis views of the aortic valve from 2 patients with mild aortic stenosis 
(top and bottom rows). On baseline CT scans (left) established regions of macro calcification 
appear white. Baseline fused 18F-fluoride PET and CT scans (middle) show intense 18F-
fluoride uptake (red, yellow regions) both overlying and adjacent to existing calcium deposits 
on the CT. 1 year follow up CT scans (right) demonstrate increased calcium accumulation in 
much the same distribution as the baseline PET activity.  
C-E; Predictors of progression in aortic valve calcium score.  An excellent correlation was 
observed between baseline 18F-fluoride activity in the aortic valve and the subsequent change 
in calcium score at 1 year r=0.66, P<0.01 (A). This matched the current gold standard 
predictor of disease progression the baseline calcium score r=0.58 P=0.01 (B). By contrast 
there was a poor correlation with 18F-FDG activity in the valve r=-0.11 P=0.66 (C).  
 
 




n=18 n=18 n=18 





We provide the first preliminary evidence that valvular 18F-fluoride uptake acts as a 
marker of calcification activity in patients with aortic stenosis. Not only did uptake 
values demonstrate a correlation with histological markers of active calcification 
(TNAP and osteocalcin) but they were also closely associated with the subsequent 
progression in aortic valve CT calcium scores at 1 year. In contrast, 18F-FDG uptake 
did not correlate with CD68 staining on histology nor the progression in calcium 
scores.  Our data indicate that 18F-fluoride holds promise as a biomarker of disease 
activity in patients with aortic stenosis.  
 
The pathophysiology of aortic stenosis is incompletely understood, delaying the 
development of biomarkers and effective medical therapies. Calcification and 
inflammation are thought to play a key pathological role,(17,18) so that non-invasive 
markers of their activity are of interest in better understanding the etiology of this 
condition as well as in predicting disease progression.  
 
Recent studies have investigated 18F-fluoride PET as a marker of vascular 
calcification in aortic stenosis (2) and atherosclerosis affecting the aorta,(218) and 
coronary (6,164) and carotid arteries.(219) However this is the first study to provide 
histological validation of 18F-fluoride uptake in vascular tissue. In bone, 18F-fluoride 
is believed to incorporate onto the surface of hydroxyapatite crystal.(193) Given that 
hydroxyapatite is also a key component of vascular calcification, it too has been the 
presumed radiotracer target in aortic stenosis and atherosclerosis. This hypothesis is 
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supported by our autoradiography and immunohistochemical data, demonstrating a 
good correlation between 18F-fluoride activity and osteocalcin staining: a well-
recognized osteogenic protein that itself binds to hydroxyapatite.  
 
Given that 18F-fluoride binds to a structural component of vascular calcification, why 
then does it not simply label all regions of macrocalcification identified by CT? Indeed 
it is common for regions of dense calcium on CT to show no 18F-fluoride uptake. This 
phenomenon is likely related to the available surface area of exposed hydroxyapatite 
crystal to which the 18F-fluoride ion can adsorb and the inactivity of established areas 
of calcification. 18F-Fluoride uptake is much greater at sites of evolving powdery 
microcalcification than established regions of field calcification in which the core of 
hydroxyapatite is internalized and therefore hidden from the 18F-fluoride tracer. Thus 
18F-fluoride binds more readily to regions of developing calcium and acts as a marker 
of calcification activity providing distinct information to calcium scoring. In contrast, 
the latter quantifies regions of established macroscopic calcium in the valve but cannot 
inform whether the process of calcification is quiescent or active. Again this 
hypothesis is supported by our data. We have demonstrated a strong correlation 
between in vivo 18F-fluoride uptake and staining for one of the key enzymes regulating 
mineralization: tissue non-specific alkaline phosphatase. This enzyme is expressed in 
the early stages of new calcium formation and is known to work by breaking down 
pyrophosphate: a potent inhibitor of mineralization.(220) Furthermore, as one would 
expect from a measure of activity, baseline 18F-fluoride uptake closely correlated with 
the subsequent change in calcium score at 1 year. Indeed 18F-fluoride uptake 
performed as well as the current gold standard method of prediction, the degree of 
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established calcium in the valve at baseline.(216,221) However, larger studies are now 
required to compare these two techniques and whilst calcium scoring may be easier to 
obtain, changes in the 18F-fluoride PET signal are likely to occur more quickly, 
making it a more attractive technique with which to assess the early and more 
immediate effects  of novel treatment strategies. 
 
Interestingly the pattern of 18F-fluoride uptake may be important, with 18F-fluoride 
uptake remote from established macrocalcification on CT offering the closest 
association with calcium score progression in our cohort. The spatial resolution of 
PET/CT is ~4 mm, and we acknowledge that the voxel-by-voxel analysis used to 
establish this observation is at the limit of resolution for PET imaging. Nevertheless 
the strong correlation with progression is of interest and indicates that further 
investigation of the spatial distribution of 18F-fluoride uptake is warranted.  
 
The results for valvular 18F-FDG imaging were somewhat disappointing and 
surprising given previous data suggesting an important role for inflammation in aortic 
stenosis.(25) Whilst correlations between 18F-FDG uptake and macrophage burden 
have previously been demonstrated in regions of aortic and carotid atheroma,(47)  we 
were unable to replicate this with respect to the valve. There are several explanations 
for this discrepancy. The first is the close proximity of the valve to the myocardium. 
As discussed, avid uptake of 18F-FDG by the left ventricular myocardium can spill 
over into the aortic valve contaminating its signal. Unfortunately even despite the 
stringent dietary restrictions and center-valve analysis technique, it remains possible 
that myocardial contamination occurred, confounding the correlation with CD68 
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immunohistochemistry. Indeed poor myocardial suppression was achieved in the 
histology group perhaps reflecting their advanced disease and symptomatic status. 
Alternative methods have been utilized to reduce further this myocardial uptake, 
including administration of heparin and a high-fat drink prior to scanning.(195,222) 
However these make the practicalities of scanning more difficult and are yet to show 
a clear advantage over dietary restrictions. An alternative explanation for the poor 
correlation with histology is that the aortic valve 18F-FDG signal relates to uptake by 
non-macrophage cell types within the valve, such as osteoblasts, or is governed by 
external factors such as hypoxia.(223) In this scenario, one might still expect 18F-
FDG to predict disease progression but once again this was not evident in our cohort. 
It would therefore appear that 18F-FDG holds less potential as a predictor of disease 
progression than 18F-fluoride, although it remains possible that longer periods of 
follow-up are required to detect such an association. Indeed on occasion we also 
observed 18F-fluoride activity that did not translate into a detectable change in calcium 
score at 1 year. Aortic stenosis is a slowly developing condition, so that it is likely to 
take time for relatively low levels of 18F-fluoride or 18F-FDG uptake to translate into 
new areas of macrocalcification detectable on CT imaging. Larger studies with longer 
follow up are therefore required to address this issue, to confirm our preliminary data 
and to assess whether 18F-fluoride PET can predict disease progression with respect 
to echocardiographic parameters of valvular stenosis.  
 
In conclusion, we provide the first preliminary data to support 18F-fluoride as a marker 
of valve calcification activity in aortic stenosis and as a potential method for predicting 
disease progression.  




Chapter 4.   
Valvular 18F-fluoride and 18F-
fluorodeoxyglucose uptake are associated 
with disease progression and clinical 
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4.1  Overview 
 
18F-Fluoride and 18F-fluorodeoxyglucose (18F-FDG) are positron emission 
tomography (PET) radiotracers of calcification and inflammation activity respectively. 
We sought to assess their ability to predict disease progression and clinical outcome 
in patients with aortic stenosis.  
 
PET and computed tomography (CT) were performed in 121 volunteers (72±8 years, 
68% men) with and without aortic valve disease (20 controls; 20 aortic sclerosis; 25 
mild, 33 moderate, and 23 severe aortic stenosis) using 18F-fluoride (125 MBq) and 
18F-FDG (200 MBq). Disease progression was assessed at 1 and 2 years using CT 
aortic valve calcium score and echocardiography. Primary clinical outcome endpoint 
was a composite of cardiovascular death and aortic valve replacement (AVR). 
 
Aortic valve calcium score increased by 61 (5–226) AU/year and aortic valve mean 
gradient increased by 0.7 (-0.2–2.9) mmHg/year. After a median of 1,526 (IQR 1475-
1615) days, 29 patients had undergone AVR whilst 7 had a cardiovascular death. 
 
Baseline valvular 18F-fluoride uptake correlated strongly with the rate of progression 
in aortic valve calcium score (r=0.80, p<0.001) and moderately with 
echocardiographic measures of progression (mean aortic valve gradient r=0.32, 
p=0.001). It emerged as independantly associated with clinical outcome after age and 
sex-adjustment (HR 1.55 [1.33-1.81], p<0.001). 
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18F-FDG demonstrated moderate correlations with disease progression as assessed by 
CT (r=0.43, p=0.001) and echocardiography (18F-FDG r=0.30, p=0.001) and also was 
associated with clinical outcomes independent of age and sex (HR 1.35 [1.16-1.58], 
p<0.001). 
 
In conclusion, valvular 18F-fluoride and 18F-FDG PET uptake are closely associated 
with disease progression and clinical outcome in calcific aortic valve disease.  
  
Novel Applications of PET in Cardiovascular Disease 
 
148 
4.2  Introduction 
 
Aortic stenosis is the commonest form of valvular heart disease in the developed world 
and a major cause of morbidity and mortality, affecting 0.5% of the adult population 
and rising to 12% of those aged over 75 years. This translates to 2.7 million elderly 
patients in North America and 4.9 million patients in Europe alone.(224) Furthermore, 
with a progressively increasing life-expectancy, the health burden attributable to this 
condition is only set to increase.(14) However, despite its prevalence, we lack 
biomarkers of disease activity, accurate clinical methods of predicting disease 
progression, and medical therapies capable of halting the disease process.  
 
Our understanding of the pathogenesis of aortic stenosis has evolved over recent years. 
What was considered a passive and degenerative process is now appreciated to be a 
complex and highly regulated response to injurious stimuli with inflammation and 
calcification playing key roles.(17,18) In particular, calcification appears to be of 
central importance in driving disease progression and valve narrowing, with its 
accumulation in the valve resulting in progressive leaflet thickening and 
stiffness.(18,225)  
 
Our group and others have investigated combined positron emission tomography 
(PET) and computed tomography (CT) as a means of measuring inflammation and 
calcification activity in aortic stenosis and other cardiovascular diseases.(2,53,58,226) 
18F-Fluorodeoxyglucose (18F-FDG) is a PET radiotracer and glucose analogue taken 
up by metabolically active cells. In the vasculature, its uptake localizes to sites of 
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macrophage infiltration and activity. On this basis, 18F-FDG has become widely used 
as a marker of vascular inflammation, and for testing the safety and efficacy of novel 
therapies.(47,162) 18F-Fluoride is an alternative radiotracer that binds hydroxyapatite, 
the key structural component of cardiovascular calcification. Recent data have shown 
that 18F-fluoride preferentially binds to regions of newly developing 
microcalcification in the vasculature (beyond the resolution of CT) and correlates with 
histological markers of calcification activity in aortic stenosis.(226,227) Given the 
central role played by calcification, 18F-fluoride therefore holds promise as a 
biomarker of disease activity in aortic stenosis. Indeed in our recent pilot study of 18 
patients, valvular 18F-fluoride PET uptake correlated closely with the progression of 
aortic valve CT calcium scores after 1 year.(226) 
 
The aim of the current study was to assess the ability of these two tracers to predict 
longer-term disease progression and adverse clinical outcomes in a larger prospective 
cohort of patients with calcific aortic valve disease.  





4.3.1  Patient Population 
 
Patients aged >50 years with aortic sclerosis and mild, moderate or severe aortic 
stenosis attending the outpatient department of the Edinburgh Heart Centre were 
approached for recruitment in this prospective cohort study alongside age- and sex-
matched control subjects, as described previously.(2,60,164,226) Exclusion criteria 
were insulin-dependent diabetes mellitus, end-stage renal failure, life expectancy of 
<2 years, and metastatic malignancy. The study was performed with the written 
informed consent of all participants, with research ethics committee approval, and in 
accordance with the Declaration of Helsinki. This study was registered with the 
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4.3.2  Baseline Assessment 
 
All participants underwent full clinical assessment at baseline and aortic stenosis 
severity was assessed using Doppler and two-dimensional echocardiography by means 
of the peak transvalvular velocity, mean gradient, peak gradient and aortic valve area 
(calculated using the continuity equation) according to American Heart Association/ 
American College of Cardiology guidelines.(228) Multiple acoustic windows with the 
S51 and D2cwc probes (Philips Medical Systems, the Netherlands) were assessed.  
Aortic sclerosis was defined as thickening of the aortic valve cusps in the absence of 
accelerated flow (<2 m/s) through the valve.(228)  We also assigned the valve a semi-
quantitative echocardiographic calcium score (ECS) as described by Rosenhek and 
colleagues.(38) Finally, aortic stenosis disease severity was assessed using an ECG-
gated breath-hold CT scan (non-contrast enhanced, 40 mA/rot [CareDose], 100 kV) 
that was used to measure the aortic valve CT calcium score.(36) 
 
PET/CT scans of the aortic valve were performed as described previously using a 
hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany) 60 
min after administration of 125 MBq of 18F-fluoride.(2)  On a separate occasion, a 
second PET/CT scan was performed using the same hybrid scanner 90 min following 
administration of 200 MBq of 18F-FDG. (2)   In an attempt to minimise cardiomyocyte 
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4.3.3  Image Analysis 
 
Calcium score analysis was performed on axial scans by an experienced investigator 
(WJ) blinded to clinical data using dedicated analysis software (Vitrea Advanced, 
Vital Images, Minnetonka, USA). Care was taken to differentiate valvular calcium 
from that in the aortic root and mitral valve annulus.  
 
Valvular 18F-fluoride and 18F-FDG uptake was quantified using an OsiriX 
workstation (OsiriX version 3.5.1 64-bit; OsiriX Imaging Software, Geneva, 
Switzerland) as reported previously.(2) Briefly, fused PET/CT images were re-
orientated to the short-axis plane of the aortic valve and circular regions of interest 
(ROIs) drawn on adjacent 3-mm slices until the entire valve apparatus had been 
examined. For 18F-fluoride, ROIs were placed around the perimeter of the valve 
(whole-valve technique). For 18F-FDG, ROIs were drawn in the center of the valve to 
reduce the impact of myocardial spillover, as described previously (center-valve 
technique).(2,53) From these regions, standard uptake values (SUV) were used to 
calculate tissue-to-background ratios (TBR) in the valve, after correcting for blood 
pool activity measured within the lumen of the superior vena cava. We have previously 
noted difficulty in defining the limits of the valve in the z-axis.  As well as introducing 
potential for bias and variability, this problem frequently results in signal dilution if 
more slices than necessary are assessed. In keeping with an image analysis technique 
established in the aorta,(163) we therefore also calculated a modified “most diseased 
segment” SUV (SUVMDS) in the aortic valve. This was based upon the average of the 
SUVmean values derived from the 2 adjacent slices within the valve that had the highest 
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signal. This value was then used to calculate the most diseased segment TBR after 
blood-pool correction (TBRMDS). 
 
In order to assess the reproducibility of our methods for measuring the CT-calcium 
score, the echocardiographic calcium score and the valvular PET uptake, the scans 
from 25 study subjects with a range of aortic valve disease were selected at random 
and analysed independently by two trained observers (WSAJ, TP). 
 
4.3.4 Assessment of Disease Progression 
 
Subjects who had survived and had not undergone AVR were invited to return for 
repeat clinical assessment and echocardiography at both 1 and 2 years after enrolment. 
A single experienced research echocardiographer performed each echocardiogram 
under standardised conditions (AW). Annualized rates of echocardiographic 
progression for aortic stenosis were calculated over three time-points: baseline, 1 year 
and 2 years. 
 
A subgroup of patients underwent repeat CT-calcium scoring after 1 year.(226) To 
limit their exposure to ionizing radiation, these subjects did not undergo further 
calcium scoring. In the remaining eligible patients, repeat CT scoring of the valve was 
performed after 2 years. The annualized change in CT calcium score was calculated 
for all subjects. For both echocardiography and CT, the same scanner and imaging 
protocol was used for all the baseline and follow up scans.  
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4.3.5 Follow-up for Clinical Events 
 
The primary outcome measure was a composite of cardiovascular mortality or aortic 
valve replacement (AVR).(229) All deaths were captured from the General Register 
of Scotland.  Cardiovascular death was defined as death due to myocardial infarction, 
sudden cardiac death, heart failure, stroke, death related to cardiovascular procedures, 
and death due to other cardiovascular causes.  Each death was classified as cardiac or 
non-cardiac by two independent investigators blinded to the imaging data, with any 
discrepancy resolved by consensus.  All events, including AVR (either surgical or 
transcutaneous), were confirmed by independent review of each patient’s healthcare 
record. All patients were managed in our tertiary cardiac center, and reviewed at a 
multi-disciplinary meeting prior to undergoing aortic valve replacement.  Only 
patients with established indications according to contemporary guidelines were 
referred for AVR.(230)  
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4.3.6 Statistical Methods 
 
Continuous variables were expressed as either mean ± standard deviation for normally 
distributed data and median (interquartile range; IQR) for skewed distributions. Non-
parametric datasets were log-transformed in an attempt to achieve normality. 
Parametric (unpaired Student’s t-test) and non-parametric (Mann-Whitney U) tests 
were used for normally distributed and skewed data respectively. Categorical data 
were presented as n (%) and compared when appropriate using a contingency table 
and Fisher’s or Chi-squared tests. Correlation was undertaken with either Pearson’s r 
or Spearman’s Rho subject to the normality of the variables tested.  
 
To assess inter and intra-observer repeatability of the two PET analysis techniques and 
the aortic valve CT-calcium scoring, the intra-class correlation coefficient (ICC) was 
calculated and Bland-Altman analysis undertaken. Due to its categorical nature, 
repeatability studies of the echocardiographic calcium score were assessed using 
Cohen’s kappa coefficient. 
 
Adjusted and unadjusted Cox regression models were used to assess whether 18F-
fluoride and 18F-FDG were associated with aortic valve replacement or cardiovascular 
mortality. Statistical analyses were performed with the use of Graph Pad Prism version 
6.0 (GraphPad Software Inc, California, USA), SPSS version 18 (SPSS Inc, Chicago, 
IL) and RStudio version 0.98.501 (2013).  Statistical significance was taken as two-
sided P<0.05. 





4.4.1. Study Population 
 
A total of 121 patients were recruited (aged 72±8 years; 69% male) and underwent 
both 18F-fluoride (66±7 min after 124±10 MBq) and 18F-FDG (94±7 min after 
197±14 MBq) PET/CT imaging of their aortic valve. The study cohort comprised 20 
control subjects, 20 patients with aortic sclerosis, and 25 patients with mild, 33 with 
moderate, and 23 with severe aortic stenosis as described previously.(2)  Subjects were 
well matched for age, sex, and comorbidity (Figure 1, Table 1). The total effective 
radiation dose from study participation was 11.03±1.26mSv: 18F-Fluoride (3.8±0.3 
mSv) and 18F-FDG (4.9±0.5 mSv) PET-CT, and repeated calcium scoring (1.3±0.5 
mSv per scan). In those patients who received a single CT calcium score, the total 
effective radiation dose was 9.73±1.19 mSv. Dietary restrictions effectively 
suppressed 18F-FDG myocardial uptake (SUV <5) in 67% of patients.(2) 
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Figure 4.1.  Study model and clinical outcomes. 
 
A flow chart describing patient assessment and follow-up. The number of patients 
undergoing each assessment are included in parentheses. 
 
 
Abbreviations: AV: aortic valve; CT: computed tomography; FDG: fluorodeoxyglucose 
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Table 4.1.  Baseline Clinical Characteristics  
 










(AVR / CV 
Death) 
Number 121 99 87 36 
Age (years) 72±8 72±8.5 72±8 71±9 
Male 83 (69) 66 (65) 45 (51) 26 (72) 
Body Mass Index (kg/m2) 27±4 28±4 28±6 29±5 
Systolic Blood Pressure (mmHg) 142±18 143±19 144±19 139±21 
Co-morbidity 
Diabetes Mellitus 18 (15) 13 (13) 12 (14) 6 (17) 
Hypertension 73 (60) 59 (60) 53 (61) 23 (64) 
Documented CAD 43 (35) 36 (36) 38 (44) 12 (33) 
Current smoker 14 (12) 11 (11) 7 (8) 8 (22) 
Serum Creatinine (mg/dL) 1.01±0.29 1.02±0.32 1.00±0.28 0.98±0.29 
Medications 
ACE inhibitors 47 (39) 36 (36) 36 (41) 16 (44) 
AIIRB 13 (11) 11 (11) 10 (11) 3 (8) 
Beta Blockers 48 (40) 41 (41) 40 (46) 15 (42) 
Statins 65 (54) 54 (54) 54 (62) 23 (64) 
Echocardiographic Assessment 
AV jet velocity (m/s) 2.8 [1.7-3.7] 2.6 [1.7-3.6] 2.6 [1.7-3.6] 4.0 (3.3-4.6) 
AV peak gradient (mmHg) 31 [11-53] 28 [11-51] 28 [12-51] 61 [42-82] 
AV mean gradient (mmHg) 16 [6-29] 14 [6-27] 14 [6-27] 34 [24-46] 








Calcium Score 1.6±0.9 1.5±0.9 1.5±0.9 2.0±0.9 
ECG Findings 
LVH 28 (23) 19 (19) 17 (20) 11 (31) 
LV Strain 13 (11) 9 (9) 8 (9) 7 (19) 
  




Total radiation dose (mSv) 11.03±1.26 - - - 
















18F-FDG Dose (MBq) 196.6±13.9 197.0±13.8 197.0±12.0 199.2±11.9 
18F-fluoride Dose (MBq) 123.8±9.5 123.6±9.0 124.0±7.8 126.6±12.4 
18F-FDG Valve uptake 
(TBRMDS) 
1.38±0.19 1.35±0.15 1.46±0.21 1.47±0.18 
18F-FDG valve uptake  
(mean TBRCV) 
1.34±0.17 1.32±0.14 1.33±0.18 1.42±0.15 
18F-fluoride Valve uptake 
(TBRMDS) 
1.80±0.47 1.73±0.45 1.64±0.45 2.18±0.39 
18F-fluoride Valve uptake 
(mean TBRWV) 
1.75±0.42 1.69±0.41 1.66±0.41 2.08±0.38 
Time in study (days) 742±38 743±38 739±32 443 (325-796) 
 
Parametric data are presented as mean±SD. Non-parametric data are presented as median 
[IQR]. Categorical data are presented as number (percentage). Abbreviations: ACE, 
angiotensin converting enzyme; AIIRB, angiotensin 2 receptor antagonists; AS, aortic 
stenosis; AV, aortic valve; CAD, coronary artery disease; CV, centre valve; FDG, 
Fluorodeoxyglucose; TBR, tissue to background ratio; AU, arbitrary unit; LV, left ventricle; 
LVH, left ventricular hypertrophy. WV, whole valve.  
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4.4.2 Image Analysis Reproducibility Studies 
 
The novel TBRMDS method demonstrated superior interobserver reproducibility 
compared to the established TBRmean approach for the quantification of valvular 18F-
FDG uptake. The two techniques performed equally well with respect to 18F-fluoride 
(Table 4.2, Figure 4.2). 
 
Baseline uptake of the two radiotracers across the cohort using the TBRmean technique 
have been reported previously.(2) The TBRMDS technique resulted in no major 
differences compared to the original observations and no fixed or proportional bias 
(Table 4.2, Figure 4.2). Indeed valvular radiotracer uptake and therefore calcification 
activity increased steadily with more advanced aortic stenosis severity and in line with 
the extent of existing calcium observed on CT calcium scoring (r=0.84 p<0.001, 
Figure 2A-B).  Moreover, the choice of uptake analysis technique had no impact on 
the strength of the correlations observed between baseline PET uptake and disease 
progression (Table 4.3).  Given the improved interobserver reliability for 18F-FDG, 
TBRMDS was used for all subsequent analyses.  
 
The intra and inter-observer repeatability of aortic valve CT calcium scoring in the 
axial plane using the Agatston technique was excellent (Table 4.4, Figure 4.4) with the 
echocardiographic calcium score performing more modestly (Table 4.4).  
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Table 4.2.  Reproducibility Studies – PET Radiotracer uptake 
 






























a Mean difference between TBR measurements (95% limits of agreement), and b ICC values 
(95% confidence intervals) for 18F-fluoride and 18F-FDG valvular uptake, assessing the use 
of mean whole/centre valve quantification technique versus the MDS technique. 
Abbreviations: FDG: fluorodeoxyglucose; ICC: intraclass correlation coefficient; MDS: most 
diseased segment; TBR: tissue to background ratio 
  




Figure 4.2.  Valvular PET Radiotracer assessment: Bland-Altman plots 
 
 
The figure below displays Bland-Altman plots with the percentage difference plotted 
against the tissue to background values for ‘mean’ and ‘most disease segment’ 
methodologies, assessing interobserver agreement in both 18F-fluoride (upper) and 
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Figure 4.3.  Positron Emission Tomography, Aortic Valve Calcification 
and the Progression in Disease Severity. 
 
A & B. Disease progression as measured by CT calcium scoring and 
echocardiography increased steadily as disease severity increased. The changes in CT 
calcium score were however larger and more consistent than those observed for 
echocardiography.  
 
C & D A close association was observed between the baseline CT calcium score and 
valvular 18F-fluoride (18F-NaF) activity (r=0.84, p<0.001). Patients with higher 
than expected 18F-fluoride uptake for a given CT calcium score (dots in the red 
section above the regression line) demonstrated disease progression rates that were 
3-fold greater than those with lower than expected 18F-fluoride uptake (dots in the 
blue section below the regression line (B). 
 
E & F. Whilst an association between 18F-FDG activity and the baseline CT calcium 
score was again observed (r=0.45, p<0.001), those with higher than expected 18F-
fluorodeoxyglucose (18F-FDG) activity did not appear to progress faster than patients 
with lower than expected PET uptake.  
 
Patient numbers are included in italics above each datapoint. 
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Abbreviations: AV: aortic valve; AU: arbitrary units; CT: computed tomography; CV: centre 
valve; FDG: fluorodeoxyglucose; MDS: Most Diseased Segment; TBR: tissue to background 
ratio; WV: whole valve 
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Table 4.4. CT calcium scoring – reproducibility studies 
 
 
 Interobserver Intraobserver 




Bias (95% limits of 
agreement) a 
ICC 
(95% CI) b 
Number 25 25 25 25 
CT Calcium Score (AU) 22 (-35 to 79) 1 (1.0 to 1.0) 10 (-67 to 88) 1 (1.0 to 1.0) 
 
 Interobserver Kappa (SE)c Intraobserver Kappa (SE)c 
Echocardiographic 
Calcium Score 
0.447 (0.138) 0.501 (0.132) 
 
a mean difference; b Intraclass correlation co-efficient. 2-way mixed effects for absolute 
agreement; c Kappa statistic.  Abbreviations: AU: arbitrary units; CT: computed tomography; 
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Figure 4.4.  CT calcium scoring: Bland-Altman plots 
 
The figure below displays Bland-Altman plots with the difference plotted against the 


































































CT Calcium Scoring - Interobserver Variability 
n=25 n=25 
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4.4.3. Patient follow-up 
 
One year after enrollment, 107 subjects returned for clinical follow-up and 
echocardiography.  As part of a pilot study, 20 subjects had received a repeat ECG-
gated cardiac CT at one year and did not undergo further CT at two years.(226)  
 
Ninety-nine subjects (81%) returned for repeat clinical assessment and 
echocardiography at the 2-year time point (median 736 [722–760] days from 
enrollment). Repeat CT calcium was performed in 77 of these subjects. Including the 
patients scanned at 1 year, a total of 97 (78%) subjects underwent a repeat ECG-gated 
cardiac CT during the 2-year follow up period. CT scans were not interpretable in 10 
subjects (including 2 at the 1-year time point) due to motion artifact and were excluded 
from subsequent analysis. In the remaining patients (n=87), the annualized change in 
the aortic valve CT calcium score was calculated and used for subsequent analysis 
(Figure 4.1). 
 
Across all disease cohorts, modest progression of each echocardiographic measure of 
aortic stenosis severity was observed (Table 4.5). Peak aortic jet velocity increased by 
0.08 (-0.02–0.18) m/s/year, the mean transvalvular gradient by 0.7 (-0.2–2.9) 
mmHg/year and the peak gradient by 1.3 (-0.3–4.0) mmHg/year. The aortic valve area 
fell by -0.06 (-0.14–0.02) cm2/year. In contrast, relatively large annualized changes in 
the CT valvular calcium scores were observed (61 [5–226] AU/year [p<0.001]), 
especially amongst patients with moderate and severe disease (Table 4.5 and Figure 
4.3). Indeed for all the variables assessed, more rapid disease progression was 
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observed in patients with more advanced aortic stenosis (median change in calcium 
score: mild AS, 65 [48-134]; moderate AS, 289 [106-443], and severe AS, 343 [164-
583] AU/year). Finally, the change in the valve CT calcium score correlated 
moderately with the different haemodynamic measures of aortic stenosis progression 
(change in mean gradient, r=0.45 [0.26-0.61], p<0.001; and change in peak gradient, 
r=0.41 [0.22-0.58], p<0.001). 
 
Clinical outcomes were assessed at a median of 1,526 (1,475-1,1615) days after 
enrollment. At this point, 29 (24%) patients had undergone either aortic valve 
replacement (AVR; n=25) or transcatheter aortic valve implantation (n=4).  There 
were 7 (6%) cardiovascular deaths (with 4 further deaths due to a non-cardiovascular 
cause). Overall, 36/121 (30%) subjects were adjudicated to have reached the primary 
end-point (Table 4.5). 
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Table 4.5.  Disease progression and clinical outcomes 
 














No. of patients 121 20 20 25 33 23 
Aortic-jet velocity 
(m/s) 















2.54±0.49 2.27±0.41 1.42±0.30 1.13±0.27 0.76±0.21 
Echocardiography  
Progression 
No. of patients 99 20 17 24 26 12 







































































No. of patients 112 20 20 23 30 19 


























No. of patients 87 18 18 21 24 6 














∆ Log10  AVC 


























All cause mortality 11 1 1 1 2 6 
Cardiovascular 
Mortality 
7 0 1 1 0 5 
Aortic-valve 
replacement 
29 0 0 0 13 16 
Composite 
outcome 
34 0 1 1 13 19 
 
Parametric data are presented as mean±SD. Non-parametric data are presented as median 
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4.4.4. Prediction of disease progression 
 
A strong correlation was observed between baseline 18F-fluoride uptake in the valve 
and the subsequent rate of progression in the aortic valve calcium score (r=0.80 [0.69–
0.87], p<0.001; Table 4.6 and Figure 4.5).  Moderate correlations were observed 
between valvular 18F-fluoride uptake and echocardiographic indices of disease 
progression, i.e. the rate of change in mean gradient (r=0.32 [0.13–0.50], p=0.001), 
peak aortic jet velocity (r=0.23 [0.03–0.41], p=0.001), and peak gradient (r=0.32 
[0.12–0.49], p=0.002). 
 
Moderate correlations were also observed between baseline 18F-FDG valvular uptake 
and the rate of progression of the CT calcium score (r=0.43 [0.23–0.59], p<0.001), the 
mean gradient (r=0.30 [0.10–0.47], p=0.002), the peak velocity (r=0.28 [0.08–0.46], 
p=0.005), and peak gradient (r=0.36 [0.17–0.53], p<0.001).  
 
There were strong associations between the baseline CT valvular calcium score and 
rate of change in calcium score (r=0.88 [0.82-0.92], p<0.001), similar to those 
observed for 18F-fluoride. Moderate associations were also observed between the 
baseline calcium score and the progression in echocardiographic measures of disease 
severity (change in mean gradient, r=0.40 [0.21–0.56], p<0.001; change in peak 
velocity, r=0.36 [0.16–0.53], p<0.001; and change in peak gradient, r=0.46 [0.27–
0.61], p<0.001).  
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Given the degree of co-linearity that exists between CT calcium scoring and 18F-
fluoride uptake in the valve, it is difficult to assess whether 18F-fluoride uptake 
provides incremental prognostic information to CT. Using the regression line between 
the CT calcium score and 18F-fluoride uptake as a cut off, patients with aortic stenosis 
and higher than expected 18F-fluoride uptake for a given CT calcium score 
demonstrated progression rates that were 3-fold greater than subjects with lower than 
expected uptake (median change in calcium score: 315 [127-492] vs 99 [51-290] 
AU/year respectively; p=0.003). When a similar analysis was performed for 18F-FDG, 
there was no significant difference (median change in calcium score: 231 [79-446] vs 
124 [61-321] AU/year, p=0.14; Figure 4.3). 
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Figure 4.5.   18F-Fluoride Positron Emission Tomography and the 
Progression in Aortic Valve Calcification  
 
Co-axial short-axis views of the aortic valve in 3 separate study subjects and disease 
severity categories. 
A Baseline CT calcium score scans with relatively little in the way of established 
calcium in the valve (white)  
B Fused PET/CT images with increased 18F-fluoride valvular uptake (red and yellow 
regions) that does not well align with the established calcium on the CT. Also note the 
increased uptake in the proximal left anterior descending coronary artery 
C Repeat CT calcium score at 2 years, demonstrating an increase in the amount of 
established macroscopic calcium in much the same distribution as the baseline PET 
uptake.  
D-E Scatterplots demonstrating the close relationship between progression in the 
aortic valve computed tomography calcium score and baseline valvular 18F-fluoride 
(D) and 18F-FDG (E) uptake. To better demonstrate the lower calcium score data a 
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Abbreviations: AV: aortic valve; AU: arbitrary unit; CT: computed tomography; FDG: 
fluorodeoxyglucose; MDS: most diseased segment; PET: positron emission tomography; 
TBR: tissue to background ratio 
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4.4.5. Associations with clinical outcome 
 
Using Cox regression analysis, valvular 18F-fluoride uptake was significantly 
associated with clinical outcome (cardiovascular mortality and AVR) independent of 
age and sex (HR (hazard ratio): 1.55, 95% CI (confidence interval): 1.33 to 1.81; 
p<0.0001). The same was true of baseline 18F-FDG activity (HR: 1.35, 95% CI 1.16 
to 1.58; p<0.001). To facilitate comparison, the HRs are expressed per decile of the 
full range of TBRMDS values for each tracer. The baseline aortic valve CT calcium 
score also emerged as independently associated with clinical outcomes (HR per 10th 
of the range change in calcium score: 4.31 95% CI: 2.60 to 7.14; p<0.0001 after 
adjustment for age and sex).  Finally we assessed the echocardiographic calcium score. 
However this performed poorly, with only a maximum score of 4 holding any 
prognostic value (Table 4.7 and Figure 4.6).  
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Figure 4.6.  Prediction of clinical outcome 
 
A 18F-Fluoride (HR are per 10th of range of mean TBRMDS values). 
B 18F-Fluorodeoxyglucose (HR are per 10th of range of mean TBRMDS values). 
C Echocardiographic calcium score (with ECS score of 0 as reference). 
D CT Calcium Score (HR are per 10th of range of AU values). 
Red bars are 95% confidence intervals. 
 
 
Abbreviations: ECS: echocardiographic calcium score; HR: hazard ratio
0.5 1.0 1.5 2.0 2.5
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Adjusted
C
0.5 1.0 1.5 2.0 2.5
Univariate
Age & Sex Adjusted
B
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Univariate
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D
Novel Applications of PET in Cardiovascular Disease 
 
179 
Table 4.7. Imaging and the prediction of clinical outcome 
 




Age and Sex 
Adjusted 
HR (95% CI) 
P 
Value 
18F-fluoride Valvular Uptake 
TBRMDS (per 10th of range) 
1.50 (1.29 - 1.73) <0.001 1.55 (1.33 – 1.81) <0.001 
18F-FDG Valvular Uptake 
TBRMDS (per 10th of range) 
1.35 (1.16 – 1.58) <0.001 1.35 (1.16 – 1.58) <0.001 
CT AV Calcium Score 
(per 10th of range) 














Calcium Score (ECS) 
ECS     
1 Reference - Reference - 
2 0.58 (0.04 - 9.31) 0.702 0.53 (0.03 - 8.458) 0.650 
3 5.35 (0.71 - 40.41) 0.104 5.36 (0.71 - 40.68) 0.104 
4 16.9 (2.19 - 130.86) 0.007 17.0 (2.18 - 132.4) 0.007 
 
Abbreviations: AV: aortic valve; AU: Arbitrary Unit; CI, confidence interval; CT: computed 
tomography; ECS: echocardiographic calcium score; FDG: fluorodeoxyglucose; HR, hazard 
ratio; MDS: Most Diseased Segment; TBR: tissue to background ratio





We here report the first prospective longitudinal study to investigate the utility of 18F-
fluoride and 18F-FDG PET/CT imaging in patients with aortic stenosis. We have 
demonstrated that both tracers are associated with disease progression and adverse 
clinical outcomes. In particular 18F-fluoride proved closely associated with the change 
in CT calcium score over a 2-year period, appearing to offer incremental information 
to baseline CT imaging. Moreover, in an exploratory analysis, it emerged 
independently associated with cardiovascular death and AVR after adjustment for both 
age and sex. This would support PET/CT imaging as a novel method for measuring 
disease activity in aortic stenosis with implications on risk stratification.  
 
The main advantage that PET holds over other mainstream imaging modalities, such 
as CT, is that it goes beyond anatomy and is able to resolve valvular biology and 
pathophysiology. PET can provide immediate non-invasive quantification of on-going 
and potentially modifiable pathological processes within the body. This includes 
vascular calcification activity. Indeed recent interest has surrounded 18F-fluoride as a 
marker of newly developing microcalcification in the coronary arteries that can be 
used to identify culprit and high-risk atheromatous plaque.(6)  This tracer has also 
been investigated in aortic stenosis, with studies confirming that 18F-fluoride uptake 
correlates closely with histological markers of valvular calcification activity.(226) In 
a small interim analysis, we have previously reported that 18F-fluoride is associated 
with the change in the aortic valve calcium score after 1 year.(226)  We here extend 
these observations to a larger, broader population with longer follow up.  




Valvular 18F-fluoride PET uptake, as a marker of calcification activity, increases 
steadily with more advanced stages of aortic stenosis.(2) In this study, we have 
confirmed that this observation translates into a similar step-wise increase in disease 
progression across patients with mild, moderate and severe aortic stenosis (Figure 4.3). 
18F-Fluoride demonstrated excellent associations with disease progression as assessed 
by CT (r=0.80, p<0.001) and standard echocardiographic haemodynamic markers . 
Whilst CT calcium scoring also predicted disease progression, our data would suggest 
that PET can provide incremental information, with patients demonstrating higher than 
expected valvular 18F-fluoride uptake progressing three times fast than subjects with 
lower than expected activity. Moreover, whilst only a small number of clinical events 
occurred in this study, 18F-fluoride uptake was independently associated with 
cardiovascular death and AVR after adjustment for age and sex.  In combination with 
the existing literature, these observations would indicate that 18F-fluoride PET is a 
non-invasive measure of disease activity in aortic stenosis, with the ability to predict 
its natural history.  
 
Might 18F-fluoride PET be of use in the clinical setting as a tool for predicting disease 
progression and risk stratifying patients? Whilst our initial data suggests that PET 
might provide some incremental prognostic information over and above CT, we have 
also demonstrated that CT calcium scoring on its own provides excellent prediction of 
disease progression (231). Although CT is unable to measure calcification activity in 
the valve directly, it is able to reliably and accurately quantify the progressive 
accumulation of macroscopic areas of established calcium within the valve. Indeed our 
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data would suggest that tracking disease progression with CT is perhaps easier than 
with traditional hemodynamic echocardiography measures given the relatively larger 
increases in the CT calcium score with time and its excellent reproducibility. 
Furthermore, because calcification activity increases proportionally with disease 
severity (thereby explaining the more rapid disease progression observed in those with 
more advanced disease, Figure 4.3), baseline CT calcium scoring also provides a good 
surrogate marker of disease activity. This would explain the excellent associations 
demonstrated between disease progression and clinical outcomes, and CT calcification 
in this and other recent studies.(39,221)  Therefore we believe that this simple and 
widely available technique is likely to assume a greater clinical role in the future, 
supported by its superior reproducibility to echocardiographic calcium scoring and 
incremental prognostic utility over and above the more traditional hemodynamic 
severity assessments.(232,233) 
 
What then is the future role of 18F-fluoride PET? As discussed it is possible that 18F-
fluoride will be able to complement the ability of CT to identify high risk phenotypes 
for disease progression. In addition we believe that it is likely to prove an excellent 
means of testing the efficacy of novel therapeutic agents in aortic stenosis.(234)  We 
have previously hypothesized that calcification is the predominant driver of disease 
progression in aortic stenosis, and that anti-calcific interventions may slow or halt 
disease progression.(17) In this context the instantaneous readout of valvular 
calcification activity provided by 18F-fluoride PET has the potential to rapidly detect 
beneficial treatment effects without the need for protracted follow up. This contrasts 
favorably with more established imaging modalities such as CT calcium scoring and 
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echocardiography that take many years to identify the anatomic and hemodynamic 
consequences of such alterations in disease activity. Ultimately 18F-fluoride PET 
therefore has the potential to reduce the duration of clinical studies investigating the 
efficacy of novel treatments, and thereby to expedite their development. Indeed this 
hypothesis will be tested in future randomised control trials using valvular 18F-
fluoride uptake as a pre-defined end-point (clinicaltrials.gov NCT02132026).  
 
In this study, we applied a novel method of assessing valvular radiotracer uptake: the 
Most Diseased Segment (MDS). This approach is simpler than previous methods and 
was highly reproducible, demonstrating a clear advantage to standard techniques with 
respect to 18F-FDG imaging.  Cardiac 18F-FDG imaging has been hampered by 
myocardial uptake, making assessment of adjacent structures such as the aortic valve 
and coronary arteries challenging. In this study, we observed a moderate association 
between baseline 18F-FDG uptake in the valve and disease progression at 2 years.  
This result should, however, be interpreted with a degree of caution as the exact 
mechanisms underlying 18F-FDG activity in the valve remain unclear.  Previous 
studies have established a correlation between macrophage burden and 18F-FDG 
uptake in carotid atheroma. We have previously failed to demonstrate any such 
association in the aortic valve.(226) This may be because we only examined severely 
stenotic valves where inflammation may be of less importance. However questions 
remain whether 18F-FDG is acting exclusively as a marker of macrophage infiltration 
in aortic stenosis, or perhaps reflect the metabolic requirements of a wide range of 
cells.(223) Further work is required to resolve this key issue and to better understand 
the information that 18F-FDG is providing in aortic stenosis.  




There are a number of limitations that we should acknowledge. The strong co-linearity 
between 18F-fluoride PET activity and the CT calcium score means that much larger 
studies are required to assess definitively whether 18F-fluoride provides incremental 
predictive information to CT. The same is true with respect to 18F-FDG. We should 
also acknowledge the relatively small number of clinical events observed in this study. 
However given that this was the first study to prospectively investigate 18F-fluoride 
PET imaging in aortic stenosis, it is possible we can improve the information provided 
by this technique by incorporating contrast CT angiography and PET motion 
correction, as we have recently employed in the coronary arteries (20).  
 
We also need to establish whether modification of 18F-fluoride PET uptake can be 
achieved by potential therapeutic interventions, such as anti-calcific therapies, and 
whether any such reduction translates in to improved clinical outcomes.  These are key 
priorities that should be addressed in prospective studies using gated PET acquisitions.  
 
In conclusion, the valvular uptake of 18F-fluoride and 18F-FDG on positron emission 
tomography is associated with disease progression and clinical outcomes in patients 
with aortic stenosis. These observations support PET/CT imaging as a novel method 
for measuring disease activity in aortic stenosis with the ability to predict its natural 
history. This may be of particular use in rapidly assessing the treatment effects of novel 
medical therapies for this important condition. 
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Cardiac Alpha-V Beta-3 Integrin Expression 














Published by Jenkins WS, Vesey AT, Stirrat C, Connell M, Lucatelli C, Neale A, 
Moles C, Vickers A, Fletcher A, Pawade T, Wilson I, Rudd JH, van Beek EJ, 
Mirsadraee S, Dweck MR, Newby DE. Cardiac Alpha-V Beta-3 Integrin Expression 
Following Acute Myocardial Infarction in Humans. Heart. 2017;103(8):607-615.  






Maladaptive repair contributes towards the development of heart failure following 
myocardial infarction (MI). The αvβ3 integrin receptor is a key mediator and 
determinant of cardiac repair. We aimed to establish whether αvβ3 integrin expression 
determines myocardial recovery following MI. 
 
18F-Fluciclatide (a novel αvβ3-selective radiotracer) positron emission tomography 
(PET) and computed tomography (CT) imaging, and gadolinium-enhanced magnetic 
resonance imaging (CMR) were performed in 21 patients 2 weeks after ST-segment 
elevation MI (anterior, n=16; lateral, n=4; inferior, n=1). Cardiac CMR was repeated 
9 months after MI. Seven stable patients with chronic total occlusion (CTO) of a major 
coronary vessel, and 9 healthy volunteers underwent a single PET/CT and CMR. 
 
18F-Fluciclatide uptake was increased at sites of acute infarction compared to remote 
myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 vs 0.85±0.17; p<0.001) 
and myocardium of healthy volunteers (TBRmean 1.34±0.22 vs 0.70±0.03; p<0.001). 
There was no 18F-fluciclatide uptake at sites of established prior infarction in CTO 
patients, with activity similar to the myocardium of healthy volunteers (TBRmean 
0.71±0.06 vs. 0.70±0.03, p=0.83). 18F-Fluciclatide uptake occurred at sites of regional 
wall hypokinesia (wall motion index ≥1 vs 0; TBRmean 0.93±0.31 vs 0.80±0.26 
respectively, p<0.001) and subendocardial infarction. Importantly, although there was 
no correlation with infarct size (r=0.03, p=0.90) or inflammation (C-reactive protein, 
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r=-0.20, p=0.38), 18F-fluciclatide uptake was increased in segments displaying 
functional recovery (TBRmean 0.95±0.33 vs 0.81±0.27, p=0.002) and associated with 
increase in probability of regional recovery.  
 
In conclusion, 18F-Fluciclatide uptake is increased at sites of recent MI acting as a 
biomarker of cardiac repair and predicting regions of recovery.  
  





Ischemic heart disease remains the leading cause of death globally, with over 1 million 
people suffering acute myocardial infarction (MI) per year in the USA alone.  As the 
acute management of MI improves, the number of patients surviving acute myocardial 
injury is higher than ever before. In this population, adverse cardiac remodeling and 
the syndrome of delayed heart failure represents a major cause of morbidity.(70) 
Understanding reparative mechanisms following infarction is becoming increasingly 
important. 
 
Repair following MI is triggered by a complex interaction of neurohormonal activation 
and up-regulation of angiogenic and pro-fibrotic transcription factors that initiate the 
restoration of a capillary network through angiogenesis and re-endothelialization, as 
well as extracellular matrix (ECM) remodeling through macrophage accumulation and 
fibroblast activation. This interplay of angiogenesis, inflammation and fibrosis 
determines the extent of preservation and restoration of myocardial integrity.(235) In 
some circumstances, maladaptive persistent processes may encourage remodeling and 
scarring to extend into the myocardium long after the initial causative injury. This may 
lead to progressive ventricular dilatation, ventricular dysfunction and heart failure.  
 
The avb3  integrin is a trans-membrane cell surface receptor that facilitates migration, 
proliferation and interaction with the ECM, thereby allowing cells to respond to, and 
in turn modify, their extracellular environment. Expressed at low levels by quiescent 
endothelial cells, αvβ3 integrin is markedly up regulated in states of angiogenesis 
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within the myocardium after infarction.(121,126)  In addition, pre-clinical and clinical 
studies document αvβ3 integrin expression by both activated cardiac myofibroblasts 
and macrophages during margination and chemotaxis. Thus, αvβ3 integrin expression 
appears central to the co-ordination of repair following MI. 
 
In this study, we investigated the expression of αvβ3 integrin following MI using the 
novel αvβ3 integrin-selective radiotracer, 18F-fluciclatide, combined with cardiac 
positron emission tomography (PET), computed tomography (CT) and cardiovascular 
magnetic resonance (CMR). The study aims were to describe and characterize the 
uptake of this radiotracer, and to correlate it with clinical markers of disease severity 










PET/CT scanning with 18F-fluciclatide and CMR were performed in 3 groups of 
participants recruited from Royal Infirmary of Edinburgh between July, 2013, and 
February, 2015. Exclusion criteria were age <40 years, women of childbearing 
potential not taking contraception, severe renal failure (serum creatinine >2.8 mg/dL) 
or hepatic failure (Childs-Pugh grade B or C), atrial fibrillation, contrast allergy, 
inability to undergo scanning and inability to provide informed consent. Studies were 
performed with approval of the local research ethics committee, in accordance with 
the Declaration of Helsinki, and with the written informed consent of each participant. 
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5.3.1. Study participants  
Acute MI group.  
 
Patients with recent acute ST-segment elevation MI and peak high-sensitivity cardiac 
troponin I (hs-cTnI) >10,000 ng/L were invited to attend for PET/CT with 18F-
fluciclatide 14±7 days after their initial presentation. CMR was performed within 7 
days of PET/CT scanning. Patients were then invited to return for a second PET/CT 
with 18F-fluciclatide 10 weeks after MI and for a follow-up CMR at 9 months. 
Chronic Total Occlusion (CTO) group.  
 
Patients with an angiographically-documented complete occlusion of a major 
epicardial artery and stable cardiac symptoms for >6 months were invited to attend for 
a single PET/CT with 18F-fluciclatide and CMR. 
Control group.  
 
Volunteers with normal left ventricular systolic function, no structural heart disease, 
and no symptoms of heart failure or MI underwent a single PET/CT with 18F-
fluciclatide and CMR. 
Histology Cohort 
 
For histological analysis, myocardial biopsy samples were obtained from patients 
undergoing coronary artery bypass grafting following recent MI. Patients with large 
ST-elevation MI (<14 days, hs-cTnI >10,000 ng/L) were considered for inclusion 
forming a separate cohort from the acute MI group. 
 




5.3.2. Imaging procedures 
 
Radiosynthesis of 18F-Fluciclatide 
 
The radiotracer was manufactured at the Clinical Research Imaging Centre, University 
of Edinburgh on an automated module (FASTlab synthesizer; GE Healthcare) by 
coupling an amino-oxy-functionalized peptide precursor (AH111695) with 4-18F-
fluorobenzaldehyde at pH 3.5 to form 18F-fluciclatide. Full description of this 




All patients underwent PET-CT imaging of the thorax with a hybrid scanner (Biograph 
mCT, Siemens Medical Systems, Erlangen, Germany) at the Clinical Research 
Imaging Centre, University of Edinburgh. No dietary restrictions were required prior 
to radiotracer administration. Subjects were administered a target dose of 230 MBq 
18F-fluciclatide. An attenuation-correction CT scan (non-enhanced 120 kV and 50 
mA, 3-mm slices) was performed, followed by the PET acquisition with 
electrocardiographic (ECG) gating. To assess tracer pharmacodynamics and the 
optimum timing of scanning, dynamic PET imaging of the thorax was initially 
performed in 10 subjects in 3-dimensional mode with a single bed position for 70 min. 
The remainder of study subjects underwent static imaging performed at the optimal 
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time point as determined from the dynamic studies (40-min post-injection) using a 
single 30-min bed position in list mode.  
 
To enable an accurate definition of cardiac anatomy cardiac CT angiography was 
performed on the hybrid scanner immediately after the PET acquisition: 330 ms 
rotation time, 100 (body mass index <25 kg/m2) or 120 (body mass index >25 kg/m2) 
kV tube voltage, 160-245 mAs tube current, 3.8 mm/rotation table feed, prospective 
(heart rate regular and <60 /min), or retrospective (heart rate >60 /min) 
electrocardiogram-gated. Depending on the body mass index, a bolus of 80-100 mL 
contrast (400 mgI/mL; Iomeron, Bracco, Milan, Italy) was injected intravenously at 5 
mL/s, after determining the appropriate trigger delay with a test bolus of 20 mL 
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5.3.3. PET Reconstruction and Analysis 
 
Kinetic PET analysis 
 
Kinetic analysis of the dynamic scans was undertaken to investigate the uptake of 18F-
fluciclatide within the myocardium. The dynamic PET data were reconstructed (Ultra-
HD, 2 iterations, 21 subsets, 256 pixels, 1.6-mm pixel size) using a dynamic protocol 
without ECG gating in following time frames; 60s x 5, 120s x 5, 180s x 5, 300s x 8. 
Regions of interest (ROI’s) were drawn in the descending aorta blood pool and 
myocardium, and used to derive time activity curves after decay correction. An input 
function calculation based on the PET image–derived activity curve from the aorta 
blood pool (199) and the myocardial time-activity curve were used to estimate the 
tissue influx rate Ki (the slope of the linear regression) and the volume of distribution 
(the y-axis intercept) using a 2-tissue irreversible Patlak model.(9,10) Thoracic 18F-
fluciclatide dynamic activity was then normalized for the blood-pool input function on 
a voxel-by-voxel basis, and after 3D Gaussian filtering (5-mm FWHM) a parametric 
3-dimensional image of 18F-fluciclatide uptake was generated (PMod version 3.409, 
Pmod technologies limited, Switzerland). Using this image, regions of 18F-
fluciclatide binding in the myocardium were identified and manually delineated for 
subsequent Ki analysis.  
 
Static PET analysis 
 
For all patients, static ECG-gated PET images were reconstructed in diastole (40-70 
min post-injection, 50–75% of the R-R interval, Ultra-HD, 2 iterations, 24 subsets, 
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zoom x2, 200 pixels). Myocardial 18F-fluciclatide uptake was assessed by an 
experienced observer (WJ) using an OsiriX workstation (OsiriX version 6.0 64-bit; 
OsiriX Imaging Software, Geneva, Switzerland). PET images were fused and aligned 
with CT angiography datasets in diastole. Myocardial radiotracer uptake was 
quantified using two methods.  
 
First, using a standardized approach PET/CT datasets were re-orientated into 
traditional short-axis, 2-chamber, 3-chamber and 4-chamber views with a slice 
thickness of 3 mm in order to fully visualize myocardial radiotracer uptake and allow 
comparison with CMR imaging. Regions of interest (ROIs) were drawn at sites that 
corresponded to the areas of acute infarction seen on CMR late gadolinium 
enhancement imaging. To define referent ‘remote’ myocardial regions, ROI’s were 
drawn within proximal regions of the myocardial territory that displayed no CMR 
evidence of infarction. Care was taken to avoid blood-pool contamination. ROIs were 
copied onto the PET dataset and mean radiotracer activity measured using standard 
uptake values (SUV; the decay corrected tissue concentration of the tracer divided by 
the injected dose per body weight).  
 
Second, the CT angiography dataset was re-orientated into the left ventricular short 
axis (slice thickness 8 mm). Basal, mid-cavity, and apical regions were manually 
delineated into segmental ROI’s according to the standard 17-segment model 
recommended by the American College of Cardiology/American Heart 
Association.(236) We excluded the true apex as it was not possible to avoid partial 
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volume effects. ROI’s were then copied onto the re-orientated PET image dataset and 
segmental SUV and TBR data extracted using the technique above.  
 
PET data were corrected for residual blood pool activity (standard uptake value, SUV) 
in the superior vena cava and expressed as a mean tissue-to-background ratio 
(TBRmean). SUVmax and TBRmax values were also calculated alongside the corrected 
SUV (SUVC) values, where blood pool activity was subtracted from myocardial 
uptake.(2,226) 
 
In a substudy of 10 randomly selected subjects, interobserver reproducibility was 
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5.3.4. CMR Imaging 
 
Cardiac MRI was performed at 3 T (MAGNETOM Verio, Siemens AG, Healthcare 
Sector, Erlangen, Germany). For the assessment of left ventricular function, short-axis 
cine images from the mitral valve annulus to the apex were obtained using a balanced 
steady-state free-precession sequence (8-mm parallel slices with 2-mm spacing). 
Quantification of left ventricular function and volumes indexed to body surface area 
was assessed using standard methods with dedicated software (Siemens AG 
Healthcare Sector, Erlangen, Germany).(270) Using this software papillary muscle 
delineation was not included in the analysis. Regional systolic function assessments 
were performed from the basal, mid, and apical short-axis slices by calculating the 
end-diastolic and end-systolic wall thicknesses and expressed as the wall motion score 
index (WMSI; 0, normal; 1, mild or moderate hypokinesia; 2, severe hypokinesia; 3, 
akinesia; 4, dyskinesia).(95)  
 
The assessment of focal replacement myocardial fibrosis was performed with late 
gadolinium enhancement (LGE) imaging, 15 min after administration of 0.1 mmol/kg 
gadobutrol (Gadovist/Gadavist, Bayer Pharma AG, Berlin, Germany). LGE imaging 
was performed between 8 and 15 min using two approaches: an inversion-recovery 
fast gradient-echo sequence and a phase-sensitive inversion recovery sequence, 
performed in two phase encoding directions to differentiate true enhancement from 
artefact. The inversion time was optimized for each slice to achieve satisfactory 
nulling of the myocardium.(212) The amount of LGE was quantified with QMASS 
software (Medis Medical Imaging Systems, Leiden, the Netherlands) using a signal 
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intensity threshold greater than twice the standard deviation above the mean value in 
a normal region of myocardium sampled on the same short-axis image. The transmural 
extent of infarction within each segment was classified using a transmurality score 
(transmurality index; 0, no LGE; 1, 1-50%; 2, 51-75% or 3, 76-100%) and recorded 
as either subendocardial (1-2) or transmural (3).(209) Areas thought to represent 
inversion artefact or blood pool contamination were manually excluded.  
 
Myocardial extracellular volume fraction (ECV) has been demonstrated to act as a 
measure of myocardial fibrosis in a variety of cardiac conditions.(210,211)  Recently, 
our group has described a highly reproducible standardized approach to analyse 
myocardial ECV. (212) To achieve this, T1 mapping was performed using the 
MOdified Look-Locker Inversion recovery (MOLLI; flip angle 358; minimum TI 100 
ms; TI increment of 80 ms; time delay of 150 ms with a heart beat acquisition scheme 
of 3-3-5) with built-in motion correction.(213) A gradient echo field map and 
associated shim were performed to minimize off-frequency artefact. Short-axis T1 
maps of the mid-cavity slice were acquired in diastole before and at 2, 5, 10, 15, 20, 
and 30 min following the administration of 0.1 mmol/kg of gadobutrol 
(Gadovist/Gadavist, Bayer Pharma AG, Germany). The basal slice was defined as the 
first complete ring of myocardium below the aortic outflow tract, and the mid-cavity 
slice as the most basal slice to include both papillary muscles. The apical slice was 
selected between the apex and the mid-cavity on the image least affected by 
trabeculations and partial volume averaging.(212) Regions of interest were drawn 
around the myocardium on the short-axis, pre-contrast, motion-corrected myocardial 
T1 maps and copied onto corresponding 20-min post-contrast maps, with minor 
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adjustments made to avoid partial volume effects and artefact (OsiriX version 4.1.1, 






∆R1=(1/postcontrast T1−1/precontrast T1). 
 
Hematocrit was sampled at the time of MRI.(214) 
 
  





For histological analysis, myocardial biopsy samples were obtained from patients 
undergoing coronary artery bypass grafting following myocardial infarction. Patients 
with recent large ST-elevation myocardial infarction (<14 days, hs-cTnI >10,000 
ng/L) were considered for inclusion. A core cardiac biopsy was taken intra-operatively 
under direct visualisation by an experienced surgeon from the peri-infarct zone. 
Samples were fresh frozen and mounted in cryosection medium. Histological 
processing was performed by trained staff in the Histopathology department at the 
Queens Medical Research Institute. The tissue samples were then cut in sequential, 
longitudinal 4-µm sections at -20 °C and thaw-mounted onto microscope slides. They 
were dried for 15 min and spray-fixed with neutral buffered formalin. After rinsing in 
distilled water, sections were stained with hematoxylin-eosin (HE) and van-Gieson 
(VG) for conventional histopathological examination. In order to optimize 
immunohistochemistry, an antigen-unmasking step was performed by microwave 
treatment for 30 s. Endogenous peroxidase was blocked by incubation with hydrogen 
peroxide for 5 min. Sections were subsequently incubated with the primary antibodies; 
smooth muscle actin, CD31, CD68 (clone PG-M1), and integrin αvβ3 antibody, clone 
LM609 (Millipore) for 30 min at room temperature. After washing the sections were 
incubated with Envision Flex (DAKO, K5007) for 30 min at room temperature, 
followed by incubation with diaminobenzamine (Sigma) for 10 min. The slides were 
finally counterstained with hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, 
UK) before visual assessment by Dr William Jenkins under the supervision of 
Consultant Pathologist Professor Donald Salter to ascertain the distribution and 
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5.3.7. Statistical Analysis 
 
We explored myocardial radiotracer uptake in 3 groups of patients, comparing them 
to CMR and clinical indices of cardiac function. Continuous data were tested for 
normality with the D’Agostino and Pearson Omnibus test.  Continuous normal 
variables were expressed as mean±standard deviation and compared using Students t-
testing or analysis of variance (ANOVA) testing when comparing more than 2 groups. 
Continuous non-normal variables were presented as median [interquartile range] and 
compared using the Mann-Whitney or Kruskal-Wallis test when evaluating two/more 
than two groups. Interobserver reproducibility was calculated by Bland-Altman 
method and presented as mean bias ±2 standard deviations, and intraclass correlation 
coefficients (ICC) with 95% confidence intervals (CI). The chi-squared test was used 
for analysis of categorical variables. Univariable and multivariable logistic regression 
models were used to determine factors associated with an improvement in segmental 
myocardial function. Statistical analysis was performed with GraphPad Prism version 
6 (GraphPad Software Inc., USA) and JMP version 10.0 (SAS Software, North 
Carolina, USA) where appropriate. A two-sided P-value<0.05 was considered 
statistically significant. 
  





5.4.1. Baseline clinical characteristics 
 
Thirty-seven subjects underwent PET/CT after injection of 229±12 MBq 18F-
fluciclatide: 21 patients with acute MI, 7 patients in the CTO group and 9 healthy 
volunteers (Table 5.1). The groups were generally well balanced for age, sex and body-
mass index. Healthy subjects had a lower prevalence of cardiovascular risk factors 
(Table 5.1). The mean radiation dose for each 18F-fluciclatide PET scan was 5.9 mSv 
(range 5.2-6.4 mSv). The mean attenuation correction CT acquisition radiation dose 
was 1.4 mSv (range 0.8-1.9 mSv). Cardiac CT contrast angiography dosing was 
6.7mSv (range 2.1-11.7 mSv); the wide dose range accounted for the potential 
presence of atrial fibrillation that prevents prospective ECG gating. The mean 
radiation dose per participant for those who received a single PET/CT imaging 
assessment was 15.1 (range 7.8-18.9) mSv, and 21.9 (range 16.5-28.7) mSv in those 
who underwent repeat PET scanning.  
  
Novel Applications of PET in Cardiovascular Disease 
 
204 























Patient Characteristics      
Age (years) 64±10 62±12 69±7 66±7 0.06 
Male Sex 27(73) 16(76) 5(71) 6(67) 0.46 
BMI (kg/m2) 28±4 28±5 31±3 27±4 0.74 
18F-Fluciclatide Dose (mBq) 229±12 227±13 227±14 232±9 0.86 
Current Smoker 9(24) 8(38) 1(14) 0(0) 0.01 
Diabetes Mellitus 4(11) 3(14) 1(14) 0(0) 0.06 
Hypertension 16(43) 7(33) 5(71) 4(44) 0.04 
Hypercholesterolemia 22(60) 14(66) 6(86) 2(22) <0.001 
Cardiovascular History 
Prior myocardial infarction 7(19) 1(5) 6(86) 0(0) <0.001 
Angiographically documented 
CAD 
28(76) 21(100) 7(100) 0(0) <0.001 
Previous PCI 4(11) 1(5) 3(42) 0(0) <0.001 
CCS Class 
0 28(76) 17(81) 2(29) 9(100) 0.02 
I or II 7(19) 4(19) 3(42) 0(0) 0.03 
III or IV 2(6) 0(0) 2(29) 0(0) 0.51 
NYHA Class 
I 29(78) 15(71) 3(42) 9(100) 0.32 
II 7(19) 5(24) 2(29) 0(0) 0.39 
III or IV 2(6) 1(5) 1(14) 0(0) 0.25 
Medications 
Aspirin 27(73) 21(100) 6 (86) 0(0) <0.001 
Clopidogrel 22(59) 19(90) 3(42) 0(0) <0.001 
Statin 29(78) 21(100) 7(100) 1(11) 0.004 
β-Blocker 26(70) 20(95) 6(86) 0(0) <0.001 
ACEi / ARB 27(73) 20(95) 5(71) 2(22) 0.02 
Clinical Features 
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Systolic BP (mm Hg) 137±22 128±18 140±24 155±21 0.06 
Heart rate (bpm) 64±12 62±13 61±11 68±10 0.42 
Creatinine (µmol/L) 79±15 82±19 77±14 73±12 0.54 
hs-CRP (mg/L) 3.5[1.3-9.8] 5.6[2.0-11.7] 2.2[1.0-9.1] 1.5[1.2-3.3] 0.008 
 
Mean±SD, median [IQR] or number (percentage). *Analysis of variance, Students t-test 
(continuous data) or Chi squared test (categorical data). Abbreviations: BMI, body-mass 
index; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CCS, 
Canadian Cardiovascular Society; NYHA, New York Heart Association; ACEi, angiotensin-
converting enzyme inhibitor, ARB, angiotensin receptor blocker; BP, blood pressure; hs-CRP, 
high-sensitivity c-reactive protein 
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5.4.2. CMR characterisation of myocardial infarction & remodeling 
 
There were no areas of infarction in control subjects. All patients within the acute MI 
cohort (n=21) had visible infarction on CMR 13±5 days after MI. These infarcts were 
large (infarct size 12±7 g/m2, peak cardiac troponin I 50,000 [26,753-50,000] ng/L) 
and featured the anterior (n=16) and lateral (n=4) territories predominantly, while 1 
patient had an inferior MI. All subjects received emergency coronary angiography 
with successful revascularization 197 [148-342] min from the onset of symptoms 
(Table 5.2). 
 
Old infarcts were present in 6 of 7 patients in the CTO group. Although there was no 
difference in infarct size [g/m2] between MI and CTO groups (p=0.34), the left 
ventricular ejection fraction (LVEF) was reduced with a larger WMI score in those 
with recent MI (p<0.01 compared to either the CTO or control group, Table 5.3).  
 
Seventeen patients from the acute MI group received follow-up CMR imaging 287±37 
days after MI. During this timeframe, there were improvements in LVEF (p<0.01) and 
regional wall motion (WMI; p<0.005). In total, 43 of 272 myocardial segments (16%) 
showed an improvement in regional wall motion, while 226 segments remained 
unchanged and 3 segments displayed functional deterioration. Infarct size and LV 
mass also improved (p=0.03 and p<0.01 respectively, Table 5.4). 
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Table 5.2.  Characteristics of patients with acute myocardial infarction 
 
Clinical Data Acute MI Group 
(n=21) 
Peak cardiac troponin I (ng/L) 50,000 [26,753-50,000] 
Percutaneous coronary intervention 20 (95) 
Symptom onset to reperfusion (min) 197 [148-342] 
Single vessel disease 10 (48) 
Myocardial Infarction Territory  
        Anterior 16 (76) 
        Lateral 4 (19) 
        Inferior 1 (5) 
Adverse Outcome 
        TIMI Flow post-PCI <3 1 (5) 
        Cardiogenic Shock 3 (14) 
        IABP 2 (10) 
        Aborted cardiac arrest 2 (10) 
 
Median [interquartile range] and number (%). Abbreviations; TIMI, trials in myocardial 
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  (n=9) 
p 
value* 
CMR Imaging  
LVEF (%) 58±10 52±9 62±8 65±5 <0.001 
LV Mass (g/m2) 79±20 85±20 66±17 75±16 0.07 
LVEDV (mL/m2) 77±18 80±18 69±13 76±17 0.35 
LVESV (mL/m2) 34±13 39±14 30±10 27±9 0.046 
WMI  0.25±0.13 0.40±0.20 0.09±0.05 0.0±0.0 <0.001 
ECV (%) 31±5 34±4 28±3 28±2 <0.001 
Presence of LGE 27(73) 21(100) 6(86) 0(0) <0.001 
Infarct size (g/m2) 8±8 12±7 8±8 0±0 <0.001 
PET Imaging  
SUVmean (kBq/mL)  
     SVC  2.73±0.51 2.85±0.51 2.57±0.39 2.58±0.57 0.27 
     Total LV uptake 2.24±0.51 2.33±0.48 1.96±0.53 1.77±0.27 <0.001 
     Myocardial Infarct Uptake  3.23±1.03 3.72±0.63 1.76±0.26 - <0.001 
     Remote Myocardial Uptake  2.21±0.60 2.41±0.57 1.62±0.14 - 0.001 
TBRmean   
     Total LV Uptake 0.77±0.16 0.82±0.18 0.71±0.06 0.70±0.03 0.08 
     Myocardial Infarct Uptake 1.05±0.37 1.34±0.22 0.70±0.14 - <0.001 
     Remote Myocardial Uptake 0.80±0.18 0.85±0.17 0.64±0.12 - 0.009 
SUVmax  (kBq/mL)  
     Total LV uptake 2.71±0.58 2.86±0.56 2.24±0.40 2.07±0.31 <0.001 
     Myocardial Infarct Uptake 3.53±1.00 3.98±0.68 2.18±0.35 - <0.001 
     Remote Myocardial Uptake 2.59±0.64 2.75±0.65 2.18±0.35 - 0.02 
TBRmax  
     Total LV uptake 0.98±0.19 1.02±0.19 0.89±0.20 0.81±0.09 0.01 
     Myocardial Infarct Uptake 1.28±0.34 1.42±0.25 0.86±0.16 - <0.001 









     Total LV uptake  -0.55±0.57 -0.52±0.55 -0.61±0.67 0.81±0.42 0.85 
     Myocardial Infarct Uptake 0.75±0.91 1.13±0.67 -0.40±0.46 - <0.001 
     Remote Myocardial Uptake -0.19±0.52 -0.11±0.54 -0.45±0.37 - 0.12 
 
Mean±SD or number (percentage). *Analysis of variance, Students t-test (continuous data) or 
Chi squared test (categorical data). Abbreviations: CMR,cardiac magnetic resonance; 
LVEF,left ventricular ejection fraction; LVEDV,left ventricular end diastolic volume; 
LVESV,left ventricular end systolic volume; WMI,wall motion index; ECV,extracellular 
volume; LGE,late gadolinium enhancement; SVC; superior vena cava; SUV,standardized 
uptake value; TBR,tissue-to-background ratio, SUVC, corrected SUV  
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Table 5.4. Acute myocardial infarction assessments   
 
CMR Imaging  p-value 





MI to CMR (days) 13±5 287±37 <0.01 
LVEF (%) 52±9 55±8 <0.01 
Indexed LV Mass (g/m2) 85±20 74±13 <0.01 
LVEDV (mL/m2) 80±18 82±16 0.88 
LVESV (mL/m2) 39±14 38±12 0.36 
Wall Motion Index 0.40±0.20 0.22±0.15 <0.01 
ECV (%) 34±4 33±2 0.58 
Infarct size (g/m2) 13 [7-17] 6 [3-14] 0.03 
PET Imaging 





MI to PET (days) 12±4 76±19 <0.01 
Total LV Uptake (TBRmean) 0.82±0.18 0.85±0.18 0.96 
Myocardial Infarct Uptake (TBRmean) 1.34±0.22 1.20±0.21 0.02 
Remote Myocardial Uptake (TBRmean) 0.85±0.17 0.82±0.15 0.38 
Segmental uptake (TBRmean) & Regional Wall Motion (WMI) 
      Normal function (0) 0.80±0.26 0.83±0.23 0.14 
      Mild-mod hypokinesia (1) 0.89±0.33 0.97±0.29 0.33 
      Severe hypokinesia (2) 0.97±0.28 0.91±0.34 0.47 
      Akinesia (3) 0.77±0.21 0.73±0.24 0.66 
      Dyskinesia (4) - - - 
Segmental uptake & Transmurality of MI (TBRmean) 
     No infarct 0.75±0.23 0.81±0.23 NA 
     Subendocardial infarct (1-75%) 0.95±0.29 1.08±0.28 NA 
     Transmural infarct (76-100%) 0.89±0.29 0.88±0.27 NA 
 
Mean±SD or median [IQR]. Abbreviations: MI, myocardial infarction; LV, left ventricle; 
TBRmean, mean tissue-to-background ratio; CMR, magnetic resonance imaging; LVEF, left-
ventricular ejection fraction; LVEDV, left-ventricular end diastolic volume; LVESV, left 
ventricular end systolic volume; WMI, wall motion index; ECV, mean extracellular volume.   
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5.4.3. Histology & Dynamic Myocardial 18F-Fluciclatide PET 
 
In an exploratory analysis, 2 patients scheduled for coronary artery bypass surgery 
within 14 days of infarction underwent myocardial biopsies from the peri-infarct zone 
(Figure 5.1). This showed predominantly viable myocardium with widespread positive 
staining for αvβ3 integrin, largely in regions that co-localized to CD31-positive 
vascular endothelial cells. Interestingly, these sites represented mainly angiogenic 
microvasculature, although there was scattered co-localisation with dual smooth 
muscle actin- and CD31-positive arterioles. There were lesser numbers of CD68-
positive inflammatory cells and smooth muscle actin-positive myofibroblasts, but 
where present, they also co-registered with αvβ3 integrin expression (Figure 5.1).  
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Figure 5.1.  αvβ3 Integrin expression in patient with recent myocardial 
infarction 
 
The figure below displays images from adjacent fresh frozen and cryosectioned 
biopsies from the peri-infarct area of a patient with recent anterior MI. 
Immunohistochemical staining for (A) αvβ3 integrin displayed multiple regions of 
positive staining that co-localize to regions of staining for vascular endothelial cells 
(CD31, B) visible at x4 magnification. At x20 magnification, these regions of αvβ3 
staining (C) correspond predominantly to arterioles and the microvasculature (D), 
and also to regions of staining for smooth muscle actin (E), representative of both 
arterioles (co-staining with CD31) and myofibroblasts. There were relatively few 
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Dynamic PET studies were performed in a subgroup of 10 patients. 18F-Fluciclatide 
activity within the region of myocardial infarction increased gradually and reached a 
plateau at around 30-40 min (Figure 5.2). The injected activity was cleared from the 
blood pool with a half-life of about 10 min, so that it remained relatively high during 
the period of PET acquisition (superior vena cava SUVmean 2.73±0.51 at 40-70 min 
post-injection). The optimum contrast between 18F-fluciclatide uptake in the site of 
infarction compared to the blood pool was observed at 40 min (Figure 5.2B). This time 
point was therefore used for subsequent static imaging.  
 
Using a 2-compartment Patlak model,(9) 18F-fluciclatide uptake displayed a distinct 
linear phase and a steep Ki slope, in keeping with irreversible binding of 18F-
fluciclatide to αvβ3 integrin during the 70-min period of evaluation (Figure 5.2D). The 
three-dimensional parametric images generated from Patlak analysis (Figure 5.2E, 
Figure 5.3F) confirmed regions of increased 18F-fluciclatide binding in sites of acute 
infarction, supporting an up-regulation of αvβ3 integrin within the infarct zone.  
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Figure 5.2.  Dynamic Analysis of 18F-Fluciclatide Uptake 
 
Axial and sagittal CT angiography of the thorax in a patient with recent anterior MI 
(A). The time-activity curves generated from the descending aorta and the apical 
interventricular septum (blue crosshairs) show increased uptake in the infarct relative 
to blood pool. Optimal contrast between 18F-fluciclatide tissue and blood pool activity 
was observed after 40 min (dotted line, B). The PET image in the axial and sagittal 
plane shows increased uptake within the apical septum, although there is some 
background activity (C). Patlak analysis of ROI’s placed in the interventricular 
septum confirms integrin binding, as evidenced by the gradient of the slope and the y-
intercept (D), and using a Ki-generated image we can better identify and delineate 
focal uptake within myocardium (E). A region of remote myocardium within the same 
patient generates a Patlak curve with significantly lower gradient and intercept in 
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5.4.4. Static 18F-Fluciclatide PET in Myocardial Infarction 
 
PET Repeatability Studies 
 
The reproducibility of 18F-fluciclatide uptake quantification was assessed in both the 
blood pool and the myocardium in 10 subjects selected at random. Residual blood pool 
radiotracer activity was quantified within both the SVC and right atrium. While both 
methods displayed no fixed or proportional biases with narrow limits of agreement 
and high ICC values of >0.94, the SVC-approach appeared to hold a slight advantage 
(ICC 0.97 [95% CI; 0.93-0.99]) and this therefore was applied throughout the study to 
quantify latent radiotracer blood activity (Table 5.5).   
 
Quantification of radiotracer uptake within the region of myocardial infarction was 
assessed using the mean Standard Uptake Value (SUVmean), the mean tissue to 
background ratio (TBRmean) and a novel method subtracting the target tissue mean 
SUV from the blood pool mean SUV (SUVtarget – blood pool).(134) The SUVmean and 
TBRmean both proved highly reproducible, displaying no fixed or proportional biases 
(mean % difference [95% limits of agreement]; 3.0 [-27.2 - 33.3], and 3.0 [-24.0-29.9] 
respectively) and a high ICC value (0.93 [0.82-0.97] and 0.94 [0.83-0.98] 
respectively). Selecting repeatable regions of remote myocardium proved less reliable, 
with wider limits of agreement (-18.9-66.2) and a moderate intra-class coefficient 
value of 0.60. Quantification of the regional 18F-fluciclatide TBRmean in individual 
myocardial segments also proved reproducible with no fixed or proportional biases 
(mean % difference -8.97 [95% CI -31.6 to 13.6]) and a high ICC value (0.90 [95% 
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CI 0.590-0.975]). The TBRmean method was therefore preferentially used for 
subsequent analysis to compensate for potential contamination from residual blood 
pool activity.  
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Table 5.5.  18F-Fluciclatide Reproducibility  
 
 Reproducibility Analysis 
 Mean % differencea Intra-class coefficientb 
Blood pool assessment (SUV)   
SVC 3.1 (-9.5–15.6) 0.971 (0.928-0.989) 
Right Atrium -0.46 (-11.7-10.7) 0.943 (0.868-0.975) 
Infarct assessment    
TBRmean 
     Whole Ventricle  -8.97 (-31.6-13.6) 0.898 (0.590-0.975) 
     Infarct 3.0 (-24.0-29.9) 0.940 (0.833-0.978) 
     Remote myocardium 23.7 (-18.9-66.2) 0.604 (-0.280-0.847) 
SUVmean   
     Whole ventricle technique -6.7 (-25.3–11.9) 0.957 (0.830-0.989) 
     Infarct 3.0 (-27.2-33.3) 0.930 (0.819-0.973) 
     Remote myocardium  21.2 (-11.1-53.7) 0.787 (0.448-0.918) 
     Infarct:remote myocardium ratio -18.2 (-60.6-24.1) 0.687 (0.187-0.879) 
SUVtarget tissue - blood pool   
     Whole Ventricle 24.1 (-19.2–67.3) 0.410 (-0.372-0.698) 
     Infarct  77.7 (-464.6–620.1) 0.933 (0.814-0.976) 
     Remote Myocardium -43.8 (-120.4-32.7) 0.574 (-0.106-0.836) 
 
a Mean % difference between standard uptake value (SUV; kBq/mL) measurements (95% 
limits of agreement), and b ICC (intraclass correlation coefficient) values (95% confidence 
intervals) for 18F-fluciclatide myocardial uptake and residual blood pool activity. 
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Static PET Studies 
 
All patients in the acute MI cohort had increased focal myocardial uptake of 18F-
fluciclatide on baseline PET/CT scanning (12±4 days after MI), which co-localized to 
regions of infarction on CMR (Figures 5.2 & 5.3, Tables 5.2 & 5.3). Hepatic uptake 
of 18F-fluciclatide was common. However, in the patient with inferior MI, basal 
inferior and infero-septal myocardial uptake of 18F-fluciclatide was quantifiable. 18F-
Fluciclatide uptake was greater in the acute myocardial infarct when compared to 
regions of old infarction in the CTO cohort and healthy myocardium in the control 
group, regardless of the measure of PET uptake used (for example, TBRmean 1.34±0.22 
vs. 0.70±0.14 vs. 0.70±0.10, p<0.001 respectively). Indeed, no focal increase in 18F-
fluciclatide uptake was observed in regions of chronic infarction, with similar PET 
uptake measurements compared to control subjects (e.g. TBRmean, p=0.83). In regions 
of myocardium remote to the site of acute infarction, 18F-fluciclatide activity was 
modestly but uniformly increased when compared to comparative regions in CTO 
patients (TBRmean 0.85±0.17 vs 0.64±0.12, p=0.009). Across our population there were 
no age-related (TBRmean, r=-0.19 [-0.53-0.19], p=0.31) or sex-related (TBRmean 
1.14±0.07 vs. 1.25±0.17, p=0.46) differences in 18F-fluciclatide uptake. 
 
Seventeen subjects agreed to return for a second 18F-fluciclatide PET/CT 76±19 days 
post-MI, with similar results noted. All these patients were clinically stable between 
the scans. 18F-Fluciclatide uptake remained elevated at the site of infarction (MI vs. 
CTO group, TBRmean 1.20±0.21 vs. 0.70±0.15 respectively, p<0.001), although the 
intensity was reduced compared to earlier imaging (p=0.01; Figure 5.3). Increased 
18F-fluciclatide uptake also persisted in regions of remote myocardium when 
Novel Applications of PET in Cardiovascular Disease 
 
220 
compared to uptake in CTO patients (TBRmean 0.82±0.15 vs 0.64±0.12 respectively, 
p=0.01) and interestingly remained equivalent in terms of intensity compared to the 
initial PET scan (TBRmean 0.85±0.17 vs 0.82±0.15 respectively, p=0.38). 
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Figure 5.3.  18F-Fluciclatide uptake in acute myocardial infarction 
 
18F-Fluciclatide uptake in 3 patients with recent subendocardial myocardial 
infarction (MI). Patient 1, 13 days after anterior MI, displaying a short-axis PET 
image of the left ventricle with crescentric 18F-fluciclatide uptake (A) that correlates 
with the interventricular septum and anterior wall on CT angiography (B). The fused 
PET/CT-angiography image (C) shows this uptake corresponds exactly to the region 
of late gadolinium enhancement (LGE) on CMR (D). Further delineation of 
myocardial uptake on PET/CT is clearer in the 2-chamber view (E) and on a fused 
CT/3D-Patlak image, which shows this uptake to follow a watershed-pattern emerging 
from the coronary stents present in the left anterior descending coronary artery (F). 
Panels G & H: patient 2, 8 days following anterior MI, displaying focal uptake of 18F-
fluciclatide in the anterior wall and apex in the 3-chamber view on PET/CT (G) which 
corresponds to the region of infarction on LGE CMR imaging (H). Panels I & J: 
patient 3, showing focal uptake of 18F-fluciclatide in the inferior wall 19 days 
following MI on PET/CT (I) that again corresponds to the infarction on CMR LGE 
imaging (J).  
 








5.4.5. Myocardial 18F-Fluciclatide Uptake and Cardiac Function 
 
The extent of 18F-fluciclatide uptake following MI was compared with clinical and 
imaging measures of MI severity and subsequent repair (Table 5.6). Although 
segmental 18F-fluciclatide uptake displayed a moderate correlation with the degree of 
extracellular volume on CMR T1 mapping (r =0.37, p<0.001), it did not correlate with 
many of the standard measures of infarct severity, in particular there were no 
associations with infarct size on CMR (r=0.03, p=0.90), LVEF (r=-0.08, p=0.72), hs-
TnI (r=0.13, p=0.36) or C-reactive protein (r=-0.20, p=0.38) (Table 5.6). This may be 
explained by the absence of increased uptake in the largest akinetic infarcts (normal 
wall motion vs. akinetic segments; TBRmean 0.80±0.26 vs. 0.77±0.21, p=0.77). Rather 
18F-fluciclatide activity was highest in segments with hypokinesis  (WMI 1&2 vs. 0; 
TBRmean 0.92±0.03 vs 0.80±0.26, p<0.001; Figure 5.4) and segments associated with 
a subendocardial pattern of LGE (subendocardial LGE vs no LGE; TBRmean 0.95±0.06 
vs. 0.75±0.03 respectively, p<0.001; Figure 5.4).  
 
18F-Fluciclatide uptake was higher in hypokinetic regions that subsequently 
demonstrated functional recovery compared to regions with no change or a worsening 
in contractile function (TBRmean 0.95±0.33 vs 0.81±0.02 respectively, p=0.002; Figure 
5.4). Using logistic regression analysis, 18F-fluciclatide TBRmean was significantly 
associated with recovery in segmental cardiac function on univariable analysis (OR 
1.27 [95% CI 1.08-1.50] per 10% increase in TBRmean, p=0.003), which persisted after 
adjustment for age and sex (OR 1.27 [95% CI 1.07-1.51] per 10% increase in TBRmean, 
p=0.005). This effect was however attenuated following additional adjustment for the 
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transmurality of LGE (OR 1.03 [95% CI 0.83-1.26] per 10% increase in TBRmean, 
p=0.80) and ECV (OR 1.02 [0.91-1.32] per 10% increase in TBRmean, p=0.35).   
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Table 5.6.  Comparison of 18F-fluciclatide uptake and indices of 
infarction 
 
Ψ ECV and PET association assessed per segment. Abbreviations: hs-cTnI, high sensitivity 
cardiac troponin I; hs-CRP, high sensitivity c-reactive protein; LVEF, left ventricular ejection 
fraction; LV, left ventricular; LVEDV, left ventricular end diastolic volume; ECV, mean 
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Figure 5.4.  18F-Fluciclatide uptake in myocardial infarction 
 
Uptake of 18F-fluciclatide in (A) patients with acute myocardial infarction at 2 and 
10 weeks, patients with chronic total occlusion and healthy control subjects. Uptake 
was greatest at 2 weeks after myocardial infarction (B). 18F-Fluciclatide uptake in 
the acute MI group was greater in regions of hypokinesis when compared to sites of 
normal function or akinesis (C). This translated to a higher 18F-fluciclatide uptake in 
those regions which subsequently improved in function on follow-up CMR (D). Data 






























































































































































































Using the novel radiotracer 18F-fluciclatide, we have for the first time described the 
temporal expression of myocardial αvβ3 integrin receptor in patients with recent acute 
MI. We demonstrate intense early uptake attributable to regions of recent infarction, 
in particular subendocardial, hypokinetic infarcts that appeared to demonstrate 
subsequent functional recovery. Our data suggest that αvβ3 integrin receptor expression 
can be readily quantified in the infarct zone, and that 18F-fluciclatide PET may hold 
promise as a clinical biomarker of healing activity with application to novel 
pharmacological or cell-based therapies aimed at improving outcome after MI. 
 
Expression of αvβ3 integrin by vascular endothelial cells facilitates myocardial salvage 
through angiogenesis in the peri-infarct zone, while also mediating the activated 
macrophage response to inflammatory signals and governing myofibroblast 
differentiation through the activation of latent TGF-b1.(118-120) The αvβ3 integrin 
contains a binding site for an RGD-peptide subunit (the arginine-glycine-aspartate 
motif) and this is the target for a number of molecular imaging probes. In murine and 
human studies of acute MI, RGD-based radiotracers accumulate at the site of 
infarction as early as 3 days, peaking at 1-3 weeks post-MI (121,135) and correlating 
with adverse remodeling and infarct scar formation at 12 months.(129,237) For the 
first time, we have here confirmed and extended these findings using the highly 
selective and sensitive PET RGD-radiotracer, 18F-fluciclatide. Moreover, given the 
study sample size and comprehensive imaging assessment, we have been able to make 
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several significant observations as well as incorporate a number of important controls 
and comparisons. 
 
We have compared 18F-fluciclatide uptake in patients with recent acute MI with 
healthy control subjects and patients with established infarction. We have 
demonstrated that 18F-fluciclatide uptake is specific for acute infarction and does not 
bind to old established infarcts. Perhaps more importantly, we did not see a correlation 
with acute infarct size, quantified as the mass of LGE on CMR. Indeed binding of 18F-
fluciclatide in akinetic infarcts was relatively low, and was instead highest in sub-
endocardial infarcts associated with hypokinesia. This would suggest that 18F-
fluciclatide uptake is not a surrogate of infarction itself but relates more to the tissue 
healing response to injury, although without additional CMR sequencing we were 
unable to distinguish between 18F-fluciclatide uptake in regions of infarction versus 
regions of viable ‘stunned’ myocardium with LGE patterns that represented 
myocardial oedema. 
 
There are a number of potential explanations for the preferential binding of 18F-
fluciclatide to subendocardial infarcts. It is possible that microvascular obstruction in 
larger infarcts prevented tissue penetration by 18F-fluciclatide or that the presence of 
tissue necrosis resulted in loss of tissue architecture and altered 18F-fluciclatide 
kinetics. However a number of our observations suggest that 18F-fluciclatide uptake 
reflects novel avb3 integrin expression due to re-endothelialisation and angiogenesis 
in the peri-infarct zone. First, ex vivo histological examination 2 weeks following MI 
demonstrated that αvβ3 integrin expression predominantly co-localizes within 
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endothelial cells of the microvasculature, aligning with prior reports of a relative 
reduction in inflammatory cell activity in the infarct and peri-infarct tissue at this 
timepoint.(63) Second, increased 18F-fluciclatide uptake was associated with 
functional recovery of hypokinetic infarcts. Third, we did not observe 18F-fluciclatide 
uptake in patients with CTO who have chronic and well established collateral 
vasculature. Fourth we did not observe large regions of microvascular obstruction on 
CMR imaging. This suggests that, within our imaging timeframe, predominantly 
newly forming vessels or repopulation of vessels with endothelial cells will result in 
αvβ3 integrin expression and 18F-fluciclatide uptake. This is consistent with similar 
observations in other diseased states such as angiogenesis associated with 
malignancy.(9,10) In our patients with MI, intense binding was observed in the peri-
infarct regions of sub-endocardial MIs with only poorly-defined uptake in the central 
necrotic area. Given these associations and the likelihood that 18F-fluciclatide 
identifies areas of re-endothelialisation and angiogenesis, it is perhaps not surprising 
that 18F-fluciclatide uptake, while visible to a certain degree throughout the region of 
myocardial infarction, appeared to intensely localise to segments that demonstrated 
subsequent functional recovery. Taken together our data suggest that assessing αvβ3 
integrin expression in the acute phase of repair might be of use in investigating the 
healing processes that occur following acute MI. Larger studies are required to confirm 
these initial findings and assess whether 18F-fluciclatide PET provides incremental 
benefit to CMR (our study was not sufficiently powered). However as a marker of 
activity 18F-fluciclatide may be of particular use in assessing the effects of novel 
therapies aimed at accelerating repair post-MI.  
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At 10 weeks following MI, 18F-fluciclatide uptake persisted in the region of infarction 
but was reduced compared to the 2-week assessment. This delayed phase of repair is 
characterized pathologically by a reduction in inflammation and angiogenesis, and a 
more moderated reorganization of the ECM through myofibroblast-driven type I and 
III collagen production.(238) From our study, we are unable to determine whether this 
reduction in 18F-fluciclatide uptake reflects the waning of re-endothelialisation and 
angiogenesis, or represents a switching to myofibroblast cell types indicative of an 
enhanced fibrotic response. There was some heterogeneity in the time course of 18F-
fluciclatide uptake since uptake increased at 10 weeks in 6 subjects. However, we 
detected no adverse effects of this increase in uptake and there was no corresponding 
increase in LGE or ECV on T1 mapping. 
 
Modification of the extracellular matrix following MI is not only limited to the site of 
infarction. Indeed, the myofibroblast-driven fibrotic expansion seen in the remote 
myocardium influences global myocardial recovery.(96) Expression of αvβ3 integrin 
in remote myocardial regions has been reported up to 6 months following MI.(86,119) 
In keeping with this, 18F-fluciclatide activity was consistently increased in the remote 
myocardium at both 2 and 10 weeks when compared to comparative myocardial 
regions in patients with CTO, and healthy controls.  
 
There are some limitations of our study that we should acknowledge. First, despite 
accounting for systolic motion using electrocardiographic gating, cardiac PET is also 
limited by respiratory motion and this may affect sensitivity in particular due to the 
high activity in the closely adjacent blood pool and hepatic tissue. This is likely to be 
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a particular problem for inferior infarcts (present in only one of our study subjects), 
although these less commonly lead to adverse remodelling and heart failure. Novel 
motion tracking may in the future help to negate some of these issues and enable even 
greater definition of regional αvβ3 integrin expression.(239) Second, limited cardiac 
tissue was available for histological assessment, preventing complete stoichiometric 
and temporal assessment of αvβ3 integrin expression in man post-MI. Fortunately 
inference can be drawn from extensive animal models of infarction. However prior to 
the validation of 18F-fluciclatide as an imaging biomarker for a specified pathological 
process, a more extensive and specific histological characterization is required, given 
the variation in pathology within an acutely healing myocardial infarct. Third, our 
study was not powered to address the incremental value of 18F-fluciclatide PET over 
established predictors markers of cardiac recovery such as CMR. This will require 
larger patient populations. Instead this study provides the first description of increased 
18F-fluciclatide in the myocardium following MI, indicating that it provides important 
information about the LV remodeling response. Further studies will be required to 
establish the clinical utility of this approach. 
 
In conclusion, we report the largest and most comprehensive analysis of an αvβ3 
integrin radiotracer in the assessment of myocardial repair following acute MI. We 
have demonstrated that increased 18F-fluciclatide uptake occurs at sites of acute 
myocardial infarction, in particular regions of sub-endocardial infarction and 
hypokinesia associated with subsequent functional recovery. Our data suggest 
myocardial αvβ3 integrin expression represents a marker of ongoing cardiac repair, and 
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that 18F-fluciclatide is a potentially useful imaging biomarker for investigating this 
healing response post-MI. 
  




Chapter 6.   
In Vivo Alpha-V Beta-3 Integrin Expression in 
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Intra-plaque angiogenesis and inflammation are key promoters of atherosclerosis and 
are mediated by the αvβ3 integrin receptor pathway. We investigated the applicability 
of the novel αvβ3-integrin receptor-selective positron emission tomography (PET) 
radiotracer 18F-fluciclatide in assessing human aortic atherosclerosis.  
 
Vascular 18F-fluciclatide binding was evaluated using ex vivo analysis of carotid 
endarterectomy samples with autoradiography and immunohistochemistry, and in vivo 
kinetic modeling following radiotracer administration. Forty-six subjects with a 
spectrum of atherosclerotic disease categorized as stable (n=27) or unstable (n=19; 
recent myocardial infarction) underwent PET and computed tomography (CT) 
imaging of the thorax after administration of 226±13 MBq 18F-fluciclatide. Thoracic 
aortic 18F-fluciclatide uptake was quantified on fused PET-CT images and corrected 
for blood-pool activity using the maximum tissue-to-background ratio (TBRmax). 
Aortic atherosclerotic burden was quantified by CT plaque thickness, plaque volume 
and calcium scoring.  
 
18F-Fluciclatide uptake co-localised with regions of increased αvβ3 integrin 
expression, and markers of inflammation and angiogenesis. 18F-fluciclatide vascular 
uptake was confirmed in vivo using kinetic modeling, and on static imaging correlated 
with each measure of aortic atherosclerotic burden: plaque thickness (r=0.57,p=0.001), 
total plaque volume (r=0.56,p=0.001) and aortic CT calcium score (r=0.37,p=0.01). 
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Patients with recent myocardial infarction had greater aortic 18F-fluciclatide uptake 
than those with stable disease (TBRmax 1.33 vs 1.21, p=0.01).  
 
In conclusion, In vivo expression of αvβ3 integrin in human aortic atheroma is 
associated with plaque burden and is increased in patients with recent myocardial 
infarction. Quantification of αvβ3 integrin expression with 18F-fluciclatide PET has 
potential to assess plaque vulnerability and disease activity in atherosclerosis. 
 
  





Atherosclerotic cardiovascular disease is the commonest cause of death worldwide, 
and elucidating the mechanisms underlying the propagation and rupture of 
atherosclerotic plaques remains a key public health goal.(1)  Although progress has 
been made in our understanding of the pathogenesis underlying atherosclerosis over 
the last two decades, the accurate prediction of clinical events remains elusive. There 
is therefore considerable interest in non-invasive imaging techniques that go beyond 
the detection of luminal stenoses and instead focus on measuring disease activity 
within the vasculature.(240,241) 
 
Combined positron emission tomography (PET) and computed tomography (CT) is a 
non-invasive hybrid imaging technique that integrates targeted functional molecular 
imaging with high-detail anatomical definition. This technique has been used to 
quantify vascular inflammation and calcification activity with success in both carotid 
and coronary atherosclerosis.(6,48,164,242) Recently, intraplaque angiogenesis and 
neovascularization has emerged as a key factor in the development, progression, and 
instability of atherosclerotic plaques.(243) The integrin αvβ3 cell surface receptor is up 
regulated on endothelial cells in states of angiogenesis and is also observed on 
macrophages at sites of increased vascular inflammation, another key contributor to 
plaque instability. This receptor helps coordinate interaction between cellular 
components and the extra-cellular matrix and contains a distinctive RGD-amino acid 
sequence in the cell-ligand interaction site. On this basis, several PET tracers targeting 
the RGD sequence have been developed for monitoring angiogenesis in malignant 
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tumours.(9,199) These tracers have also shown promise in monitoring atherosclerotic 
activity in pre-clinical models (181,182,243-245) and in a recent small study of 
patients with carotid atheroma.(242)  
 
18F-Fluciclatide is a novel RGD-based PET radiotracer with high affinity for the αvβ3 
integrin receptor.(9,10,190) We hypothesized that 18F-fluciclatide may act as an 
imaging marker of atherosclerotic disease activity in vivo, informing about both 
inflammation and angiogenesis. In this study we sought to characterize the cellular and 
imaging characteristics of 18F-fluciclatide uptake in human atherosclerosis using a 
clinical cohort of patients with both stable and unstable clinical disease.  
  





6.3.1. Study populations 
 
In total we studied 50 patients. Four patients were recruited who had sustained a recent 
stroke and were undergoing carotid endarterectomy. In these patients, excised carotid 
plaques were examined using histology and 18F-fluciclatide autoradiography. For in 
vivo imaging, 46 patients were recruited from the Royal Infirmary of Edinburgh 
between July 2013 and December 2014. This cohort comprised 19 unstable patients 
with a recent acute ST-segment elevation myocardial infarction,(246) and 27 stable 
patients with either stable angina (n=6) or asymptomatic atherosclerotic disease (n=21; 
12 had calcific aortic valve disease). Exclusion criteria were age <40 years, women of 
childbearing potential, severe renal failure (estimated glomerular filtration rate <30 
mL/min/1.73 cm2) or hepatic failure (Childs-Pugh grade B or C), atrial fibrillation, 
known contrast allergy, inability to undergo scanning and inability to provide informed 
consent. All 46 subjects underwent 18F-fluciclatide PET imaging alongside clinical 
assessment that included evaluation of cardiovascular risk and high sensitivity C-
reactive protein (hs-CRP) measurement (Biocheck inc.; Foster City, California). 
 
Studies were approved by the local research ethics committee, and conducted in 
accordance with the Declaration of Helsinki and with the written informed consent of 
each participant.  
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6.3.2.  Radiosynthesis of 18F-Fluciclatide 
18F-Fluciclatide was manufactured at the Clinical Research Imaging Centre on an 
automated module (FASTlab synthesiser; GE Healthcare) by coupling an amino-oxy-
functionalized peptide precursor (AH111695) with 4-18F-fluorobenzaldehyde at pH 
3.5 to form 18F-fluciclatide.(247) A full description of this synthesis has been 
published previously.(190)  
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6.3.3. Histological validation 
 
After obtaining informed consent, four human carotid intimal samples were obtained 
from patients undergoing carotid endarterectomy for symptomatic carotid artery 
atherosclerotic disease.(192)  Both atheromatous and non-atheromatous segments of 
dissected carotid atheroma were frozen in mounting medium. The tissue samples were 
then cut in sequential, longitudinal 4 µm and 20 µm slices sections at -20°C and thaw-
mounted onto microscope slides. Effort was made to align segments of ruptured plaque 
alongside non-atheromatous segments within the same slide. The slides were then 
dried for 15 min and spray-fixed with neutral buffered formalin. After rinsing in 
distilled water the 4 µm sections were stained with hematoxylin-eosin (HE) and van-
Gieson (VG) for conventional histopathological examination. In order to optimize 
immunohistochemistry, an antigen-unmasking step was performed by microwave 
treatment for 30 s. Endogenous peroxidase was blocked by incubation with hydrogen 
peroxide for 5 min. Sections were subsequently incubated with the primary antibodies; 
smooth muscle actin, CD31, CD68 (clone PG-M1), and integrin αVβ3 antibody, clone 
LM609 (Millipore) for 30 min at room temperature. After washing, the sections were 
incubated with Envision Flex (DAKO, K5007) for 30 min at room temperature, 
followed by incubation with diaminobenzamine (Sigma) for 10 min. The slides were 
finally counterstained with hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, 
UK). Image analysis was performed on ImageJ32 software (NIH, Bethesda, 
Maryland). Staining was expressed as a percentage of the total plaque area and with 
an object size set threshold applied at 20 x 10 pixels, to limit counting to cell-sized 
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objects. The density of cell staining in the endarterectomy tissue was expressed as cells 
per mm2.(226)  
 
 
Clinical PET systems have limited resolution. To gain more detailed information about 
the precise localization of 18F-fluciclatide binding in atherosclerotic tissue, we 
undertook autoradiography. The 20 µm frozen sections adjacent to those used for 
immunohistochemical analysis were warmed to room-temperature and bathed in a 
solution of 18F-fluciclatide at a concentration close to in vivo imaging concentrations 
(1 kBq/mL) for 60 minutes and then rinsed with phosphate buffer solution. An 
unlabeled highly concentrated solution of fluciclatide was added to selected slides in 
order to competitively bind to αvβ3 to assess for non-specific tracer uptake. A freshly 
blanked phosphor screen was then placed over the slides and an overnight exposure 
undertaken. The screen was read using a FujiFilm FLA-5100 Fluorescent Image 
Analyser (Raytek Scientific Limited, Sheffield, UK). Sections were then manually 
registered and examined for co-localization with histological markers of 
atherosclerotic disease activity by Dr. William Jenkins and Dr. Alexander Vesey under 
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6.3.4. Clinical 18F-fluciclatide PET imaging  
 
All patients in the imaging cohort underwent PET-CT imaging of the thorax with a 
hybrid scanner (Biograph mCT, Siemens Medical Systems, Erlangen, Germany) at the 
Clinical Research Imaging Centre, University of Edinburgh. Subjects were 
administered a target dose of 230 MBq 18F-fluciclatide. An attenuation correction CT 
scan (non-enhanced 120 kV and 50 mA, 3-mm slices) was performed prior to PET 
acquisition. To define tracer pharmacodynamics and the optimum timing of scanning, 
dynamic PET imaging of the thorax was performed in the initial 20 patients in 3-
dimensional mode using a single bed position for 70 min. For the remainder of the 
study subjects, static imaging was performed at the optimal time point (found to be 40 
min post-injection) using a single 30-min bed position in list mode with 
electrocardiographic gating.  
 
Immediately after PET acquisition, thoracic CT angiography was performed: 330 ms 
rotation time, 100 (body mass index <25 kg/m2) or 120 (body mass index >25 kg/m2) 
kV tube voltage, 160-245 mAs tube current, 3.8 mm/rotation table feed, prospective 
(heart rate regular and <60 /min), or retrospective (heart rate >60 /min) 
electrocardiogram-gated. Depending on body mass index, a bolus of 80-100 mL 
contrast (400 mgI/mL; Iomeron, Bracco, Milan, Italy) was injected intravenously at 5 
mL/s, after determining the appropriate trigger delay with a test bolus of 20 mL 
contrast material.  
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6.3.5. PET image reconstruction and analysis 
 
Kinetic analysis was performed on the dynamic PET studies to investigate the 
pharmacodynamics of 18F-fluciclatide uptake within atheroma. PET data were 
reconstructed (Ultra-HD, 2 iterations, 21 subsets, 256 pixels, 1.6-mm pixel size) in a 
dynamic profile using the following time frames; 60s x 5, 120s x 5, 180s x 5, 300s x 
8. Regions of interest (ROI’s) were drawn both in the blood pool and sites of aortic 
atheroma visible on CT and used to derive time activity curves after decay correction. 
These were used to define a timeframe for static imaging based upon the point at which 
optimum contrast between blood pool and tissue activity was observed. To define 18F-
fluciclatide uptake in aortic atheroma, a kinetic modeling input function calculation 
was based on the PET image-derived activity curve from the aortic blood pool (PMod 
version 4.3.1, Pmod technologies limited, Switzerland).(9) This input function was 
applied to a tissue activity curve generated from ROI’s placed in the myocardial 
interventricular septum, to estimate the tissue influx rate Ki (the slope of the linear 
regression) and the volume of distribution (the intercept with the y axis) using a 2-
tissue irreversible Patlak model, with t* set to 20 min, as described previously.(9,10) 
Thoracic 18F-fluciclatide dynamic activity was then normalized for the blood-pool 
input function on a voxel-by-voxel basis, and after 3D Gaussian filtering (5-mm 
FWHM), a parametric 3-dimensional image of 18F-fluciclatide uptake was generated 
accordingly. Using this image, regions of 18F-fluciclatide binding in the vasculature 
were identified and manually delineated for subsequent Ki analysis.  
 
 
Novel Applications of PET in Cardiovascular Disease 
 
244 
 In all patients, static electrocardiogram-gated PET images were reconstructed in 
diastole (40-70 min post-injection, 50–75% of the R-R interval, Ultra-HD, 2 iterations, 
21 subsets, zoom x2, 200 pixels). Images were analyzed by experienced observers 
blinded to the demographic data (WJ, AV) using an OsiriX workstation (OsiriX 
version 6.0 64-bit; OsiriX Imaging Software, Geneva, Switzerland). PET images were 
fused with the attenuation correction CT, and regions of interest (ROIs) drawn around 
the thoracic aorta on serial axial slices just beyond the discernible adventitial border. 
Aortic uptake was assessed in three regions: the ascending thoracic aorta (from the 
level of mid-right pulmonary artery (RPA) up to the last slice where the aorta 
maintained its circular cross-sectional appearance), the descending thoracic aorta (the 
region extending from the tip of the diaphragm up to the last circular slice) and the 
aortic arch (the region of the aorta connecting the ascending and descending aortae). 
Within these regions, mean and maximum tracer activities were measured using 
standard uptake values (SUV; the decay corrected tissue concentration of the tracer 
divided by the injected dose per body weight, kBq/mL) and corrected for mean 
radiotracer blood pool activity to provide a mean of the maximum tissue-to-
background ratios (mean TBRmax), as described previously. (2,6,161,248) The blood 
pool radiotracer activity was quantified in the superior vena cava (SVC), measured in 
the axial plane on 4-5 sequential 5-mm axial slices above the level of the junction of 
the left innominate vein. In a sub-study of 10 randomly selected subjects, images were 
assessed independently by two experienced observers (Dr. William Jenkins, Dr. Anna 
Vickers) and the inter-observer reproducibility of 18F-fluciclatide SUV and TBR 
measurements assessed.  
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6.3.6. CT image reconstruction and analysis 
 
The aortic CT calcium score was calculated for the aorta as a whole and for its different 
regions using axial slices on the attenuation correction CT dataset (OsiriX version 6.0 
64-bit; OsiriX Imaging Software, Geneva, Switzerland) and expressed in arbitrary 
units (AU).(60) Further measures of the aortic atherosclerotic plaque burden were 
made using CT angiography datasets on dedicated plaque analysis software (Vital 
Images, Minnetonka, Minnesota, USA). Using the sagittal plane, the entire portion of 
the descending thoracic aorta within the field of contrast CT acquisition was delineated 
and the luminal blood pool removed using semi-automated thresholding. The mean 
aortic wall thickness was recorded and corrected for the vessel diameter providing the 
indexed wall thickness. Additionally the aortic wall volume was recorded and 
corrected for total vessel volume to provide an indexed plaque volume.  
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6.3.7. Statistical analysis 
 
Continuous data were tested for normality visually and with the D’Agostino and 
Pearson Omnibus test.  Continuous parametric variables were expressed as 
mean±standard deviation and compared using Pearson correlation. Non-parametric 
data were presented as median [interquartile range] and compared using Spearman 
correlation or Wilcoxon signed-rank test as appropriate. Aortic calcium score and hs-
CRP were log-transformed to base 10 to achieve normality prior to statistical analysis. 
Interobserver reproducibility was calculated by Bland Altman method and presented 
as mean bias ± 2 standard deviations, and intraclass correlation coefficients 
(ICC).(215) Student’s t-test or Mann-Whitney U test was used for analysis of 
categorical variables. Statistical analysis was performed with Graph Pad Prism version 
6 (GraphPad Software Inc., California USA). A two-sided P<0.05 was taken as 
statistically significant.  





6.4.1. Plaque autoradiography and histology  
 
Autoradiography of carotid plaque demonstrated focal 18F-fluciclatide binding in 
regions of advanced atherosclerosis that was blocked by un-labeled fluciclatide 
(Figure 6.1 A and B). Regions of ex vivo 18F-fluciclatide uptake co-localised with 
intense cellular staining of αvβ3 integrin (45.2 [29.1-66.9] cells/mm2, % area 4.2 [3.2-
5.7]), microvascular endothelial cells at sites of angiogenesis and positive remodeling 
(CD31+; 23.0 [6.5-63.0] cells/mm2, % area 2.5 [2.2-4.9]), and inflammatory 
macrophages deeper adjacent to the necrotic core (CD68+; 32.0 [21.0-49.8] cells/mm2, 
% area 3.7 [2.4-5.6], Figure 6.1 C-H). By comparison control regions of the carotid 
endarterectomy specimens without visible atheroma did not demonstrate 18F-
fluciclatide uptake, and had much lower levels of αvβ3 integrin receptor expression (4.5 
[4.3-5.2] cells/mm2, % area 0.6 [0.5-2.0], both p=0.05 compared to areas with 
increased 18F-fluciclatide expression), as well as staining for both angiogenic 
endothelial cells (CD31+; 2.1 [1.8-2.4] cells/mm2, % area 0.9 [0.6-1.2], both p=0.05) 
and inflammatory macrophages (CD68+; 4.3 [2.8-4.4] cells/mm2, % area 0.6 [0.5-1.2], 
both p=0.03) . 
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Figure 6.1. 18F-Fluciclatide Uptake in Carotid Atheroma 
 
(A) Autoradiography image of segments of ruptured carotid plaque (left) and proximal 
healthy segments (right). Greater 18F-fluciclatide uptake is visible within plaque 
rupture segments. Uptake within the tissue segments (demarcated) was successfully 
blocked by the addition of a more concentrated un-labelled solution of fluciclatide (B). 
Adjacent tissue sections displayed intense cellular staining of αvβ3 integrin (C [x4 
magnification] and D, [x20 magnification]) that co-localised to the regions of ex vivo 
18F-fluciclatide uptake (A) and also featured dense cellular staining for vascular 
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6.4.2. In Vivo Imaging Cohort  
 
A total of 46 subjects underwent PET imaging with CT angiography (age 66±10 years, 
74% male; Table 6.1) following injection of 226±13 mBq 18F-fluciclatide. Of the 46 
subjects recruited, 19 had suffered a recent myocardial infarction (unstable cohort), 
and 27 had imaging evidence of aortic atherosclerosis on CT but no recent 
cardiovascular events (stable cohort: 6 with stable angina and 21 with sub-clinical 
disease who were asymptomatic with no prior cardiovascular events). Those in the 
stable cohort had greater aortic calcification than patients in the unstable group (AU 
[IQR]; 326 [11-1114] vs 19 [0-483], p<0.01), reflecting their greater age (years; 70±8 
vs 61±12, p<0.01). The groups were well matched for gender (p=0.97) and body-mass 
index (p=0.25), and were both characterized by a high prevalence of atherosclerotic 
risk factors, with more smokers in the unstable group (p=0.02) and more patients with 
hypertension in the stable group (p=0.001). No adverse events were reported following 
administration of 18F-fluciclatide. The mean radiation dose for each 18F-fluciclatide 
PET scan was 5.9 mSv (range 5.2-6.4 mSv). The mean attenuation correction CT 
acquisition radiation dose was 1.4 mSv (range 0.8-1.9 mSv). Cardiac CT contrast 
angiography dosing was 6.7mSv (range 2.1-11.7 mSv); the wide dose range accounted 
for the potential presence of atrial fibrillation that prevents prospective ECG gating. 
The average total radiation dose per participant was 15.1 mSv. 
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Age (years) 66±10 70±8 61±12 0.006 
Male Sex 34 (74) 20 (74) 14 (74) 0.97 
BMI (kg/m2) 28±4 28±4 29±5 0.25 
Systolic BP (mmHg) 140±22 149±19 127±19 <0.001 
18F-Fluciclatide dose 
(MBq) 




26 (57) 7 (26) 19 (100) <0.001 
Prev MI 24 (52) 5 (19) 19 (100) <0.001 
Prev PCI 20 (43) 2 (7) 18 (95) <0.001 
Prev CVD 4 (11) 4 (14) 0 (0) 0.08 
Risk Factors 
Current smoker 9 (20) 1 (4) 8 (42) 0.001 
Diabetes Mellitus 6 (13) 4 (14) 2 (10) 0.58 
Prior hypertension 23 (50) 18 (67) 6 (32) 0.02 
Prior Hypercholester-
olemia 
25 (54) 12 (44) 12 (63) 0.21 
hs-CRP (mg/l) 3.5 [1.4-7.8] 2.7 [1.4-5.8] 5.6 [2.0-11.7] <0.001 
Log10 hs-CRP (mg/l) 0.51±0.51 0.41±0.44 0.65±0.56 <0.001 
Medications 
Aspirin 28 (61) 10 (37) 19 (100) <0.001 
Clopidogrel 19 (41) 4 (14) 19 (100) <0.001 
Statin 31 (67) 13 (48) 19 (100) <0.001 
β-Blocker 27 (59) 8 (30) 19 (100) <0.001 
ACEi/ARB 31 (67) 10 (37) 18 (95) <0.001 
Calcium Channel Blocker 7 (15) 6 (22) 1 (5) 0.11 
 
Categorical data are displayed as n (%). Normally distributed data displayed as mean±SD. 
Non-normally distributed data displayed as median [interquartile range]. Abbreviations: IHD 
- ischemic heart disease; AS - aortic stenosis; CAD - coronary artery disease; MI - myocardial 
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infarction; CVD – cerebrovascular disease; PCI - percutaneous coronary intervention; hs-
CRP - high sensitivity c-reactive protein; ACEi - ACE-inhibitor; ARB - Angiotensin Receptor 
Blocker.  
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6.4.3. Dynamic analysis of aortic 18F-fluciclatide aptake 
 
On kinetic analysis, activity within aortic atheroma increased gradually, reaching a 
plateau at 40–70 min. Injected 18F-fluciclatide activity has a biexponential blood pool 
clearance with a half-life of about 10 min consisting of a fast redistribution component 
with a slower clearance component, causing relatively high residual blood pool 
activity during PET acquisition (40-70 min post-injection, SVC SUVmean 2.74±0.49; 
Figure 6.2). Consequently, whilst 18F-fluciclatide uptake in aortic atheroma was 
measurable above background, tissue-to-background ratios were relatively low 
(TBRmax range 1.08-1.68; Table 6.2, Figures 6.2, 6.3). In the 3-D Patlak slope (Ki) 
parametric images, 6 datasets (30%) were uninterpretable due to patient movement. In 
the remaining studies, increased aortic 18F-fluciclatide uptake was observed in half of 
subjects. Patlak modelling demonstrated a discernible linear phase suggesting 
irreversible ligand-receptor binding over the selected acquisition time and a greater Ki 
slope in these subjects compared to patients with no aortic uptake (Figure 6.2).  
Subjects with uptake present on Patlak analysis also appeared to have higher 18F-
fluciclatide uptake on standard analysis (TBRmax 1.32±0.05 vs 1.19±0.03, p=0.08) and 
greater aortic calcification (aortic calcium score 704 [28-1788] vs 0 [0-119] AU, 
p=0.06) than those without visible uptake, although this did not reach statistical 
significance.  
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Figure 6.2.  Kinetic analysis of aortic 18F-fluciclatide uptake 
Sagittal views of the thorax following kinetic analysis in two participants with (patient 1: A-E) and without (patient 2; F-H) aortic arch 18F-
fluciclatide uptake. Computed tomography (CT) images confirm presence (A) or absence (F) of aortic arch calcification as a marker of 
established atheroma. Patlak slope (Ki) parametric images (B and G) identify focal uptake within the aortic arch in the region of atheroma 
(red arrow) localising to the vessel wall on the fused Patlak and CT images (C and H). Patlak modelling (D) confirms irreversible integrin 
binding within the region of aortic arch calcification (red arrow). Time activity curves (TAC) within the same region (E) show a persistently 
high blood pool fraction, but uptake within atheroma that exceeds the blood pool fraction beyond 40 min (dash




Figure 6.3.  18F-Fluciclatide aortic uptake 
 
Patient 3: Modified coronal view of the aortic arch showing radiotracer uptake at the 
inner curvature of the aortic arch closely related to a region of aortic calcification. 
This activity is demonstrated on axial sections of the aorta (i and ii). Red lines indicate 
the adventitial borders of the aortic arch used for quantification of PET uptake. 
Patient 4: Sagittal view of the thorax displaying focal 18F-fluciclatide uptake within 
a region of vascular calcification in the aortic arch.  
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18F-Fluciclatide PET uptake 
SVC, SUVmean 2.74±0.49 2.62±0.46 2.54±0.40 2.9±0.48 0.02 
Whole aorta, SUVmax 3.59±0.62 3.40±0.62 3.19±0.65 3.84±0.55 0.001 
Ascending aorta, SUVmax 3.60±0.66 3.42±0.70 3.16±0.56 3.87±0.51 <0.001 
Aortic Arch, SUVmax 3.51±0.62 3.29±0.61 3.05±0.52 3.84±0.48 <0.001 
Descending aorta, SUVmax 3.61±0.68 3.46±0.65 3.28±0.65 3.83±0.66 0.01 
Whole aorta, TBRmax 1.32±0.14 1.30±0.12 1.26±0.09 1.33±0.18 0.14 
Ascending aorta, TBRmax 1.32±0.16 1.31±0.17 1.25±0.10 1.34±0.17 0.05 
Aortic Arch, TBRmax 1.30±0.14 1.26±0.14 1.21±0.1 1.33±0.15 0.008 
Descending aorta, TBRmax 1.32±0.17 1.32±0.13 1.29±0.11 1.33±0.21 0.56 
CT Calcium Score (AU) 
Whole aorta 95 [0-852] 326 (11-1114) 36 (0-469) 19 [0-483) 0.85 
Ascending aorta 0 [0-11] 0 (0-46) 0 (0-0) 0 [0-0} 0.15 
Aortic arch 29 [0-352] 102 (0-586) 13 (0-469) 0 [0-263] 0.76 
Descending aorta 7.5 [0-78] 0 (0-123) 0 (0-123) 8 [0-71] 0.43 
CTA Plaque analysis (descending aorta) 
Mean wall thickness 
(% vessel diameter) 
10.3±4.9 8.4±2.8 8.4±3.1 14.0±6.3 0.003 
Plaque burden 
(% total volume) 
9.1±3.9 7.7±2.3 7.7±2.5 12.0±4.7 0.004 
 
Ψ Stable group subjects paired to equivalent calcium score in unstable group. * P-values are 
quoted for comparisons between matched stable and unstable groups.  SUV - standard uptake 
value; TBR - tissue-to-background ratio 
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6.4.4. Aortic 18F-fluciclatide uptake reproducibility studies  
 
Using static PET images, the quantification of 18F-fluciclatide activity in the SVC 
blood pool demonstrated excellent interobserver reproducibility, with no fixed or 
proportional biases (SUVmean mean difference; -0.11 [-0.36 – 0.15]) and an excellent 
intraclass correlation co-efficient (0.95, Table 6.3). The quantification of 18F-
fluciclatide uptake in the aorta using the established mean TBRmax approach (2,6) also 
displayed no fixed or proportional bias (mean difference; 0.08 [-0.01–0.16]) with an 
excellent intra-class correlation (0.92) (Table 6.3). 
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Table 6.3.  Vascular 18F-fluciclatide uptake reproducibility analysis 
 
18F-Fluciclatide activity Mean absolute differencea 
Intra-class 
coefficientb 
Superior Vena Cava 
Mean SUV (SUV [kBq/cc]) -0.11 (-0.36 – 0.15) 0.947 
Aorta 
Mean SUV (SUV [kBq/cc]) -0.005 (-0.14 – 0.13) 0.986 
Mean SUVMDS (SUV [kBq/cc]) 0.01 (-0.17 – 0.15) 0.980 
Max SUV (SUV [kBq/cc]) 0.07 (-0.13 – 0.27) 0.971 
Max SUVMDS (SUV [kBq/cc]) 0.06 (-0.22 – 0.34) 0.957 
Mean TBR 0.04 (-0.02 – 0.10) 0.954 
Mean TBRMDS 0.04 (-0.04 – 0.10) 0.940 
Max TBR 0.08 (-0.01 – 0.16) 0.912 
Max TBRMDS 0.07 (-0.03 – 0.17) 0.919 
SUV Target-background 0.19 (-0.05 – 0.43) 0.612 
 
a Mean difference between TBRmax measurements (95% limits of agreement), and b ICC values 
for 18F-Fluciclatide throughout the thoracic aorta and SVC. Abbreviations: ICC: intraclass 
correlation coefficient; MDS: most diseased segment; TBR: tissue to background ratio; SVC: 
Superior Vena Cava 
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6.4.5. Aortic 18F-fluciclatide uptake and atheroma burden 
 
Our study cohort comprised patients with a wide spectrum in aortic atherosclerotic 
disease burden (aortic calcium score range 0-6857 AU). Using static images, aortic 
18F-fluciclatide uptake demonstrated a close relationship with disease burden in the 
aorta regardless of whether it was measured using CT calcium scoring (r=0.37 [0.08-
0.60], p=0.01) or the indexed plaque volume (r=0.56 [0.26-0.75]; p<0.001) (Table 6.4, 
Figure 6.4). Interestingly a good correlation was also observed with the relative vessel 
wall thickness (expressed as a percentage of vessel diameter, r=0.57 [0.28-0.76]; 
p<0.001). There was no correlation between aortic 18F-fluciclatide uptake and the 
systemic inflammatory marker C-reactive protein (log10 hs-CRP r=0.18, p=0.28).  
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Table 6.4.  PET uptake and baseline characteristics 
 
 Total Aortic 18F-Fluciclatide Uptake (TBRmax) 
 All patients Stable Cohort Unstable Cohort 
Continuous variables 








Mean wall thickness  







Plaque volume  







































Diabetes mellitus 1.40±0.10 vs 
1.30±0.05 
p=0.15 






Current Smokers 1.36±0.10 vs 
1.30±0.04 
p=0.30 




Ψ18F-Fluciclatide uptake assessed in the descending aorta only, to correspond with CT 
analysis. 
CT – computed tomography; hs-CRP - high sensitivity C-reactive protein; IHD – ischaemic 
heart disease  
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Figure 6.4.  18F-Fluciclatide uptake, atheroma burden and clinical 
stability 
 
Graphs displaying the relationship between aortic 18F-fluciclatide uptake and aortic 
plaque burden, assessed using both the plaque volume when available (A) and calcium 
score (B). Moreover 18F-Fluciclatide uptake was greater in patients with unstable 
(recent myocardial infarction) versus stable (no recent cardiovascular events) 
atherosclerotic disease (C).  Data bars represent the mean and standard deviation. 
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6.4.6. Aortic 18F-fluciclatide uptake in stable and unstable patients 
 
To establish whether 18F-fluciclatide uptake may be a marker of unstable 
atherosclerotic activity, we compared uptake in patients who had sustained a recent 
myocardial infarction to those with stable atheroma. Given the strong relationship 
between 18F-fluciclatide activity and plaque burden, we matched patients in the two 
groups according to CT calcium score. We demonstrated increased 18F-fluciclatide 
aortic uptake in the patients with recent myocardial infarction compared to those in 
the stable cohort (TBRmax; 1.33±0.15vs 1.21±0.1, p=0.008) despite equivalent aortic 
calcium scores (Table 6.2, Figure 6.4). Moreover, in patients with recent myocardial 
infarction, a stronger correlation was observed between aortic plaque burden and 18F-
fluciclatide uptake than in the patient population as a whole (aortic wall thickness 
r=0.68, p=0.02). When aortic SUV measurement were assessed these were 
consistently increased in the unstable groups compared to the stable groups across all 
regions of the aorta even before attempts were made to match these groups by calcium 
score (p<0.05 for all aortic regions, Table 6.2). 
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6.4.7. Aortic 18F-fluciclatide and cardiovascular risk factors 
 
Amongst patients in the stable cohort aortic 18F-fluciclatide uptake correlated with a 
number of risk factors (Table 6.4). 18F-fluciclatide activity was higher in patients with 
hypercholesterolemia compared to those without (1.37±0.04 vs 1.24±0.06, p=0.007). 
Apparent observed trends were also seen in patients with diabetes (1.41±0.08 vs 
1.28±0.02, p=0.06) and those with an established diagnosis of coronary heart disease 
(1.37±0.04 vs 1.28±0.03, p=0.08). Again a strong correlation was observed between 
18F-fluciclatide uptake and the CT calcium score (r=0.62, p<0.001) in this subgroup.  





We present the largest multimodality imaging study to date evaluating the application 
of an RGD-based αvβ3 integrin receptor radiotracer in the assessment of human 
atheroma. We have demonstrated that ex vivo 18F-fluciclatide binding co-localises to 
sites of αvβ3 integrin receptor expression in excised carotid plaques, and this was 
associated with regions of both angiogenesis and inflammation. We have further 
demonstrated in vivo that 18F-fluciclatide uptake increased with progressive 
atherosclerotic plaque burden and is higher in patients with unstable versus stable 
clinical disease. These data would suggest that 18F-fluciclatide holds promise as a 
non-invasive marker of disease activity in atherosclerosis, informing us about two key 
characteristics of high risk atheroma: inflammation and angiogenesis. This tracer may 
therefore aid our pathophysiological understanding of this important condition and 
help identify patients at increased risk of adverse cardiovascular events.  
 
Plaque inflammation and angiogenesis are two key pathological processes associated 
with atheroma progression, plaque rupture and clinical events. Macrophages drive 
expansion of the necrotic core and secrete matrix metalloproteinases that weaken the 
fibrous cap, predisposing it to rupture. Angiogenesis is believed to occur in response 
to hypoxic conditions within the necrotic core and is associated with high-risk plaque 
characteristics.(167) In addition these new vessels are prone to leakage and rupture 
resulting in plaque hemorrhage that itself results in an intense inflammatory response, 
plaque destabilization and clinical events. A non-invasive imaging technique that can 
inform about the activity of these two adverse pathological processes might therefore 
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be useful in identifying patients with active high-risk atheroma. Indeed it is hoped that 
non-invasive markers of atherosclerotic disease activity may identify the vulnerable 
patient and provide incremental risk prediction to an assessment of radiographic 
disease burden alone.(147,240) We have here demonstrated that 18F-fluciclatide PET-
CT is an emerging and promising approach to achieve these aims. 
 
Our autoradiographic data showed focal 18F-fluciclatide binding within carotid 
atheroma that localised to αvβ3 integrin expression with no evidence of non-specific 
binding. Regions of 18F-fluciclatide uptake on autoradiography also corresponded to 
sites of immunohistochemical cellular staining for vascular endothelial cells and 
macrophages. This is in keeping with previous RGD-radiotracer studies and supports 
its role as a selective marker for angiogenic and inflammatory components of 
atherosclerotic activity.(135,186) Due to the close relationship between intraplaque 
inflammation and angiogenesis, it was challenging to ascertain whether 18F-
fluciclatide was binding preferentially to one or the other of these processes. However 
high sensitivity c-reactive protein concentrations did not correlate with aortic 18F-
fluciclatide uptake, perhaps suggesting that uptake of this tracer relates more closely 
to plaque angiogenesis and local cellular inflammation rather than systemic 
inflammation. This issue warrants further study in larger histological cohorts. 
 
Dynamic in vivo imaging studies in 20 subjects confirmed irreversible 18F-fluciclatide 
binding over the selected acquisition time to regions of aortic atherosclerosis and 
demonstrated that the optimum time for 18F-fluciclatide imaging in the aorta is 
between 40 and 70 min. This timeframe was used for subsequent static PET imaging 
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across the cohort as a whole. Static in vivo imaging demonstrated reproducible 
quantification of 18F-fluciclatide in aortic atheroma of all 46 patients, and this was 
closely correlated with the severity of aortic atherosclerotic burden. Indeed 
associations were observed with the aortic calcium score, aortic plaque thickness and 
overall plaque volume.(249,250) In patients with clinically stable disease, aortic 
uptake of 18F-fluciclatide was increased in subjects with hypercholesterolemia with 
strong trends towards higher uptake in patients with diabetes mellitus and those with 
ischemic heart disease.  Perhaps most importantly, 18F-fluciclatide uptake in aortic 
atheroma was increased in patients with unstable clinical disease (recent myocardial 
infarction) irrespective of plaque burden. Interestingly, using 18F-
fluorodeoxyglucose, we have previously demonstrated a similar pattern of increased 
metabolic activity in aortic atheroma amongst patients with recent myocardial 
infarction.(161) These data therefore lend support to the hypothesis that acute 
myocardial infarction causes inflammation and instability in systemic atherosclerosis, 
as has been suggested in preclinical murine models.(251) It also provides further 
validity to the concept that 18F-fluciclatide uptake can identify higher risk plaques. 
However whether this increased disease activity truly represents a response to the 
infarct or rather the underlying trigger remains to be determined. 
 
We acknowledge that there are some limitations of our study that include potential 
partial volume artefacts, a limited histological cohort and the use of surrogate 
measures for aortic histology. The dynamic imaging approach proved sensitive to 
patient movement during the prolonged period of acquisition, limiting its overall 
utility, but in the future this may be readdressed by novel motion tracking systems that 
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allow for correction of both cardiac and respiratory motion to enable even greater 
definition of regional αvβ3 integrin expression.(239) Nonetheless, we believe that the 
totality of our comprehensive evidence using multiple approaches and imaging 
modalities provides a robust and cogent argument to support our findings. 
 
In conclusion, this is the largest study to date assessing αvβ3 integrin expression in 
human atherosclerotic disease. We have demonstrated that 18F-fluciclatide uptake 
localises to regions of inflammation and angiogenesis, correlates with the plaque 
burden and is increased in patients with clinically unstable disease. Although further 
study is required, our data indicate that 18F-fluciclatide shows major promise as a non-
invasive marker of disease activity and instability in atherosclerosis. 
 
  




Chapter 7.  
Conclusions and Future Directions 
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7.1  Summary of Findings 
 
Despite advances seen over recent decades, cardiovascular disease remains the most 
common cause of death worldwide.(1)  Although the clinical manifestation of a 
cardiovascular event is commonly unanticipated, the preceding pathophysiological 
processes are chronic, asymptomatic and may be difficult to detect on both an 
individual or population perspective.(147) When developing and delivering medical 
therapy for a chronic disease process, and particularly aortic stenosis, ventricular 
remodeling and atherosclerotic disease, ascertaining short- and long-term efficacy 
poses a significant challenge, both within an individual and a population. We counter 
this chronicity through meta-analyses or large multicenter trials, thus increasing the 
expense of novel drug development due a prerequisite for large numbers of 
participants and prolonged follow-up, which often may identify only marginal 
treatment responses.(252) 
 
Combined PET/CT now provides a method of combining high resolution anatomical 
imaging with the real-time quantification of adverse biological processes in vivo, and 
as a consequence has generated significant interest as a novel imaging tool in 
cardiovascular disease.(5,240,253) This technology should encourage the practice of 
individualized medicine through targeting therapy based upon real-time disease 
activity, providing new biological insights, risk stratifying patients, and providing a 
non-invasive measure of early therapeutic response that may otherwise not be 
clinically manifested for several years.  
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The purpose of this thesis was to study the utility of PET to identify fundamental 
pathophysiological processes driving 3 forms of cardiovascular disease: aortic 
stenosis, myocardial infarction, and atherosclerosis. Our comprehensive 
multimodality approach featured both novel and established cardiovascular imaging 
techniques including PET, CT, MRI and echocardiography, and findings were 
supported with ex vivo and in vivo methods of validation. From the series of studies 
presented in this thesis, we can conclude that the use of 18F-fluoride PET, and to a 
lesser extent 18F-FDG PET, holds major promise as a marker of disease activity 
(chapter 3), with important prognostic implications (chapter 4). Furthermore, the αvβ3 
integrin radiotracer 18F-fluciclatide holds great potential as a marker of acute 
ventricular remodeling and functional recovery following myocardial infarction 
(chapter 5), and aortic atherosclerotic disease activity (chapter 6). 
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7.1.1. Aortic Valvular 18F-Fluoride uptake is associated with both 
valvular calcification activity and clinical disease progression in aortic 
stenosis. 
 
Progressive valvular calcification and inflammation are key pathophysiological 
processes driving aortic stenosis.  18F-Fluoride is a PET radiotracer that preferentially 
binds to regions of newly forming vascular micro-calcification beyond the resolution 
of computed tomography(227), while 18F-FDG has been widely used to measure 
vascular inflammation.(48) Recent studies have suggested that these tracers can 
measure the activity of these processes in aortic stenosis, although validation of this 
technique has previously been lacking.(2,58)  
 
In this study, we sought to provide such validation, comparing aortic valve 18F-
fluoride and 18F-FDG uptake with both histological measures of calcification and 
inflammatory activity, and the progression of aortic valve calcification on CT.  
Valvular 18F-fluoride uptake on PET imaging performed prior to aortic valve 
replacement demonstrated a strong correlation with histological markers of 
calcification activity on the excised aortic valve tissue. No such association with 
histological markers was seen with 18F-FDG. We extended our findings to a small 
cohort of patients with aortic stenosis who underwent 18F-fluoride and 18F-FDG PET 
and CT-calcium scoring of the aortic valve both at baseline and after 1 year. In this 
cohort, a good correlation was observed between baseline 18F-fluoride uptake and 
progression in valve calcification. There was no such association seen with 18F-FDG.  
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Our results therefore provided the first validation of 18F-fluoride as a marker of 
calcification activity in the aortic valve. To determine the utility of 18F-fluoride PET 
further, we extended our period of follow-up to a larger cohort of patients with a range 
of calcific aortic valve disease, and examined the role of PET imaging as a means of 
predicting haemodynamic progression and clinical outcome in aortic stenosis (chapter 
4).  
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7.1.2. Valvular 18F-Fluoride and 18F-FDG uptake on PET are associated 
with disease progression and clinical outcome in Aortic Stenosis. 
 
Within this chapter, we expanded on the validation of 18F-fluoride in Chapter 3 to 
report the first prospective longitudinal study to investigate whether 18F-fluoride 
and 18F-FDG may be associated with disease progression and clinical outcome in 
aortic stenosis. 
 
In total, 121 volunteers with and without aortic valve disease previously imaged 
with 18F-fluoride and 18F-FDG PET/CT (2) underwent clinical follow-up 
including assessment of disease progression using CT aortic valve calcium scoring 
and echocardiography at 1 and 2 years. Volunteers were followed for a primary 




After 2 years, new valvular calcium on CT was visible in a similar distribution as 
the 18F-fluoride activity on baseline PET imaging. Baseline 18F-fluoride uptake 
correlated strongly with the subsequent rate of progression in aortic valve calcium 
score and with echocardiographic measures of haemodynamic progression. 18F-
FDG demonstrated moderate correlations with disease progression. Both 18F-
fluoride and 18F-FDG emerged independently associated with of adverse clinical 
outcome after multivariate adjustment. 
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There were strong associations between the baseline CT valvular calcium score and 
rate of change in calcium score. Indeed, on baseline imaging assessment the aortic 
valve calcification score was more closely associated with disease progression and 
clinical outcome than established gold-standard echocardiographic assessments of 
valve disease severity. Given the degree of co-linearity between CT calcium scoring 
and 18F-fluoride uptake in the valve, assessing whether 18F-fluoride uptake 
provides incremental information to CT was challenging. However, in a 
retrospective analysis using the regression line between the CT calcium score and 
18F-fluoride uptake as a cut off, patients with aortic stenosis and higher than 
expected 18F-fluoride uptake for a given CT calcium score progressed three times 
faster than subjects with lower than expected uptake. When a similar analysis was 
performed for 18F-FDG, no significant difference was observed.  
 
In conclusion, we demonstrated that both 18F-fluoride and 18F-FDG may predict 
disease progression and adverse clinical outcome in aortic stenosis. In particular, 
18F-fluoride demonstrated close correlations with the change in CT calcium score, 
appearing to be of incremental value to baseline CT imaging. Larger studies are 
required to confirm the incremental predictive value of PET compared to CT. 
However our data would support PET/CT as a novel method for measuring disease 
activity in aortic stenosis, with the ability to prognosticate natural history. This may 
be of particular value in studies investigating novel therapies, where beneficial 
treatment effects are likely to be detected rapidly without the need for protracted 
follow-up.  
  
Novel Applications of PET in Cardiovascular Disease 
 
276 
7.1.3. 18F-Fluciclatide uptake is increased at sites of recent MI acting as a 
biomarker of cardiac repair. 
 
The incidence of heart failure in survivors of myocardial infarction (MI) remains high 
and infers poor clinical outcome. Indeed, most deaths after MI occur in patients who 
develop heart failure, with the greatest risk experienced in patients with late- versus 
early-onset heart failure.(254) These changes call for new approaches to understand 
the mechanisms of adverse remodeling following MI, to both guide the short-term 
allocation of therapy and resources, and predict long-term clinical outcome.  
 
In this chapter, we evaluated the utility of the novel αvβ3-selective PET radiotracer 
18F-fluciclatide as a marker of myocardial remodeling after MI. The cell surface 
receptor integrin αvβ3 is markedly upregulated on activated vascular endothelial 
cells, macrophages and myofibroblasts and as such plays a multifaceted role in 
regulating the inflammatory, angiogenic and fibrotic processes that restore 
myocardial integrity following MI, potentially contributing to maladaptive 
ventricular remodeling and the progression to heart failure.  
 
In a study of 37 volunteers using PET imaging with kinetic analysis, computed 
tomography (CT) contrast angiography and cardiac magnetic resonance imaging 
we have demonstrated 18F-fluciclatide binding with αvβ3 integrin receptors in 
regions of acute myocardial infarction and in the remote myocardium, both early 
and late after MI. In patients with established myocardial scar and stable ischaemic 
heart disease, myocardial uptake approximated that seen in healthy control patients. 
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18F-fluciclatide uptake correlated with functional impairment and may be 
associated with myocardial recovery.  
 
Our study fulfils a key step validating αvβ3 integrin receptor imaging in humans 
following MI. This novel characterisation of myocardial remodeling may hold 
potential as a biological end-point in the study of novel therapies following MI.  
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7.1.4. Quantification of αvβ3 integrin expression in human aortic atheroma 
using 18F-fluciclatide is associated with plaque burden and is increased 
following myocardial infarction. 
 
Atherosclerotic cardiovascular disease is the commonest cause of death worldwide. 
However, despite recent advances in diagnostic techniques an accurate prediction 
of clinical events remains elusive, and there is considerable interest in non-invasive 
imaging techniques that go beyond the detection of luminal stenoses and instead 
focus on measuring disease activity within the vasculature.  
 
Intra-plaque angiogenesis and inflammation are key promoters of atherosclerosis 
and are mediated by the αvβ3 integrin receptor pathway. In chapter 6 we investigated 
the applicability of the novel αvβ3-integrin receptor-selective PET radiotracer 18F-
fluciclatide in assessing human aortic atherosclerosis. We undertook CT and PET 
imaging of the thorax with 18F-fluciclatide in 46 volunteers with a spectrum of 
stable and unstable coronary disease. 18F-Fluciclatide binding with αvβ3 integrin 
expressed on inflammatory and angiogenic cells within atheroma was confirmed 
using ex-vivo histological assessment and in-vivo kinetic modeling. Aortic 18F-
fluciclatide uptake correlated with vascular calcification and atheroma burden. In 
keeping with recent findings demonstrating an upregulation of atherogenesis 
following myocardial infarction,(251) we demonstrated an increase in aortic 18F-
fluciclatide atheroma uptake following acute myocardial infarction when compared 
to patients with stable atheroma. 
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In conclusion, in the largest study to date assessing αvβ3 integrin expression in 
atherosclerosis we demonstrated that 18F-fluciclatide uptake localises to regions of 
inflammation and angiogenesis, and correlates with disease burden and activity. 
Although further study is required, our data indicate that 18F-fluciclatide shows 
promise as a non-invasive marker of disease activity in atherosclerosis. 
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7.2. Future Directions 
 
Several opportunities arise from the conclusions of this thesis, with potential to expand 
and strengthen the role of novel imaging techniques in the assessment of 
cardiovascular pathology, disease activity and prognosis. Several projects are ongoing 
that aim to exploit the data and expertise gained during the formulation of this thesis.  
 
Specifically, work is ongoing evaluating; 
a) 18F-fluoride PET as an imaging biomarker in the assessment of novel therapies 
for aortic stenosis. 
b) the assessment of valvular calcification in aortic stenosis using CT. 
c) 18F-fluciclatide as a marker of αvβ3 integrin-related myocardial fibrosis in 
aortic stenosis. 
d) pulmonary 18F-fluciclatide uptake as a marker of αvβ3 integrin-related 
pulmonary fibrogenesis in interstitial lung disease. 
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7.2.1. 18F-fluoride PET as an imaging biomarker in the assessment of 
novel therapies for aortic stenosis. 
 
In Chapters 3 and 4, we have demonstrated that calcification activity is the major driver 
to disease progression in aortic stenosis and that this can be measured using 18F-
fluoride PET.  Further assessment is now required to define a role for 18F-fluoride 
PET imaging in the clinical setting. The standard management of patients with 
asymptomatic aortic stenosis relies upon repeated evaluations of cardiac physiology 
using clinical history, examination and multimodality imaging. At present, an 
individualisation of disease trajectory and prognosis at the time of diagnosis is 
challenging, particularly in the setting of mild calcific disease or prosthetic aortic 
valve. 18F-Fluoride PET may therefore hold a role at the point of clinical diagnosis in 
stratifying indolent compared to accelerated states of valvular calcification, thereby 
identifying high-risk patients appropriate for closer clinical observation or future drug 
therapies. However, larger longitudinal studies are required to define thresholds of 
valvular 18F-fluoride activity that hold clinical relevance.  
 
Funding has now been awarded and recruitment has commenced for a double-blind, 
randomised, placebo-control trial in patients with calcific aortic stenosis, using 18F-
fluoride as a biomarker of calcification activity and as an end-point measuring the 
efficacy of novel pharmacotherapy in aortic stenosis. (NCT02132026; Study 
Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of 
Calcific Aortic Stenosis. [SALTIRE II]) 
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In total, 150 subjects with aortic stenosis of moderate haemodynamic severity will be 
randomized to taking either taking a weekly dose of a matched placebo, the 
bisphosphonate ‘alendronate’ or the human monoclonal antibody to RANKL 
‘denosumab’, which is a potent inhibitor of osteoclast differentiation and bone 
resorption. The study intends to demonstrate that, in patients with aortic stenosis, 
therapies targeted at calcium metabolism, such as bisphosphonates and denosumab, 
will reduce valvular calcification activity in vivo using 18F-fluoride PET imaging, and 
halt or delay disease progression.  
 
Aortic stenosis severity will be assessed at baseline and at 1 and 2 years by CT calcium 
scoring and echocardiography. 18F-Fluoride PET uptake will be measured at baseline, 
3 months and 1 year to assess the early (3 months) and sustained (1 year) impact of 
the intervention on valvular calcification activity. Recruitment is ongoing, and since 
commencing the study 20 patients have undergone repeat PET/CT imaging within 2 
weeks of their baseline scan to investigate scan-rescan reproducibility, demonstrating 
excellent repeatability with minimal variation in valve signal between imaging 
assessments.(255) 
 
A modification of disease-pathways not directly influencing valvular calcification may 
also be effective, particularly in the early stages of valvular remodeling that precede 
gross macroscopic calcification. Indeed, an effective drug therapy for aortic stenosis 
should target valve-specific signaling pathways while achieving optimal 
biomechanical function, by restoring or at least preserving valve function and tissue 
integrity.(256) The failure of statin therapy to attenuate aortic stenosis is well 
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documented; however, alternative forms of lipid modulation will likely be assessed in 
the near-future, in particular lipoprotein(a)-lowering therapies.(257) Serum 
lipoprotein(a) concentrations are not impacted by statin therapy, and in a recent study 
of almost 7000 participants, serum lipoprotein(a) concentrations are closely associated 
with the development of calcific aortic stenosis.(256,258) Other therapeutic strategies 
include modulators of the renin-angiotensin system (RAS), given the apparent 
contribution of  RAS to the initiation and propagation of leaflet thickening, and a 
recent trial of ACE-inhibition using CMR and echocardiographic end-points has 
shown promising results.(259). However, given the complexity and chronicity of 
aortic stenosis pathophysiology, a multifaceted approach to disease-modification is 
likely required, with 18F-fluoride PET providing an effective imaging-based 
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7.2.2. The assessment of valvular calcification in aortic stenosis using 
computed tomography. 
 
Calcification of the aortic valve is the prevailing pathological mechanism driving 
aortic stenosis.(18) Recently, aortic valve calcification (AVC) quantification using CT 
has been closely associated with disease severity and clinical outcome,(39,216)  and 
in a small study, has been shown to correlate with aortic stenosis progression.(221) In 
our study we have demonstrated that AVC quantification outperforms 
echocardiographic assessments of aortic stenosis in both associations with 
haemodynamic progression and clinical outcome.  
 
Prior to the adoption of CT AVC quantification as a clinical method of evaluating AS 
severity, further assessments must be made to establish clinically appropriate 
thresholds for AS severity. This is of particular relevance given the significant 
disparity between genders in the quantity of valvular calcification required to generate 
haemodynamically severe aortic stenosis, even after correcting for differences in body 
size and LVOT diameter.(260) Therefore our group is heading an international 
multicenter collaboration to form a cohort of 918 patients with moderate to severe 
aortic stenosis who have received aortic valve CT calcium scoring. The group’s aim 
is to validate previously proposed thresholds that identify severe calcific aortic valve 
disease (232) and clarify the prognostic utility of AVC quantification using a 
multinational dataset. We acknowledge that while unlikely to replace 
echocardiography in the diagnosis and surveillance of aortic stenosis, CT AVC 
quantification should hold value in cases of unclear severity, where discordant 
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echocardiographic findings (such as low-gradient aortic stenosis with low aortic valve 
area), low haemodynamic flow states or unclear symptomatology may cloud clinical 
judgement. These cases account for up to a third of patients presenting with significant 
haemodynamic obstruction,(232) and the presence of severe aortic valve calcification 
on CT holds significant prognostic implications that may guide clinical decision 
making and ultimately influence patient outcome.(39) 
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7.2.3. 18F-Fluciclatide as a marker of αvβ3 integrin-related myocardial 
fibrosis in aortic stenosis  
 
Fibrosis plays a key role in aortic stenosis, both in progressive leaflet thickening and 
within the myocardium, where fibrogenesis occurs as the hypertrophic response of the 
left ventricle decompensates. Indeed progressive myocardial fibrosis is believed to be 
a key driver in the progression from hypertrophy to heart failure.(261)  Established 
myocardial replacement fibrosis in aortic stenosis can be identified using CMR with 
LGE, where a mid-wall pattern of fibrosis is associated with advanced hypertrophy 
and an 8-fold increase in mortality.(16)   
 
As demonstrated in Chapter 5, the integrin αvβ3 is upregulated by activated cardiac 
myofibroblasts and vascular endothelial cells in states of angiogenesis and fibrosis, 
and may be visualized in-vivo using the PET radiotracer 18F-fluciclatide. An imaging 
tool capable of detecting fibrogenesis in the early stages of ventricular decompensation 
secondary to haemodynamically severe aortic stenosis, prior to the establishment of 
replacement fibrosis, would therefore be of great value, affording the prediction of left 
ventricular decompensation.  
 
Patients with a spectrum of calcific aortic stenosis severity were recruited for imaging 
with 18F-fluciclatide PET/CT and CMR with assessment of LGE (NCT01837160, 
‘Angiogenesis and Fibrosis in Aortic Stenosis’). In total, 12 patients with aortic 
stenosis underwent imaging assessment; this cohort was included in our assessment of 
18F-fluciclatide in atherosclerotic disease (Chapter 6). Early results suggest that the 
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sub-acute nature of myocardial fibrogenesis in such pressure-overload models of 
myocardial remodeling may be insufficient to generate an identifiable myocardial 
uptake due to the low signal-to-noise ratio. However, further advances may be 
anticipated with the evolution of both dual cardiac/respiratory gating, which may 
minimalise myocardial PET signal loss from respiratory movement,(262) and hybrid 
PET/MRI technology.  
 
Similar to PET/CT, MRI and PET scanners are loaded on to the same gantry, 
facilitating co-registration of the scans and attenuation correction. PET/MRI therefore 
harnesses the cardiac imaging strengths of MRI which principally relate to cine 
imaging of the right and left ventricles and myocardial tissue characterization.(263)  
In particular this may be of value for fibrosis radiotracers, where myocardial PET 
activity may be compared to the distribution of late gadolinium enhancement or other 
CMR markers of myocardial fibrosis in order to define ongoing remodeling activity. 
 
Ultimately however, a potential future drawback of integrin αvβ3 receptor imaging may 
be the lack of specificity the integrin αvβ3 receptors hold to a single pathophysiological 
process. While 18F-fluciclatide PET/CT may prove a sensitive marker of remodeling 
activity after myocardial infarction, a lack of specificity in its myocardial signal may 
reduce its utility as an investigative tool in trials of focused anti-angiogenic or anti-
fibrotic therapy. Development of such specific fibrogenic or angiogenic radiotracers 
is ongoing. Collagen-specific radiotracer probes, in particular, appear to provide a 
direct means of quantifying fibrotic activity in vivo. A collagen-targeted 
peptidomimetic of the platelet collagen receptor Glycoprotein VI has proven effective 
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in identifying focal myocardial fibrotic activity in mouse models of myocardial 
infarction,(264) while more recently the amino acid, proline, a major constituent of 
collagen and widely used as a marker of collagen synthesis, has been incorporated into 
radiotracers for the assessment of type III collagen production in pulmonary and 
musculoskeletal systems.(265,266) The translation of these tracers beyond murine 
models of ischaemia is in progress, while alternative tracers targeting the 
renin/angiotensin/aldosterone axis, which is believed to drive fibrosis both in the valve 
and myocardium, may also prove of use. Recently, 11C-KR31173 has been used to 
investigate cardiac angiotensin II type 1 receptor (AT1R) expression in the left 
ventricle of humans and in a pig model of myocardial infarction, demonstrating no 
adverse effects and a detectable cardiac signal.(267) 
 
Aside from the integrin αvβ3 receptor, targets for clinical imaging of myocardial 
angiogenesis are limited to the vascular endothelial growth factor (VEGF) receptor. 
Receptors for this potent angiogenesis-stimulating factor have been extensively 
imaged in the context of tumour angiogenesis, and radiotracer accumulation the 
murine myocardium has been demonstrated early after experimental myocardial 
infarction.(132,268) However, as per a number of other pre-clinical angiogenic 
imaging targets described, including the α7 nicotinic acetylcholine receptor,(269) 
reports of successful VEGF-receptor imaging in human hearts is awaited, highlighting 
the difficulty and expense of translating these advanced technologies into a clinically 
useful imaging tool. 
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7.2.4. Pulmonary 18F-fluciclatide uptake as a marker of αvβ3 integrin-
related pulmonary fibrogenesis in interstitial lung disease. 
 
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown cause characterised by 
progressive injury, inflammation, and fibrosis of the lung parenchyma. Systemic 
sclerosis is a complex connective tissue disorder featuring pulmonary hypertension 
and pulmonary fibrosis predominantly. The pathogenesis of pulmonary fibrosis is 
incompletely understood, but TGF-ß activation mediated by integrins including αvβ3 
is an accepted common pathway.(87)  
 
From our study cohort of patients with calcific aortic stenosis (NCT01837160), 
concomitant fibrotic lung disease was present on CT imaging in one patient. We 
demonstrated a significant focal increase in 18F-fluciclatide uptake within the region 
of fibrotic changes when compared to the contralateral lung region. On this basis 
funding was granted for a pilot study of 20 patients with either IPF or systemic 
sclerosis to undergo PET/CT with 18F-fluciclatide to determine the utility of 18F-
fluciclatide PET in assessing fibrogenesis in fibrotic lung disease. Tracer uptake will 
be correlated with volumetric CT and CT pulmonary perfusion as imaging markers of 
pulmonary fibrosis and microvascular changes. If validated, this technique may be 
employed to assess drug efficacy and disease progression. Indeed as a secondary 
objective serial lung function tests will be performed over 12 months to determine any 
association between 18F-fluciclatide uptake and rates of disease progression. 
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7.3.     Perspective 
 
The novel imaging techniques described in this thesis have illuminated the potential 
that molecular imaging holds to fundamentally alter our approach to the assessment 
and the quantification of cardiovascular disease processes in vivo. By applying these 
technologies, we may continue to evolve the practice of individualized medicine 
within cardiovascular science, while developing a scaffold by which to trial the real-
time effects of emergent treatments, including stem cell therapies. Particularly in this 
thesis we have developed robust methodologies to potentially study large numbers of 
patients using molecular imaging in a spectrum of cardiovascular disease. Further 
work is now required to ensure that these techniques ultimately translate to an 
improvement in the clinical care of patients. 
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ROLE OF INFLAMMATION IN THE PROGRESSION OF AORTIC 
STENOSIS 
  THE RING OF FIRE 
 
 
You are being invited to take part in a research study. Before you decide 
whether or not to participate, it is important that you understand why the 
research is being done and what it will involve. Please read the following 
information and discuss it with others if you wish. If there is anything that you 
are still unclear about or any questions that you would like to ask you can 
contact us for further information. You can also contact Dr Bloomfield who is 
not directly involved with this study but can give you independent advice. He 
can be contacted through the Royal Infirmary switchboard  (0131 242 1000) 
by asking for his secretary. 
 
 
Thank you for taking the time to read this information sheet. 
 
Why are we doing this study?  
 
Aortic stenosis is a condition caused by narrowing of one the major valves 
within the heart. The reasons why this narrowing develops are poorly 
understood. As a result there are no treatments to stop the disease except 
major heart surgery when the valve becomes very seriously narrowed. 
Furthermore we have no means of predicting how quickly valve narrowing will 
progress. Sometimes the valve gets narrow quickly and in other patients it 
stays much the same for many years.  
 
We want to study two processes, inflammation and calcification. These are 
thought to play a role in the development of aortic stenosis and why the valve 
gets narrower. We will use a special scan called PET CT to tell us whether 
these processes are indeed occurring in narrowed valves.  
 
We hope that the information provided by this study will help identify new 
treatments that can then be targeted to stop the progression of aortic stenosis. 




Novel Applications of PET in Cardiovascular Disease 
 
314 
Why have I been chosen to take part? 
We are looking for patients with a range of aortic stenosis to study using these 
scans.  
Using PET CT we will assess how much inflammation and calcification is 
occurring on your valve. We will then assess how quickly your valve narrowing 
worsens over a two year period. By doing the same thing in 120 patients we 
will develop a good understanding of how important these two process are, 
where on the valve they occur and when are they most important.  
 
It is up to you to decide whether or not to take part. If you decide to take part 
you will be given this information sheet to keep and you will be asked to sign 
a consent form. Even once you have signed the form you can still withdraw at 
any time and you do not have to give a reason.  
You will not benefit directly from this study. However, the information we get 





What will happen to me if I decide to take part? 
 
We will need to perform three different assessments of you and your valve. 
The first will happen we you first agree to participate. The second after 1 year 
and the third after 2 years.   
 
Assessment when you register in the trial 
You will be invited to the clinic. The following will happen. We will talk about 
whether you have any symptoms; perform a full examination of your heart; 
take some blood tests; and organise an echo (ultrasound) scan of your heart. 
The echo test is not painful and involves no harmful affects to you. You will 
already have had one of these scans in the clinic.  
 
We will call you back for a PET CT scan. For the 48 hours leading up to the 
scan we will ask that you eat an Atkins diet (high fat, low carbohydrate). When 
you arrive we will need to place a plastic tube (cannula) in one of your veins. 
We will inject you with a special tracer. After 90 minutes of sitting in a quiet 
room we will perform the PET CT scan. You will need to lie still on a bed for 
around 20 minutes whilst the scan takes place. It is not painful. 
 
The next day we will ask you to return for another scan. This will involve exactly 
the same process but we will use a different tracer.  
 
The molecules for inflammation and calcification have already been used 
frequently in humans and are not harmful. 
 
Assessment after 1 year 
This will involve the same assessment as your baseline assessment described 
above.  




Assessment after 2 years 
This will involve the same assessment as those performed above. However 
this time we will not be performing either of the PET CT scans.  
 
What happens to the blood samples that are taken? 
A proportion will be tested right away for various tests. A portion of the blood 
samples taken will be frozen, and stored in an anonymised manner so that 
further tests may be performed on them in the future. Any further tests would 
require future ethical approval 
 
Is there anything else that I have to do? 
There are no restrictions on your lifestyle through participating in this study. 
 
Will taking part in this study affect my treatment? 
No – you will still be followed up by your cardiologist as if you were not 
participating in the trial.  
 
What are the side effects of taking part? 
Performing PET CT scans will expose you to a dose of radiation. The amount 
of radiation varies but is around 8 times the amount you would normally receive 
in a year from background natural sources of radiation. The lifetime risk of 
developing cancer from the radiation used in the scan is small: less than 1 in 
1000. To put this number in context in the average population 1 in 4 people will 
develop cancer. Therefore the risk to participants taking part in the trial 
increases from 250 per 1000, to 251 per 1000.  
 
If you are female and there is a possibility you might be pregnant then we 
would like you to perform a pregnancy test. Radiation can cause damage to 
babies in the womb and so we want to ensure that no scans are performed on 
pregnant ladies.  
 
The CT scanner takes detailed images of a small area of your chest so there 
is a small chance that we will find another abnormality in this area. Often these 
abnormalities turn out to be of no significance to your health. However, if this 
happens we will let you and your GP know and arrange for you to see a 
specialist for any further tests that are required. 
 
What are the possible disadvantages of taking part? 
Involvement in the trial will mean you attending for various appointments and 
scans. Whenever possible we will ensure that these occur during the same 
visit.  
 
What are the possible benefits of taking part? 
There will not be any direct benefit to you of taking part in the study, however 
it is hoped that the findings of this study will benefit other patients with aortic 
stenosis in the future. The information from the PET CT scans will provide us 
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with extra information about your heart and your aortic valve. We are unsure 
as to how useful this will prove. It is the purpose of this study to find that out.  
 
Will my GP be informed? 
As long as you agree we would like to inform your General Practitioner of your 
participation in this study. 
 
What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special 
compensation arrangements, although in the case of negligent harm, subjects 
will be covered by the University of Edinburgh insurance policy. If you are 
harmed as a result of the study you may have grounds for legal action but you 
may have to pay for this. If you are not satisfied with any aspect of the way you 
were approached or your treatment during this study, please contact the 
Faculty of Medicine at the University of Edinburgh. This study has been 
reviewed by the Lothian Local Research and Ethics Committee. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the research will 
be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it. 
 
What will happen to the results of the research study? 
Once we have completed the study and analysed the results, we will write a 
paper which will be submitted for publication in one of the medical journals. 
We do not routinely contact participants to inform them of the outcome of the 
research but would be happy to do so if requested. If you would like a copy of 
the results please contact Dr Marc Dweck using the contact details listed 
below. You will not be personally identified in any report/publication.  
 
Who is organising the research? 
The study is being organised through the University of Edinburgh. Your doctors 
will not be paid for including you in this study. 
 
Who has reviewed the study? 
The study has been reviewed by the South East Scotland Research Ethics 
Committee 2. 
 
Where can I obtain further information about the study? 
You can get further information from Dr Marc Dweck or Prof Newby who will 
arrange to meet you.  
You could also discuss the study with Dr Bloomfield who is another doctor 
working in this hospital who is not involved in the study and can therefore act 
as an independent advisor. 
Dr Marc Dweck can be reached by contacting his mobile on 07813 619 208; 
his email marcdweck@hotmail.com: or by letter addressed to the 
Cardiovascular Research Unit, Chancellor’s Building, 49 Little France 
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Crescent, Edinburgh EH16 SU4. Prof Newby can be contacted via the hospital 
switchboard (0131 536 1000). 
 
To speak to Dr Bloomfield ask for to be put through to his secretary at the 
Royal Infirmary of Edinburgh. 
 
Thank you once again for reading this information sheet. 
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Identification of In Vivo Angioneogenesis and Fibrosis in 
Myocardial Infarction using Positron Emission Tomography. 
 
You are being invited to take part in a research study. Before you decide 
whether or not to participate, it is important that you understand why the 
research is being done and what it will involve. Please read the following 
information and do discuss it with others if you wish. If there is anything that 
you are still unclear about, or any questions that you would like to ask, you can 
contact us for further information. We aim to re-contact you in 1 – 3 days from 
when you receive this form, to discuss whether you would like to proceed with 
the study.  
 
Thank you for taking the time to read this information sheet. 
 
Why are we doing this study? 
 
Heart attacks are one of the commonest causes of ill health in the United 
Kingdom. Whilst the treatment immediately following a heart attack continues 
to improve, the repair mechanisms through which the heart heals itself are not 
fully understood, and we find it difficult to identify those patients who will go on 
to suffer from 'heart failure' at a later stage. 
 
We would like to study two processes; new blood vessel growth (angiogenesis) 
and scar formation (fibrosis), in patients who have suffered a heart attack. 
These are essential for heart muscle repair, and we will use two special scans 
called PET-CT and MRI to tell us where and when these processes are 
happening in the heart. 
 
We aim to help identify those patients who are at risk of developing further 
problems and help us identify new treatments that can aid heart muscle 
recovery. 
 




Why have I been chosen to take part? 
We are looking for patients who have had a heart attack, and undergone an 
angiogram and 'stenting' (unblocking) of the blocked blood vessel. Using PET-
CT we will assess how much new blood vessel formation and scarring is 
occurring in the heart.  We would like to do this initially 2 weeks following your 
heart attack, and then again 7 weeks later. We will also perform an MRI scan 
soon after your heart attack, and 6 – 12 months later, to assess the impact of 
the heart attack and how well the heart is healing. 
 
Do I have to take part? 
No. It is up to you to decide whether you would like to take part. If you decide 
to take part you will be given this information sheet to keep and you will be 
asked to sign a consent form. Even once you have signed the form you can 
still withdraw at any time and you do not have to give a reason.  
 
You will not benefit directly from this study. However, the information we get 
could help us to improve the way we treat patients with heart attacks in the 
future. 
 
What will happen to me if I decide to take part? 
Once you have been discharged from hospital you will be invited back 2 weeks 
after your heart attack to our research department, which is immediately next 
to the Edinburgh Royal Infirmary. We will discuss the study again and Dr Will 
Jenkins will ask you to sign a consent form. We will talk about your symptoms, 
perform a full examination of your heart and place a plastic tube (cannula) in 
your vein. We will use this to take some blood tests (30 mls or 2 tablespoon of 
blood) and then inject you with an experimental imaging agent called '18F-
fluciclatide'. This contains a small amount of radiation which we can detect 
using a specialized camera called a PET scanner. Fluciclatide has previously 
been used safely in people but has not yet been approved for routine use. We 
will measure your blood pressure and heart rate, and will repeat this a number 
of times during your visit. After approximately 60 min of sitting in a quiet room 
we will perform the PET-CT scan. You will need to lie still on a bed for around 
20 min whilst the scan takes place. It is not painful. 




Towards the end of the scan we will inject a dye known as ‘contrast’ that will 
enable us to see the arteries supplying the heart in greater detail. This 
technique is known as a CT-coronary angiogram. If required we may slow your 
heart down slightly to around 60 beats per minute using a medication called 
metoprolol. It is similar to the 'beta-blocker' medication that is commonly 
started following a heart attack, and will be given through your cannula so will 
not be painful. We may also give you a tablet to dissolve underneath the 
tongue called 'GTN', which dilates the blood vessels around your heart so that 
we can see them clearer. These two medications are very commonly 
prescribed by GP's and Hospital Doctors and are safe. GTN can cause a brief 
headache in some patients. The medications enable us to obtain good quality 
scans to ensure that we can use all the information gained by our study in the 
best possible ways. 
 
On the same day as your PET-CT scan, we will perform another scan called a 
cardiac MRI scan. We will inject a different type of dye called ‘gadobutrol’ into 
your vein for this scan. This will show us the size of the heart attack and will 
help us interpret the pictures we have from the CT-PET scan. In the other arm 
we will inject a medication called adenosine, which dilates your heart vessels.  
A small number of patients experience symptoms such as light-headedness, 
nausea, chest discomfort or mild breathlessness with this medication.  These 
effects are short-lived and they usually resolve spontaneously with time. You 
will need to lie still on this bed inside the scanner for one hour, and we will give 
you headphones so that you can listen to music during this time. This will help 
block out any noise that the scanner makes. The scan is not painful. 
 
Nine weeks after your heart attack we will ask you to return again for a 
second PET-CT scan. The process explained above will be repeated. We will 
again take some blood tests (30 mls or 2 tablespoon of blood) and insert a 
cannula.  
 
Finally, 6 to 12 months after your heart attack we will ask you to return for 
a final MRI scan. This will show us whether what we see on the first two scans 
predicts the amount of scar tissue in the heart at this later stage. We will need 
again to insert a cannula to give the dye. 
 





In a small group of patients, for the first CT-PET scan, we will need to have 
two cannulas (small plastic tubes) put in your arm – one in a vein, one in an 
artery (at your wrist).  These cannulas will allow us to inject the tracer as well 
as take some extra blood samples during the scan. After the cannulas have 
been inserted we will inject the tracer and immediately start performing the 
scan.  This scan will take 80 minutes and will include the CT-coronary 
angiogram.  At the end of the scan, we will remove the cannulas and you will 
be free to leave. 
 
What happens to the blood samples that are taken? 
A proportion will be tested right away for various tests. A portion of the blood 
samples taken will be frozen, and stored in an anonymised manner so that 
further tests may be performed on them in the future (under NHS Lothian's 
Tissue Governance standards). We also intend to study your DNA using a 
process called ‘genome-wide assessment’ to help us understand if genes 
determine whether your body develops heart disease. Please note that we 
cannot use this data and information to test for other genetic conditions. 
 
Is there anything else that I have to do? 
There are no restrictions on your lifestyle through participating in this study. 
You should let your doctor know if you experience any symptom that you think 
may be related to this study. 
 
Will taking part in this study affect my treatment? 
No – you will still be followed up by your medical team (if required) as if you 
were not participating in the trial.  
 
What are the side effects of taking part? 
Performing PET CT and CT-coronary artery scans will expose you to a dose 
of radiation. The amount of radiation varies but is around 8 times the amount 
you would normally receive in a single year from background natural sources 
Heart attack
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of radiation. The lifetime risk of developing cancer from the radiation used in 
the scan is small: less than 1 in 750. To put this number in context in the 
average population 1 in 4 people will develop cancer in their lifetime.  
Therefore the risk to participants increases from 500 in 2000 to 501 in 2000 
 
The MRI scanner uses powerful magnets but no radiation. Therefore any 
patients who have any metal in their bodies cannot take part in our study. This 
includes anyone with cochlear implants, aneurysm clips, pacemakers, or those 
who have ever had metal in their eyes. 
 
The dyes used in our MRI and CT scans are used every day in hospitals 
throughout the world. They can affect the kidneys especially in patients with 
preexisting kidney problems. The contrast given in CT scans contains iodine 
and can occasionally have side effects ranging from headache and itch all the 
way to severe allergic reactions but these are extremely rare.  
 
Fluciclatide is an experimental imaging agent that has limited experience to 
date but appears to be generally well tolerated. In three clinical trials, only two 
subjects have experienced any potential side effects (indigestion and 
headache). One further patient had a change in one of their blood counts that 
may have been related to fluciclatide. If you were found to be allergic to 
Fluciclatide or its components, you would be excluded from the study. 
 
We will not include any female who has the potential to become pregnant. 
Radiation can cause damage to babies in the womb and so we want to ensure 
that no scans are performed on pregnant ladies.  
 
The CT and MRI scanner takes detailed images of a small area of your chest 
so there is a small chance that we will find another abnormality in this area. 
Often these abnormalities turn out to be of no significance to your health. 
However, if this happens we will let you and your GP know and arrange for 
you to see a specialist for any further tests that are required. 
 
What are the possible disadvantages of taking part? 
Involvement in the trial will mean you attending for various appointments and 
scans. Whenever possible we will ensure that these occur during the same 
visit. If required we can also reimburse you for travel costs. Please discuss this 
at the time of your appointment. 
 
What are the possible benefits of taking part? 
There will not be any direct benefit to you in taking part in the study, however 
it is hoped that the findings of this study will benefit other patients with heart 
attacks in the future. The information from the PET CT and MRI scans will 
provide us with extra information about your heart, and some of the blood 
vessels in your body. We are unsure as to how useful this will prove. It is the 
purpose of this study to find that out.  
 
Will my GP be informed? 
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As long as you agree we would like to inform your General Practitioner of your 
participation in this study. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the research will 
be kept strictly confidential. Any information about you that leaves the hospital 
will have your name and address removed so that you cannot be recognised 
from it. 
 
What will happen to the results of the research study? 
We will use the information that we will obtain from your scans in the best 
possible way, including analysing the other blood vessels and organs in your 
body to see if we can use this technique to benefit people with other medical 
conditions. Once we have completed the study and analysed the results, we 
will write a paper which will be submitted for publication in one of the medical 
journals. We do not routinely contact participants to inform them of the 
outcome of the research but would be happy to do so if requested. If you would 
like a copy of the results please contact Dr William Jenkins using the contact 
details listed below. You will not be personally identified in any 
report/publication. The data of the study will also be shared with General 
Electric Healthcare Medical Diagnostics. 
 
Who is organising the research? 
The study is being organised through the University of Edinburgh and NHS 
Lothian. Your doctors will not be paid for including you in this study. 
 
Who has reviewed the study? 
The study has been reviewed by the South East Scotland Research Ethics 
Review Service. 
 
Where can I obtain further information about the study? 
You can get further information from Dr William Jenkins or Professor Newby 
who will arrange to meet you. You can also contact Dr Henriksen who is not 
directly involved with this study but can act as an independent advisor. He can 
be contacted through the Royal Infirmary switchboard  (0131 242 1000) by 
asking for his secretary. 
 
Dr William Jenkins can be reached by contacting him on 0131 242 6428; his 
email  williamjenkins@doctors.net.uk : or by letter addressed to the 
Cardiovascular Research Unit, Chancellor’s Building, 49 Little France 
Crescent, Edinburgh EH16 SU4. Prof Newby can be contacted via the hospital 
switchboard (0131 536 1000). 
 
What if I wish to make a complaint? 
If you wish to make a complaint about the study please contact NHS Lothian: 
NHS Lothian Complaints Team 
2nd Floor, Waverley Gate 
2-4 Waterloo Place 
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Edinburgh EH1 3EG 
Tel: 0131 465 5708 
 
Thank you once again for reading this information sheet. 
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Identification of In Vivo Angioneogenesis and Fibrosis in Aortic Stenosis 
Using Positron Emission Tomography. 
 
 
You are being invited to take part in a research study. Before you decide whether or 
not to participate, it is important that you understand why the research is being done 
and what it will involve. Please read the following information and do discuss it with 
others if you wish. If there is anything that you are still unclear about, or any questions 
that you would like to ask, you can contact us for further information. We aim to re-
contact you in 1 – 3 days from when you receive this form, to discuss whether you 
would like to proceed with the study.  
 
Thank you for taking the time to read this information sheet. 
 
Why are we doing this study? 
 
Aortic stenosis is a condition caused by narrowing of one the major valves within the 
heart. The reasons why this narrowing develops are poorly understood. As a result 
there are no treatments to stop the disease except major heart surgery when the valve 
becomes very seriously narrowed. Furthermore we have no means of predicting how 
quickly valve narrowing will progress.  
 
We want to study two processes; new blood vessel growth (angiogenesis) and scar 
formation (fibrosis). These are thought to play a role in the development of aortic 
stenosis, why the valve gets narrower and how the heart compensates for it. We will 
use two special scans called PET-CT and MRI to tell us whether these processes are 
indeed occurring in narrowed valves.  
 
We hope that the information provided by this study will help identify new treatments 
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that can then be targeted to stop the progression of aortic stenosis. In the future this 
may mean we are able to delay or even prevent the need for surgery.  
 
Why have I been chosen to take part? 
 
We are looking for patients with aortic stenosis to study using these scans. Using PET 
CT we will assess how much new blood vessel growth and scar formation is occurring 
on your valve and in the surrounding heart muscle. From this we will get good 
understandings of how important these two processes are, where on the valve they 
occur and whether it varies with the severity of aortic stenosis. We will also perform 
an MRI scan to more accurately assess how well the heart is working. 
 
You will not benefit directly from this study. However, the information we get could 
help us to improve the way we treat patients with aortic stenosis in the future. 
 
Do I have to take part? 
 
No. It is up to you to decide whether or not to take part. If you decide to take part you 
will be given this information sheet to keep and you will be asked to sign a consent 
form. Even once you have signed the form you can still withdraw at any time and you 
do not have to give a reason.  
 
What will happen to me if I decide to take part? 
 
If you are happy to participate in our study, we will ask you to attend the Royal 
Infirmary for a repeat echocardiogram scan of your heart. At that first meeting Dr 
William Jenkins will go through the information sheet again with you before asking 
you to sign a consent form. You will then be invited back to our research department, 
which is immediately next to the Edinburgh Royal Infirmary. We will talk about your 
symptoms, perform a full examination of your heart and place a plastic tube (cannula) 
in one of your veins. We will use this to take some blood tests (30 mls or 2 tablespoon 
of blood) and then inject you with an experimental imaging agent called '18F-
fluciclatide'. This contains a small amount of radiation which we can detect using a 
specialized camera called a PET scanner. Fluciclatide has previously been used safely 
in people but has not yet been approved for routine use. . We will measure your blood 
pressure and heart rate, and will repeat this a number of times during your visit. After 
approximately 60min of sitting in a quiet room we will perform the PET-CT scan. You 
will need to lie still on a bed for around 20 min whilst the scan takes place. It is not 
painful. 
 
Towards the end of the scan we will inject a dye known as ‘contrast’ that will enable 
us to see the arteries supplying the heart in greater detail. This technique is known as 
a CT-coronary angiogram. We may be required slow your heart down slightly to 
around 60 beats per minute using a medication called metoprolol. This is a 'beta-
blocker' and will be given through your cannula so will not be painful. We may also 
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give you a tablet to dissolve underneath the tongue called 'GTN', which dilates the 
blood vessels around your heart so that we can see them more clearly. These two 
medications are very commonly prescribed by GP's and Hospital Doctors. GTN can 
cause a brief transient headache in some patients. The medications enable us to 
obtain good quality pictures to ensure that we can use all the information gained by 
our study in the best possible ways. 
 
Around the same time as your PET-CT scan, we will perform another scan called a 
cardiac MRI scan.  This will help us interpret the pictures we have from the PET-CT 
scan. We will inject a different type of dye called ‘gadobutrol’ into your vein for this 
scan. You will need to lie still on a bed inside the scanner for one hour, but we will give 
you headphones so that you can listen to music during this time. This will also help 
block out any noise that the scanner makes. The scan is not painful.  
 
Finally, 1 to 2 years after your initial scan, we will ask you to return for a final 
echocardiogram, an MRI scan and more blood samples (approximately 30mls or two 
tablespoons). With this information we can establish whether the amount of new 
blood vessel formation and scar tissue formation seen on your initial scan can predict 
the function of the heart and the overall amount of scar tissue within the heart at this 





In a small group of patients, for the first CT-PET scan, we will need to have two 
cannulas (small plastic tubes) put in your arm – one in a vein, one in an artery (at your 
wrist).  These cannulas will allow us to inject the tracer as well as take some extra 
blood samples during the scan (approximately 100mls / 7 tablespoons of blood). After 
the cannulas have been inserted we will inject the tracer and immediately start 
Injection of 







Cardiac MRI scan 
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performing the scan.  This scan will take 80 minutes and will include the CT-coronary 
angiogram.  At the end of the scan, we will remove the cannulas and you will be free 
to leave. 
 
What happens to the blood samples that are taken? 
A proportion will be tested right away for various tests. A portion of the blood samples 
taken will be frozen, and stored in an anonymised manner so that further tests may 
be performed on them in the future (under NHS Lothian's Tissue Governance 
standards). We also intend to study your DNA using a process called ‘genome-wide 
assessment’ to help us understand if genes determine how your body responds to the 
heart valve disease. Please note that we cannot use this data and information to test 
for other genetic conditions. 
 
Is there anything else that I have to do? 
There are no restrictions on your lifestyle through participating in this study. You 
should let your doctor know if you experience any symptom that you think may be 
related to this study. 
 
Will taking part in this study affect my treatment? 
No – you will still be followed up by your medical team (if required) as if you were not 
participating in the trial.  
 
What are the side effects of taking part? 
Performing PET CT and CT-coronary artery scans will expose you to a dose of radiation. 
The amount of radiation varies but is around 8 times the amount you would normally 
receive in a single year from background natural sources of radiation. The lifetime risk 
of developing cancer from the radiation used in the scan is small: less than 1 in 750. 
To put this number in context in the average population 1 in 4 people will develop 
cancer in their lifetime.  Therefore the risk to participants increases from 500 in 2000 
to 501 in 2000. 
 
The MRI scanner uses powerful magnets but no radiation. Therefore any patients who 
have any metal in their bodies cannot take part in our study. This includes anyone with 
cochlear implants, aneurysm clips, pacemakers, or those who have ever had metal in 
their eyes. 
 
The dyes used in our MRI and CT scans are used every day in hospitals throughout the 
world. They both affect the kidneys especially in patients with preexisting kidney 
problems. The contrast given in CT scans contain iodine and can occasionally have side 
effects ranging from headache and itch all the way to severe allergic reactions but 
these are extremely rare.  
 
Fluciclatide is an experimental imaging agent that has limited experience to date but 
appears to be generally well tolerated. In three clinical trials, only two subjects have 
experienced any potential side effects (indigestion and headache). One further patient 
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had a change in one of their blood counts that may have been related to fluciclatide. 
If you were found to be allergic to Fluciclatide or its components, you would be 
excluded from the study. 
 
We will not include any female who has the potential to become pregnant. Radiation 
can cause damage to babies in the womb and so we want to ensure that no scans are 
performed on pregnant ladies.  
 
The CT and MRI scanner takes detailed images of a small area of your chest so there 
is a small chance that we will find another abnormality in this area. Often these 
abnormalities turn out to be of no significance to your health. However, if this happens 
we will let you and your GP know and arrange for you to see a specialist for any further 
tests that are required. 
 
What are the possible disadvantages of taking part? 
Involvement in the trial will mean you attending for various appointments and scans. 
Whenever possible we will ensure that these occur during the same visit. If required 
we can also reimburse you for travel costs. Please discuss this at the time of your 
appointment. 
 
What are the possible benefits of taking part? 
There will not be any direct benefit to you in taking part in the study, however it is 
hoped that the findings of this study will benefit other patients with heart attacks in 
the future. The information from the PET CT scans will provide us with extra 
information about your heart, your heart valves, and some of the blood vessels in your 
body. We are unsure as to how useful this will prove. It is the purpose of this study to 
find that out.  
 
Will my GP be informed? 
As long as you agree we would like to inform your General Practitioner of your 
participation in this study. 
 
Will my taking part in this study be kept confidential? 
All the information collected about you during the course of the research will be kept 
strictly confidential. Any information about you which leaves the hospital will have 
your name and address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
We will use the information that we will obtain from your scans in the best possible 
way, including analysing the other blood vessels and organs in your body to see if we 
can use this technique to benefit people with other medical conditions. Once we have 
completed the study and analysed the results, we will write a paper which will be 
submitted for publication in one of the medical journals. We do not routinely contact 
participants to inform them of the outcome of the research but would be happy to do 
so if requested. If you would like a copy of the results please contact Dr William Jenkins 
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using the contact details listed below. You will not be personally identified in any 
report/publication. The data of the study will also be shared with General Electric 
Healthcare Medical Diagnostics. 
 
Who is organising the research? 
The study is being organised through the University of Edinburgh and NHS Lothian. 
Your doctors will not be paid for including you in this study. 
 
Who has reviewed the study? 
The study has been reviewed by the South East Scotland Research Ethics Review 
Service. 
 
Where can I obtain further information about the study? 
You can get further information from Dr William Jenkins or Professor Newby who will 
arrange to meet you. You can also contact Dr Henriksen who is not directly involved 
with this study but can act as an independent advisor. He can be contacted through 
the Royal Infirmary switchboard  (0131 242 1000) by asking for his secretary. 
 
Dr William Jenkins can be reached by contacting him on 0131 242 6428; his email  
williamjenkins@doctors.net.uk: or by letter addressed to the Cardiovascular Research 
Unit, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 SU4. Prof 
Newby can be contacted via the hospital switchboard (0131 536 1000). 
 
If you wish to make a complaint about the study please contact NHS Lothian: 
 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh, EH1 3EG 
Tel: 0131 465 5708 
 












ROLE OF INFLAMMATION IN THE PROGRESSION OF AORTIC 
STENOSIS: THE RING OF FIRE 
 
Participant Name  
Participant DOB  
Participant identification No for this trial  
 
   I confirm that I have read and understood the accompanying 
information sheet. 
 
   I agree to take part in the above research project as described in the 
information sheet. 
 
   I understand that this will not influence the medical treatment that is 
planned for me in any way.  
 
   I understand that I am under no obligation to participate in this 
research, that I may withdraw from the study at any stage and that doing so 
will not influence my treatment in any way. 
 
   I understand that each of the CTPET scans performed will be 
associated with exposure to a dose of radiation.  
 
      I understand that any information related to my case will be stored in 
an anonymised manner 
 
I understand that blood samples will be stored for future use. I agree 
to them being used in future studies subject to ethical approval  
 
  I consent to my GP being informed as to my participation in the trial. 
 
Signed……………………………  Date …………………………….. 
 
Name of patient………………………………………………………. 
 




I confirm that the nature of the research, and the voluntary nature of the 
study have been explained in terms understandable to the patient 
 
Signed  ………………………..   Date……………………………….. 
 
Name of investigator ……………………………………………….. 
  






Patient Identification Number for this trial: 
CONSENT FORM 
Identification of In Vivo Angioneogenesis and Fibrosis in Myocardial Infarction using 
Positron Emission Tomography. 
 
Myocardial Infarction Group  
(re-vascularised  /  non-revascularised) 
 
Name of Researcher: Professor David E. Newby 
Please initial all boxes  
1. I confirm that I have read and understand the information sheet dated 15/01/13 (Post MI group 
- revascularised, version 1.5, or Post MI group – non-revascularised, version 1.5) for the above 
study.  I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily.   
2. I agree to participate, understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or legal rights being 
affected. 
3. I understand that this will not influence the medical treatment that is planned for me in any 
way. 
4. I understand that the CTPET scan performed will be associated with exposure to a dose of 
radiation. 
5. I understand that the CT, PET and MRI scans will require the administration of drugs. 
6. I understand that any information related to my case will be stored in an  
anonymised manner. 
 
7.  I understand that anonymised blood samples and anonymised DNA will be stored (under NHS Lothian's 
Tissue Governance standards) for future research studies. 
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8. I understand that relevant sections of my medical notes and data collected during the trial may 
be looked at by the trial researchers and individuals from the Sponsor, regulatory authorities, 
the NHS organization or from General Electric Healthcare, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to my records. 
9. I agree to my GP being informed of my participation in the study, and that he will be informed 
of any incidental findings on my scans.   
10. I agree to the further use of identifiable data/tissue in the event of a loss of capacity.  
11. I agree that blood and tissue samples may be used for genetic analysis. 
   
 
 
            
Name of Participant   Date    Signature 
                                
            
Name of Person   Date    Signature  










Patient Identification Number for this trial: 
CONSENT FORM 
Identification of In Vivo Angioneogenesis and Fibrosis in Aortic Stenosis using Positron 
Emission Tomography. 
 
Aortic Stenosis Study Group 
 
Name of Researcher: Professor David E. Newby 
Please initial all boxes  
12. I confirm that I have read and understand the information sheet dated 15/01/2013  (AS Study 
Group version 1.5) for the above study.  I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.   
13.  I agree to participate, understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care or legal rights being 
affected. 
14. I understand that this will not influence the medical treatment that is planned for me in any 
way. 
15. I understand that the CTPET scan performed will be associated with exposure to a dose of 
radiation. 
16. I understand that the CT, PET and MRI scans will require the administration of drugs. 
17. I understand that any information related to my case will be stored in an  
anonymised manner. 
 
18. I understand that anonymised blood samples and anonymised DNA will be stored (under NHS Lothian's 
Tissue Governance standards) for future research studies.  
 
19. I understand that relevant sections of my medical notes and data collected during the trial may 
be looked at by the trial researchers and individuals from the Sponsor, regulatory authorities, 
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the NHS organisation or from General Electric Healthcare, where it is relevant to my taking 
part in this research. I give permission for these individuals to have access to my records. 
20. I agree to my GP being informed of my participation in the study, and that he will be informed 
of any incidental findings on my scans.   
21.  I agree to the further use of identifiable data/tissue in the event of a loss of capacity.  
22. I agree that blood and tissue samples may be used for genetic analysis. 
   
 
 
            
Name of Participant   Date    Signature 
                                
            
Name of Person   Date    Signature  











































The mechanisms underlying aortic stenosis (AS) remain incompletely understood, and the accurate prediction of 
disease progression remains a challenge.1 Calcification and 
inflammation are thought to play key pathophysiological 
roles. Indeed, the amount of established calcium in the valve 
correlates with disease severity and predicts future adverse 
cardiovascular events.2,3 Although computed tomography 
(CT) and echocardiography can provide measures of estab-
lished valvular calcification, they cannot directly assess ongo-
ing calcification activity, which is considered to be the main 
driver of disease progression.
Clinical Perspective on p 378
Recent reports have investigated 2 positron emission 
tomography (PET) radiotracers, 18F-sodium fluoride (18F-
NaF) and 18F-fluorodeoxyglucose (18F-FDG), as measures 
of calcification activity and inflammation, respectively, in the 
aortic valve,4 coronary arteries,5,6 and major vessels.7 18F-
FDG PET has become a widely used tool for the assessment 
of inflammation in the aorta and carotid arteries, with uptake 
correlating with macrophage burden.8 Several studies have 
investigated its uptake in AS, although histological validation 
Background—18F-Sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) are promising novel biomarkers of 
disease activity in aortic stenosis. We compared 18F-NaF and 18F-FDG uptake with histological characterization of the 
aortic valve and assessed whether they predicted disease progression.
Methods and Results—Thirty patients with aortic stenosis underwent combined positron emission and computed 
tomography using 18F-NaF and 18F-FDG radiotracers. In 12 patients undergoing aortic valve replacement surgery (10 
for each tracer), radiotracer uptake (mean tissue/background ratio) was compared with CD68 (inflammation), alkaline 
phosphatase, and osteocalcin (calcification) immunohistochemistry of the excised valve. In 18 patients (6 aortic sclerosis, 
5 mild, and 7 moderate), aortic valve computed tomography calcium scoring was performed at baseline and after 1 
year. Aortic valve 18F-NaF uptake correlated with both alkaline phosphatase (r=0.65; P=0.04) and osteocalcin (r=0.68; 
P=0.03) immunohistochemistry. There was no significant correlation between 18F-FDG uptake and CD68 staining 
(r=−0.43; P=0.22). After 1 year, aortic valve calcification increased from 314 (193–540) to 365 (207–934) AU (P<0.01). 
Baseline 18F-NaF uptake correlated closely with the change in calcium score (r=0.66; P<0.01), and this improved further 
(r=0.75; P<0.01) when 18F-NaF uptake overlying computed tomography–defined macrocalcification was excluded. No 
significant correlation was noted between valvular 18F-FDG uptake and change in calcium score (r=−0.11; P=0.66).
Conclusions—18F-NaF uptake identifies active tissue calcification and predicts disease progression in patients with calcific 
aortic stenosis.
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is lacking.4,9 18F-NaF has been used as a bone tracer for >40 
years, displaying increased activity in conditions associated 
with increased bone metabolism such as Paget disease. In 
bone, it is thought to bind and then incorporate into exposed 
hydroxyapatite crystals via an exchange mechanism with 
hydroxyl groups to form fluoroapatite. Given that hydroxy-
apatite is also a key structural component of calcification in 
the aortic valve and vascular atheroma, it is presumed that 
similar mechanisms explain its accumulation in these tissues. 
However, this remains hypothetical. The principal aims of the 
present study were, therefore, to validate the use of 18F-NaF 
and 18F-FDG in AS by comparing in vivo radiotracer uptake 
with immunohistochemistry of calcification and inflammation 
in excised valvular tissue and to investigate whether either of 
these agents predicts disease progression at 1 year.
Methods
Patient Populations
Two cohorts of patients with AS were recruited into this study: (1) 12 
patients undergoing valve replacement surgery, and (2) 18 patients 
with asymptomatic disease under surveillance at the Edinburgh Heart 
Center. The latter cohort was randomly selected for repeat scanning 
from a larger, previously described population who underwent base-
line PET imaging.4,5,10
All patients were >50 years of age, and exclusion criteria included 
a normal aortic valve, insulin-dependent diabetes mellitus, end-stage 
renal failure, life expectancy of <2 years, and metastatic malignancy. 
Patients with severe AS were excluded from the cohort of patients un-
der surveillance because of the potential for disease progression and 
symptom development before the follow-up 1-year scan. The study 
was performed in accordance with the Declaration of Helsinki and 
after local research ethics committee approval. All patients provided 
written informed consent before participating.
Baseline Assessment
All patients underwent full clinical assessment at baseline, and AS se-
verity was assessed using Doppler and 2-dimensional echocardiogra-
phy by means of the peak transvalvular velocity, mean gradient, and 
aortic valve area according to American Heart Association/American 
College of Cardiology guidelines.11 Aortic sclerosis was defined as 
thickening of the aortic valve cusps in the absence of accelerated flow 
(<2 m/s) through the valve. Combined PET and CT scans of the aortic 
valve were performed using a hybrid scanner (Biograph mCT; Siemens 
Medical Systems, Erlangen, Germany) 60 minutes after administration 
of 125 MBq of 18F-NaF. Subsequently, a second PET/CT scan was 
performed using the same hybrid scanner 90 minutes after administra-
tion of 200 MBq of 18F-FDG. Glucose is a major energy source of 
the myocardium, so that intense 18F-FDG uptake frequently occurs, 
spilling over and contaminating the signal in the valve. We attempted to 
reduce myocardial uptake by asking patients to avoid carbohydrates for 
24 hours before their 18F-FDG scan, thereby switching the myocardi-
um from glucose to free fatty-acid metabolism. Myocardial 18F-FDG 
uptake was assessed within regions of interest (ROIs) placed in the 
basal septum of the left ventricle and classified as being adequately 
suppressed if mean standard uptake values were <5.0.4 An ECG-gated 
breath-hold CT scan (noncontrast enhanced, 40 mA/rot [CareDose]; 
100 kV) was performed for calculation of the aortic valve calcium score 
using dedicated analysis software (VScore; Vital Images, Minnetonka, 
MN) on axial scans.12 Particular care was taken to differentiate valvular 
calcium from that in the aortic root and mitral valve annulus.6 At 1-year 
follow-up, patients in the surveillance cohort underwent repeat clinical 
assessment and CT calcium scoring using the same protocol.
Quantification of Aortic Valve PET Activity
18F-NaF and 18F-FDG uptake in the aortic valve was quantified 
using an Osirix workstation (OsiriX version 3.5.1 64-bit; OsiriX 
Imaging Software, Geneva, Switzerland) as reported previously.4,5 
Briefly, fused PET-CT images were reoriented into the plane of the 
valve and circular ROIs drawn on adjacent 3-mm slices until the entire 
valve had been examined. For 18F-NaF, ROIs were placed around the 
perimeter of the valve while excluding the aortic root (whole-valve 
technique). To reduce the potential for myocardial 18F-FDG activity 
contaminating the aortic valve signal, ROIs for this tracer were drawn 
in the center of the valve as previously described (center-valve tech-
nique).4,9 Within these ROIs, mean standard uptake values were cal-
culated for each slice, averaged, and corrected for blood pool activity 
to provide mean tissue/background ratios. Mean tissue/background 
ratios were selected prospectively for subsequent comparisons with 
histology and disease progression because this measure was felt to 
best represent tracer uptake across the valve as a whole.
Distribution of 18F-NaF in the Aortic Valve Relative to 
Calcium Scoring
We undertook a voxel-by-voxel analysis comparing the distribution 
of calcium on CT with 18F-NaF uptake. ROIs were drawn around 
the valve, and each voxel was assessed for the presence of calcium 
(>130 HU) and increased 18F-NaF uptake (tissue/background ratio 
max >1.97 based on the highest uptake in the control cohort of our 
previous study)4 using dedicated software MATLAB (Mathworks 
Inc, Natick, MA). We hypothesized that regions of completely novel 
calcium development might have an even more important effect on 
disease progression, and therefore we calculated the percentage of the 
valve with increased radiotracer uptake in the absence of underlying 
calcium on CT (% of PET-positive but CT-negative pixels).
Histological Assessment
In the patients undergoing aortic valve replacement, the aortic valve 
was removed at the time of operation, with care taken to preserve the 
integrity of the valve architecture. Samples were then fixed in 4% 
paraformaldehyde for 24 hours. Plaques were decalcified in EDTA 
for 10 days and embedded in paraffin, and 5-μm sections were pre-
pared. Immunohistochemical staining for osteocalcin (antihuman 
mouse mAb ab13418; Abcam), CD68 (antihuman mouse clone 
PG-M1 m0876, DAKO), and tissue nonspecific alkaline phospha-
tase (TNAP; antihuman rabbit pAb CAT#LF PA50004; Abfrontier) 
was then undertaken after heat-induced epitope retrieval using a 
Citrate Buffer pH 6 (Novocastra Leica microsystems) in a decloak-
ing chamber. Osteocalcin staining required no heat-induced epitope 
retrieval. Sections were stained using a Leica Vision Biosystems 
Bond×immunostaining robot. After blocking in peroxide for 10 min-
utes, sections were incubated with the specific antihuman antibodies 
for 2 hours at room temperature at the following dilutions: osteocal-
cin 1:200, TNAP 1:100, and CD68 1:100. All incubation steps were 
followed by washing in TBS/Tween. Sections for osteocalcin and 
CD68 were incubated for 15 minutes with prepolymer/postprimary 
followed by 15 minutes with polymer (HRP) for all antibodies before 
3,3′-diaminobenzidine visualization and hematoxylin counterstain. 
Sections were dehydrated in graded ethanol and cleared in xylene 
before cover slipping in Pertex.
Images were taken on a Zeiss Axioskop2 fitted with an Axiocam 
MRc digital camera using Axiovision software. Tissue  cross-sectional 
area on each section was manually delineated using Image Pro Plus 
5 (Rockville, MD). Immunohistochemical staining for osteocalcin 
and TNAP was identified by visual assessment and quantified using 
automated color-based segmentation by a trained observer blinded 
to the PET data. Staining was expressed as a percentage of the total 
valve area. Macrophage infiltration using CD68 was assessed using 
a similar approach but with an object size set threshold applied at 
20×10 pixels to limit counting to cell-sized objects. The density of 
cell staining in the valve tissue was expressed as cells per square mil-
limeter. This technique was also used to identify cellular staining for 
TNAP and osteocalcin.
Reproducibility Studies
Interobserver reproducibility of the immunohistochemical data was 
investigated. Tissue staining with alkaline phosphatase, CD68, and 
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osteocalcin was quantified in 5 valves independently by 2 trained ob-
servers (W.S.A.J. and A.T.V.).
Autoradiography
Clinical PET systems have limited resolution. To gain further infor-
mation about the precise localization of the 18F-NaF signal in aortic 
valve tissue, we undertook autoradiography. Nondecalcified valvu-
lar tissue was rapidly cooled in dry ice and then sectioned at 7-μm 
thickness using a cryostat (CM1520; Wetzlar, Germany). Sections 
for autoradiography were mounted on Superfrost slides (Gerhard 
Menzel, Braunschweig, Germany) before treatment with spray fixa-
tive. Sections were bathed in a solution of 18F-NaF at a concentration 
close to in vivo imaging concentrations (1 kBq/mL) for 60 minutes 
and then rinsed with PBS. A freshly blanked phosphor screen was 
then placed over the slides and an overnight exposure undertaken. 
The screen was then read using a FujiFilm FLA-5100 Fluorescent 
Image Analyser (Raytek Scientific Limited, Sheffield, UK). Sections 
adjacent to those used for autoradiography were stained for elemen-
tal phosphate (ie, calcium orthophosphate) using Von Kossa stain, 
and after surface decalcification in situ with Von Ebner solution, for 
TNAP and osteocalcin. Sections were then manually registered and 
examined for colocalization with 18F-NaF signal.
Statistical Methods
Continuous variables were assessed for normality both visually and 
using the D’Agostino-Pearson test. Variables were expressed as ei-
ther mean±SD or median with interquartile ranges (IQRs) subject to 
whether they approximated a normal distribution. Categorical data 
were presented as n (%). The 95% normal range for differences be-
tween sets of immunohistochemical measurements (the limits of 
agreement) were estimated using Bland–Altman analysis by multi-
plying the SD of the mean difference by 1.96.13 Intraclass correla-
tion coefficients with 95% confidence intervals were calculated for 
interobserver variation. Baseline and follow-up calcium scores ap-
proximated a normal distribution and were compared using a paired 
t test. However, despite attempts at data transformation, the changes 
in calcium scores were not normally distributed, and correlations 
with CT progression data were assessed using Spearman correlation 
and linear regression analysis. We acknowledge the limitations in us-
ing linear regression in the context of a non-normal distribution. A 
2-sided P<0.05 was regarded as statistically significant. Statistical 
analysis was performed with the use of Graph Pad Prism version 6.0 
(GraphPad Software Inc, San Diego, CA).
Results
Histology Cohort
Twelve patients with symptomatic AS were recruited into 
the histology cohort (8 men; 76±6 years of age; peak aortic 
valve velocity, 4.6±0.9 m/s). Patients underwent PET scan-
ning a median of 92 days before surgical aortic valve replace-
ment. Eight patients received both 18F-NaF and 18F-FDG 
PET scans. In addition, 2 had a single 18F-NaF scan, whereas 
2 more had a single 18F-FDG scan. Thus, 10 valves were 
available for the histological validation of each tracer. No 
patient had a significant perioperative complication (Table 1). 
Effective myocardial suppression of 18F-FDG activity was 
achieved in 40% (median myocardial standard uptake value, 
5.4; IQR, 1.9–10.4).
Immunohistochemistry and Autoradiography
All valve samples displayed positive cellular staining for 
TNAP (225 cells/mm2 valve tissue; IQR, 143–328), osteo-
calcin (130 cells/mm2 valve tissue; IQR, 85–274), and CD68 
(172 cells/mm2 valve tissue; IQR, 73–271; Figure 1). Exten-
sive TNAP and osteocalcin staining was also observed in the 
extracellular matrix, occupying approximately a sixth of the 
valve area sampled (17±5% and 17±7%, respectively).
On autoradiography, 18F-NaF uptake was observed to 
colocalize closely with staining for structural calcium phos-
phate, TNAP, and osteocalcin (Figure 1). However, signal was 
also clearly apparent in areas free of macroscopically visible 
calcium, thus highlighting the sensitivity of 18F-NaF in the 
detection of newly evolving calcification.
Reproducibility of Immunohistochemistry
Interobserver reproducibility was good for the quantifica-
tion of osteocalcin and TNAP staining, as well as CD68 cell 
Table 1. Baseline Characteristics of Progression Cohort
Total Aortic Sclerosis Mild Aortic Stenosis Moderate Aortic Stenosis
No. 18 6 (33) 7 (39) 5 (28)
Age, y 75 (71–79) 74 (70–78) 74 (69–80) 79 (70–83)
Men 15 (83) 4 (66) 7 (100) 4 (80)
Hypertension 13 (72) 3 (50) 5 (71) 5 (100)
Hyperlipidemia 12 (67) 4 (66) 5 (71) 3 (60)
Diabetes mellitus 5 (28) 1 (16) 4 (57) 0 (0)
Ischemic heart disease 13 (72) 4 (66) 6 (86) 3 (60)
Serum creatinine, μmol/L 92±29 85 (72–92) 91 (67–125) 84 (69–133)
Cigarette smoking 0 (0) 0 (0) 0 (0) 0 (0)
Peak aortic valve velocity, m/s 2.6 (1.8–3.1) 1.7 (1.6–1.8) 2.4 (2.1–2.6) 3.4 (3.2–3.6)
Aortic valve area, cm2 1.68 (1.26–2.28) 1.92 (1.8–2.1) 1.63 (1.42–1.87) 1.03 (0.78–1.18)
Mean gradient, mm Hg 10.8 (7.0–16.5) 6.2 (4.8–7.0) 11.0 (9.3–14.0) 22.0 (18.8–27.2)
Aortic valve calcium score, AU 314 (193–540) 106 (13–204) 355 (211–536) 1167 (436–1472)
Time between CT scans, d 386 (377–409) 390 (375–408) 394 (376–426) 183 (360–399)
18F-FDG dose injected, MBq 193 (188–196) 193 (185–205) 191(185–194) 194 (190–206)
18F-NaF dose injected, MBq 123 (120–126) 124 (117–127) 123 (117–128) 123 (120–126)
Categorical displayed as total number (%). Median (interquartile range). CT indicates computed tomography; 18F-FDG, 18F-fluorodeoxyglucose; 
and 18F-NaF, 18F-sodium fluoride.
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counting. All observations were characterized by an absence 
of fixed or proportional biases, narrow limits of agreement 
(−13.4% to 9.3%, −8.0% to 5.0%, and −7.9% to 9.6%, respec-
tively), and interclass correlation coefficient values of 0.90 
(0.35–0.99), 0.88 (0.60–0.97), and 0.99 (0.99–1.00), respec-
tively (Tables 2 and 3).
Correlation With Radiotracer Uptake
There was a good correlation between in vivo valvular  18F-NaF 
uptake and both alkaline phosphatase (r=0.65 [95% confidence 
interval, 0.03–0.90]; P=0.04) and osteocalcin (r=0.68 [0.10–
0.91]; P=0.03; Figure 2) staining of the excised tissue. In com-
parison, there was no association between 18F-FDG uptake 
and CD68 staining in the valve (r=−0.43; P=0.22).
Disease Progression
Of the 18 patients (75±6 years of age; 17 men; peak aortic-jet 
velocity, 2.6±0.9 m/s) reassessed at a median interval of 386 
days (Table 1), 6 had aortic sclerosis, 7 had mild AS, and 5 had 
moderate AS. Effective myocardial suppression of 18F-FDG 
uptake was achieved in 66% (median myocardial standard 
uptake value, 3.6; IQR, 2.0–5.4).
A correlation was observed between baseline aortic valve 
calcium scores on CT and 18F-NaF activity on PET (r=0.74 
[0.42–0.90]; P≤0.001). However, as described previously, 
the pattern of 18F-NaF uptake was distinct from the distri-
bution of established calcium.4,5,14 Indeed 18F-NaF uptake 
in the absence of underlying calcium occupied a median of 
8.3% (IQR 1.6–23.4) of the total valve area, emphasizing that 
 18F-NaF provides distinct and complementary information to 
CT calcium scoring (Figure 1).
At 1 year, aortic valve calcium scores increased from 314 
(193–540) to 365 (207–934) AU (P<0.01). Interestingly, these 
regions of novel calcium developed in much the same distri-
bution as the observed baseline 18F-NaF uptake (Figure 3A 
and 3B). Indeed, we observed an excellent correlation between 
baseline valvular 18F-NaF PET uptake and the change in 
calcium score after 1 year (r=0.66 [0.27–0.86]; P=0.003; 
Figure 3C). This was similar to that observed for the current 
gold standard method of prediction: the baseline calcium score 
(r=0.58 [0.15–0.82]; P=0.01; Figure 3D) improved further 
when only increased 18F-NaF uptake in the absence of underly-
ing CT macrocalcification was considered (r=0.75 [0.42–0.90]; 
Figure 1. Histology and 18F-sodium 
fluoride (NaF) autoradiography of excised 
aortic valve tissue from patients with aor-
tic stenosis. A–F, Fixed, decalcified, and 
paraffin-embedded aortic valve tissue 
after exposure to tissue nonspecific alka-
line phosphatase (TNAP), osteocalcin, 
and CD68 antibodies. A–C, Widespread 
positive staining for TNAP, osteocalcin, 
and CD68 (magnification ×4) in the extra-
cellular matrix, which is also observed on 
an individual cellular level (D–F, magnifi-
cation ×20), respectively. G-I, Three adja-
cent and consecutive aortic valve leaflet 
sections displaying positive immunohisto-
chemical staining for osteocalcin (I, mag-
nification ×4) that colocalizes to areas of 
maximal 18F-NaF uptake on autoradiog-
raphy (H). These likely represent areas 
of ongoing calcification activity, which 
extend beyond the areas of established 
calcium identified in black by Von Kossa 
stain (G, magnification ×4).
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P=0.01). No statistically significant correlation was observed 
between 18F-FDG uptake and the subsequent change in CT cal-
cium score (r=−0.11 [−0.56 to 0.39]; P=0.66; Figure 3E).
Discussion
We provide the first preliminary evidence that valvular 
18F-NaF uptake acts as a marker of calcification activity in 
patients with AS. Not only did uptake values demonstrate 
a correlation with histological markers of active calcifica-
tion (TNAP and osteocalcin), but they were also a good 
predictor of the subsequent progression in aortic valve CT 
calcium scores at 1 year. In contrast, 18F-FDG uptake did 
not correlate with CD68 staining on histology or the pro-
gression in calcium scores. Our data indicate that 18F-NaF 
holds promise as a biomarker of disease activity in patients 
with AS.
The pathophysiology of AS is incompletely understood, 
delaying the development of biomarkers and effective medical 
therapies. Calcification and inflammation are thought to play 
a key pathological role,1 so that noninvasive markers of their 
activity are of interest in better understanding the cause of this 
condition and in predicting disease progression.
Recent studies have investigated 18F-NaF PET as a marker 
of vascular calcification in AS3 and atherosclerosis affecting 
the aorta,7 coronary,5,6 and carotid arteries.15 However, this is 
the first study to provide histological validation of 18F-NaF 
uptake in vascular tissue. In bone, 18F-NaF is thought to 
incorporate onto the surface of hydroxyapatite crystal.14 Given 
that hydroxyapatite is also a key component of vascular calci-
fication, it too has been the presumed radiotracer target in AS 
and atherosclerosis. This hypothesis is supported by our auto-
radiography and immunohistochemical data, demonstrating a 
good correlation between 18F-NaF activity and osteocalcin 
staining: a well-recognized osteogenic protein that itself binds 
to hydroxyapatite.
Given that 18F-NaF binds to a structural component of 
vascular calcification, why then does it not simply label all 
regions of macrocalcification identified by CT? Indeed it 
is common for regions of dense calcium on CT to show no 
18F-NaF uptake. This phenomenon is likely related to the 
available surface area of exposed hydroxyapatite crystal to 
which the 18F-fluoride ion can adsorb and the inactivity of 
established areas of calcification. 18F-NaF uptake is much 
greater at sites of evolving powdery microcalcification than 
established regions of field calcification in which the core 
of hydroxyapatite is internalized and, therefore, hidden 
from the 18F-NaF tracer. Thus, 18F-NaF binds more read-
ily to regions of developing calcium and acts as a marker 
of calcification activity, providing distinct information to 
calcium scoring. In contrast, the latter quantifies regions 
of established macroscopic calcium in the valve but cannot 
Table 2. Histology Cohort Data
Baseline characteristics
  No. 12
  Age, y 76±6
  Men 9 (75)
  Hypertension 8 (66)
  Hyperlipidemia 5 (42)
  Ischemic heart disease 4 (33)
  Cigarette smoking 1 (8)
  Diabetes mellitus 0 (0)
  Serum creatinine, μmol/L 87±26
  Peak aortic valve velocity (m/s) 4.6±0.9
  Aortic valve area, cm2 0.70 (0.53–0.97)
  Mean gradient, mm Hg 48 (44–65)
  Aortic valve calcium score, AU 5343 (3114–6292)
  Aortic sclerosis 0 (0%)
  Mild aortic stenosis 0 (0%)
  Moderate aortic stenosis 3 (25%)
  Severe aortic stenosis 9 (75%)
  Time between 18F-NaF scan and AVR, d 92 (24–345)
  Time between 18F-FDG scan and AVR, d 96 (23–331)
  18F-FDG dose injected, MBq 200 (193–209)
  18F-NaF dose injected, MBq 129 (119–132)
In vivo aortic valve PET data
  18F-NaF uptake (mean TBR) 2.15 (1.98–2.48)
  18F-FDG uptake (mean TBR) 1.40 (1.31–1.76)
Categorical data are displayed as n (%). Normally distributed data are 
displayed as mean±SD. Non-normally distributed data are distributed as 
median (interquartile range). AVR indicates aortic valve replacement; FDG, 
fluorodeoxyglucose; NaF, sodium fluoride; PET, positron emission tomography; 
and TBR, tissue/background ratio.
Table 3.  Immunohistochemical  Analysis
Histology Osteocalcin TNAP CD68
No. 10 10 10
Mean valve area analyzed, mm2 234±152 253±116 190±86
% staining of the valve 17±7 17±5 n/a
Positive cellular staining, cells/mm2 130 (85–274) 225 (143–328) 172 (73–271)
Interobserver reproducibility
  Mean difference −2.1% −1.5% 0.8%
  Limits of agreement −13.4% to 9.3% −8.0% to 5.0% −7.9% to 9.6%
  ICC 0.88 (0.60–0.97) 0.90 (0.35–0.99) 0.99 (0.99–1.00)
Categorical data are displayed as n (%). Normally distributed data are displayed as mean±SD. Non-normally 
distributed data are distributed as median (interquartile range). ICC as value (95% confidence interval). ICC 
indicates interclass correlation coefficient; n/a, not applicable; and TNAP, tissue nonspecific alkaline phosphatase.
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inform whether the process of calcification is quiescent or 
active. Again this hypothesis is supported by our data. We 
have demonstrated a strong correlation between in vivo 
18F-NaF uptake and staining for 1 of the key enzymes reg-
ulating mineralization: TNAP. This enzyme is expressed in 
the early stages of new calcium formation and is known to 
work by breaking down pyrophosphate: a potent inhibitor 
of mineralization.16 Furthermore, as one would expect from 
a measure of activity, baseline 18F-NaF uptake closely 
correlated with the subsequent change in calcium score at 
1 year. Indeed, 18F-NaF uptake performed as well as the 
current gold standard method of prediction, the degree of 
established calcium in the valve at baseline.2,3 However, 
larger studies are now required to compare these 2 tech-
niques, whereas calcium scoring may be easier to obtain; 
changes in the 18F-NaF PET signal are likely to occur 
more quickly, making it a more attractive technique with 
which to assess the early and more immediate effects of 
novel treatment strategies.
Interestingly, the pattern of 18F-NaF uptake may be impor-
tant, with 18F-NaF uptake remote from established macrocal-
cification on CT offering the best prediction of calcium score 
progression in our cohort. The spatial resolution of PET/CT is 
≈4 mm, and we acknowledge that the  voxel-by-voxel analysis 
used to establish this observation is at the limit of resolution 
for PET imaging. Nevertheless, the strong correlation with 
progression is of interest and indicates that further investiga-
tion of the spatial distribution of 18F-NaF uptake is warranted.
The results of valvular 18F-FDG imaging were somewhat 
disappointing and surprising given previous data suggesting 
an important role for inflammation in AS.17 Although correla-
tions between 18F-FDG uptake and macrophage burden have 
previously been demonstrated in regions of aortic and carotid 
atheroma,8 we were unable to replicate this with respect to the 
valve. There are several explanations for this discrepancy. The 
first is the close proximity of the valve to the myocardium. 
As discussed, avid uptake of 18F-FDG by the left ventricular 
myocardium can spill over into the aortic valve contaminating 
its signal. Unfortunately, despite the stringent dietary restric-
tions and center-valve analysis technique, it remains possible 
that myocardial contamination occurred, confounding the 
correlation with CD68 immunohistochemistry. Indeed poor 
myocardial suppression was achieved in the histology group, 
perhaps reflecting their advanced disease and symptomatic sta-
tus. Alternative methods have been used to reduce further this 
myocardial uptake, including administration of heparin18 and 
a high-fat drink before scanning.19 However, these make the 
practicalities of scanning more difficult and have yet to show a 
clear advantage over dietary restrictions. An alternative expla-
nation for the poor correlation with histology is that the aortic 
valve 18F-FDG signal relates to uptake by nonmacrophage cell 
types within the valve, such as osteoblasts, or is governed by 
external factors, such as hypoxia.20 In this scenario, one might 
still expect 18F-FDG to predict disease progression, but once 
again this was not evident in our cohort. It would, therefore, 
seem that 18F-FDG holds less potential as a predictor of dis-
ease progression than  18F-NaF does, although it remains pos-
sible that longer periods of follow-up are required to detect 
such an association. Indeed on occasion, we also observed 
18F-NaF activity that did not translate into a detectable change 
in calcium score at 1 year. AS is a slowly developing condition, 
so it is likely to take time for relatively low levels of 18F-NaF 
or 18F-FDG uptake to translate into new areas of macrocalci-
fication detectable on CT imaging. Larger studies with longer 
follow-up are, therefore, required to address this issue, confirm 
our preliminary data, and assess whether 18F-NaF PET can 
predict disease progression with respect to echocardiographic 
parameters of valvular stenosis.
Figure 2. Correlations between in vivo aortic valve positron emis-
sion tomography (PET) activity and histological markers of calci-
fication and inflammation. A, 18F-Sodium fluoride (NaF) vs tissue 
nonspecific alkaline phosphatase (TNAP). A good correlation was 
observed between the percentage aortic valve tissue staining for 
TNAP and the valvular 18F-NaF activity (mean tissue to back-
ground ratio [TBR]); r=0.65, P=0.04. B, 18F-NaF vs osteocalcin. 
Again a strong correlation was observed between the percentage 
surface area of the valve stained with osteocalcin and the aortic 
valve 18F-NaF PET activity (mean TBR); r=0.68, P=0.03.  
C, 18F-fluorodeoxyglucose (FDG) vs CD68. A poor correlation 
was observed between CD68 staining on immunohistochem-
istry and 18F-FDG PET activity in the aortic valve (mean TBR); 
r=−0.43, P=0.22.
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Conclusions
We provide the first preliminary data to support 18F-NaF as a 
marker of valve calcification activity in AS and as a potential 
method for predicting disease progression.
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CLINICAL PERSPECTIVE
Aortic stenosis is the most common form of valvular heart disease in the developed world; however, its rate of progression 
can vary greatly between patients, and as yet we lack effective medical therapies. Progressive valvular calcification is a 
key pathophysiological process driving aortic stenosis. Recent studies have suggested that the positron emission tomog-
raphy (PET) tracer 18F-sodium fluoride (18F-NaF) can measure vascular calcification activity, although validation of this 
technique has previously been lacking. In this study, we sought to provide such validation, comparing aortic valve 18F-
NaF uptake with both histological measures of calcification activity and the progression of aortic valve calcium scores on 
computed tomography. Ten patients scheduled for aortic valve replacement underwent 18F-NaF PET before their operation 
with valvular PET uptake, demonstrating a significant correlation with histological markers of calcification activity on the 
excised aortic valve tissue. In a separate cohort, we assessed 18 patients with calcific aortic valve disease who underwent 
18F-NaF PET and computed tomography calcium scoring of the aortic valve both at baseline and after 1 year. Once again 
a good correlation was observed between the baseline PET uptake and change in calcium score. Our results are promising, 
providing the first preliminary validation of 18F-NaF as a marker of calcification activity in the aortic valve. More studies 
are now required to investigate 18F-NaF PET as a method for predicting disease progression in aortic stenosis and assessing 
the early efficacy of novel treatments aimed at reducing calcification activity in this condition.













18F-Fluoride is a positron emission tomography (PET)
radiotracer that preferentially binds to regions of
newly forming vascular microcalcifications beyond
the resolution of computed tomography (CT) (1).
18F-Fluorodeoxyglucose (18F-FDG) has been widely
used to measure vascular inflammation (2). This is the
first prospective longitudinal study to investigate
whether these tracers predict disease progression and
clinical outcomes in aortic stenosis.
Patients age >50 years attending the outpatient
department of the Edinburgh Heart Centre were
approached for recruitment in this prospective
cohort study alongside age- and sex-matched con-
trols, as described previously (2). PET and CT were
performed in 121 volunteers (age 72 ! 8 years; 68%
men) with and without aortic valve disease (20
controls, 20 with aortic sclerosis, and 25 with mild,
33 with moderate, and 23 with severe aortic stenosis)
using 18F-fluoride (125 MBq) and 18F-FDG (200 MBq).
Uptake in the valve was measured using the most
diseased segment tissue: background ratio, based
upon averaging the mean standard uptake values in
the 2 adjacent valve slices with the highest signal,
corrected for blood-pool activity. Disease progression
was assessed at 1 and 2 years using CT aortic valve
calcium scoring and echocardiography. The primary
clinical outcome endpoint was a composite of cardio-
vascular death and aortic valve replacement.
Ninety-nine participants (81%) returned for repeat
clinical assessment and echocardiography at the
2-year time point (median 736 [interquartile range
(IQR): 722 to 760] days from enrollment). Ninety-
seven patients returned for repeat CT calcium
scoring (10 scans were uninterpretable). Aortic valve
calcium score increased by 61 (IQR: 5 to 226) AU/year,
and aortic valve mean gradient increased by
0.7 (IQR: "0.2 to 2.9) mm Hg/year. After a median of
1,526 (IQR: 1,475 to 1,615) days, 29 patients had un-
dergone aortic valve replacement, whereas 7 experi-
enced cardiovascular death.
After 2 years, new valvular calcium on CT was
visible in a similar distribution as the 18F-fluoride
activity on baseline PET imaging (Figure 1). Indeed,
baseline 18F-fluoride uptake correlated strongly with
the subsequent rate of progression in aortic valve
calcium score (Spearman r ¼ 0.80; p < 0.001) and with
echocardiographic measures of hemodynamic pro-
gression (mean gradient r ¼ 0.32; p ¼ 0.001). In an
exploratory analysis, 18F-fluoride emerged as an in-
dependent predictor of clinical outcome after age and
sex adjustments (hazard ratio: 1.55; 95% CI: 1.33 to
1.81; p < 0.001). 18F-FDG demonstrated moderate
correlations with disease progression assessed by CT
(Spearman r ¼ 0.43; p ¼ 0.001) and echocardiography
(18F-FDG r ¼ 0.30; p ¼ 0.001) and predicted clinical
outcomes independently of age and sex (hazard ratio:
1.35; 95% CI: 1.16 to 1.58; p < 0.001).
There were strong associations between the base-
line CT valvular calcium score and rate of change in
calcium score (Spearman r ¼ 0.88; 95% CI: 0.82
to 0.92; p < 0.001). Given the degree of collinearity
between CT calcium scoring and 18F-fluoride uptake
in the valve (2), assessing whether 18F-fluoride uptake
provided incremental predictive information to CT
was challenging. However, in a retrospective analysis
using the regression line between the CT calcium
score and 18F-fluoride uptake as a cutoff, patients
with aortic stenosis and higher than expected 18F-
fluoride uptake for a given CT calcium score progressed
3 times faster than participants with lower than ex-
pected uptake (median change in calcium score 315
[IQR: 127 to 492] AU/year vs. 99 [IQR: 51 to 290]
AU/year, respectively; p ¼ 0.003) Figures 1 and 2.
When a similar analysis was performed for 18F-FDG, no
FIGURE 1 Valvular 18F-Fluoride Uptake Predicts the Progression of Calcification in
Aortic Stenosis
Two patients with calcific aortic valve disease. (Left) Baseline computed tomography (CT)
images. (Middle) Fused positron emission tomography (PET)/CT images showing increased
18F-fluoride valvular uptake (red/yellow areas). (Right) Repeat CT scans after 2 years
with new areas of macroscopic calcium (white areas) in a similar distribution to that
of baseline PET uptake.
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significant difference was observed (median change in
calcium score: 231 [IQR: 79 to 446] AU/year vs. 124
[IQR: 61 to 321] AU/year; p ¼ 0.14). Neither tracer
offered independent prediction of clinical outcomes
after correction for CT calcium scoring, perhaps
reflecting the small number of events and again the
collinearity between imaging parameters.
In conclusion we demonstrated that both 18F-fluo-
ride and 18F-FDG predicted disease progression and
adverse clinical outcomes in aortic stenosis. In partic-
ular, 18F-fluoride provided excellent prediction of the
change in CT calcium score, appearing to be of incre-
mental value to baseline CT imaging. Larger studies are
required to confirm the incremental predictive value
of PET compared with CT. However, our data would
support PET/CT as a novel method for measuring dis-
ease activity in aortic stenosis, with the ability to
predict its natural history. This may be of particular
value in studies investigating novel therapies, in
which beneficial treatment effects are likely to be
detected rapidly without the need for protracted
follow-up. (Role of Active Valvular Calcification
and Inflammation in Patients With Aortic Stenosis;
NCT01358513)
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The Devil Is in the Details
We read with great interest the paper by Pant et al. (1)
regarding trends in infective endocarditis (IE) inci-
dence using the Nationwide Inpatient Sample (NIS)
database to address a nagging question that has right-
fully garnered much attention and gravity: have recent
changes in IE prophylaxis guidelines for dental pro-
cedures in this country and abroad resulted in an
increase in IE incidence caused by viridans group
streptococci (VGS)? As investigators who have previ-
ously used the NIS database (2,3), we pose 2 concerns
to Pant et al. First, they unfortunately used ICD-9-CM
codes that included enterococcal (04104) and non-
VGS (038.2 Streptococcus pneumoniae septicemia, and
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18F-NaF Valvular Uptake vs Baseline Calcium Score
Δ
Patients with higher than expected 18F-fluoride uptake for a given CT calcium score (dots in
red above regression line) demonstrated disease progression rates 3-fold greater than those
with lower than expected uptake (dots in blue below regression line). The samewas not true
for 18F-fluorodeoxyglucose. AS ¼ aortic stenosis; TBRMDS ¼ most diseased segment tissue:
background ratio; 18F-NaF ¼ 18F-fluoride.
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ORIGINAL ARTICLE
Cardiac αVβ3 integrin expression following acute
myocardial infarction in humans
William S A Jenkins,1 Alex T Vesey,1 Colin Stirrat,1 Martin Connell,2
Christophe Lucatelli,2 Anoushka Neale,1 Catriona Moles,1 Anna Vickers,1
Alison Fletcher,2 Tania Pawade,1 Ian Wilson,3 James H F Rudd,4
Edwin J R van Beek,2 Saeed Mirsadraee,2 Marc R Dweck,1 David E Newby1
ABSTRACT
Objective Maladaptive repair contributes towards the
development of heart failure following myocardial
infarction (MI). The αvβ3 integrin receptor is a key
mediator and determinant of cardiac repair. We aimed to
establish whether αvβ3 integrin expression determines
myocardial recovery following MI.
Methods 18F-Fluciclatide (a novel αvβ3-selective
radiotracer) positron emission tomography (PET) and CT
imaging and gadolinium-enhanced MRI (CMR) were
performed in 21 patients 2 weeks after ST-segment
elevation MI (anterior, n=16; lateral, n=4; inferior, n=1).
CMR was repeated 9 months after MI. 7 stable patients
with chronic total occlusion (CTO) of a major coronary
vessel and nine healthy volunteers underwent a single
PET/CT and CMR.
Results 18F-Fluciclatide uptake was increased at sites
of acute infarction compared with remote myocardium
(tissue-to-background ratio (TBRmean) 1.34±0.22 vs
0.85±0.17; p<0.001) and myocardium of healthy
volunteers (TBRmean 1.34±0.22 vs 0.70±0.03;
p<0.001). There was no 18F-fluciclatide uptake at sites
of established prior infarction in patients with CTO, with
activity similar to the myocardium of healthy volunteers
(TBRmean 0.71±0.06 vs 0.70±0.03, p=0.83).
18F-Fluciclatide uptake occurred at sites of regional wall
hypokinesia (wall motion index≥1 vs 0; TBRmean
0.93±0.31 vs 0.80±0.26 respectively, p<0.001) and
subendocardial infarction. Importantly, although there
was no correlation with infarct size (r=0.03, p=0.90) or
inflammation (C reactive protein, r=−0.20, p=0.38),
18F-fluciclatide uptake was increased in segments
displaying functional recovery (TBRmean 0.95±0.33 vs
0.81±0.27, p=0.002) and associated with increase in
probability of regional recovery.
Conclusion 18F-Fluciclatide uptake is increased at sites
of recent MI acting as a biomarker of cardiac repair and
predicting regions of recovery.
Trial registration number NCT01813045; Post-results.
INTRODUCTION
Ischaemic heart disease remains the leading cause
of death globally, with over 1 million people suffer-
ing acute myocardial infarction (MI) per year in the
USA alone. As the acute management of MI
improves, the number of patients surviving acute
myocardial injury is higher than ever before. In this
population, adverse cardiac remodelling and the
syndrome of delayed heart failure represent the
major cause of morbidity.1 Understanding repara-
tive mechanisms following infarction is becoming
increasingly important.
Repair following MI is triggered by a complex inter-
action of neurohormonal activation and upregulation
of angiogenic and pro-fibrotic transcription factors
that initiate the restoration of a capillary network
through angiogenesis and re-endothelialisation, as well
as extracellular matrix (ECM) remodelling through
macrophage accumulation and fibroblast activation.
This interplay of angiogenesis, inflammation and
fibrosis determines the extent of preservation and
restoration of myocardial integrity.2 In some cir-
cumstances, maladaptive persistent processes may
encourage remodelling and scarring to extend into
the myocardium long after the initial causative
injury. This may lead to progressive ventricular dila-
tation, ventricular dysfunction and heart failure.
The αvβ3 integrin is a transmembrane cell surface
receptor that facilitates migration, proliferation and
interaction with the ECM, thereby allowing cells to
respond to, and in turn modify, their extracellular
environment. Expressed at low levels by quiescent
endothelial cells, αvβ3 integrin is markedly upregu-
lated in states of angiogenesis within the myocar-
dium after infarction.3 4 In addition, preclinical
and clinical studies document αvβ3 integrin expres-
sion by both activated cardiac myofibroblasts and
macrophages during margination and chemotaxis.
Thus, αvβ3 integrin expression appears central to
the coordination of repair following MI.
In this study, we investigated the expression of
αvβ3 integrin following MI using the novel αvβ3
integrin-selective radiotracer, 18F-fluciclatide, com-
bined with cardiac positron emission tomography
(PET), CT and cardiovascular MRI (CMR). The
study aims to describe and characterise the uptake
of this radiotracer and to correlate it with clinical
markers of disease severity and functional recovery
in patients with recent MI.
METHODS
PET/CT scanning with 18F-fluciclatide and CMR
were performed in three groups of participants
recruited from Royal Infirmary of Edinburgh
between July 2013 and February 2015. Exclusion
criteria were age <40 years, women of childbearing
potential not taking contraception, severe renal
failure (serum creatinine >2.8 mg/dL) or hepatic
failure (Child-Pugh grade B or grade C), atrial
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